<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Intravenous immunoglobulin for the treatment of Kawasaki disease - Broderick, C - 2023 | Cochrane Library</title> <meta content="Intravenous immunoglobulin for the treatment of Kawasaki disease - Broderick, C - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014884.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Intravenous immunoglobulin for the treatment of Kawasaki disease - Broderick, C - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014884.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD014884.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Intravenous immunoglobulin for the treatment of Kawasaki disease" name="citation_title"/> <meta content="Cathryn Broderick" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="cathryn.broderick@ed.ac.uk" name="citation_author_email"/> <meta content="Shinobu Kobayashi" name="citation_author"/> <meta content="National Center for Child Health and Development" name="citation_author_institution"/> <meta content="Maiko Suto" name="citation_author"/> <meta content="National Center for Child Health and Development" name="citation_author_institution"/> <meta content="Shuichi Ito" name="citation_author"/> <meta content="Graduate School of Medicine, Yokohama City University" name="citation_author_institution"/> <meta content="Tohru Kobayashi" name="citation_author"/> <meta content="National Center for Child Health and Development" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD014884.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/01/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014884.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014884.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014884.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Acute Coronary Syndrome; Aspirin [adverse effects]; Fever [drug therapy, etiology]; Immunoglobulins, Intravenous [adverse effects]; Inflammation; *Mucocutaneous Lymph Node Syndrome [drug therapy]; Prednisolone [therapeutic use]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014884.pub2&amp;doi=10.1002/14651858.CD014884.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Ko3zGe0H";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD014884\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD014884\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014884\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014884\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","th","ms","ja","fa","pl","fr"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD014884.pub2",title:"Intravenous immunoglobulin for the treatment of Kawasaki disease",firstPublishedDate:"Jan 25, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014884.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014884.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD014884.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD014884.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014884.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD014884.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD014884.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD014884.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD014884.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD014884.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10251 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD014884.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-sec-0122"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-sec-0105"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/appendices#CD014884-sec-0127"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/supinfo/CD014884StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/supinfo/CD014884StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Intravenous immunoglobulin for the treatment of Kawasaki disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/information#CD014884-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Cathryn Broderick</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/information#CD014884-cr-0005">Shinobu Kobayashi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/information#CD014884-cr-0006">Maiko Suto</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/information#CD014884-cr-0007">Shuichi Ito</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014884.pub2/information#CD014884-cr-0008">Tohru Kobayashi</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/information/en#CD014884-sec-0131">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 January 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD014884.pub2">https://doi.org/10.1002/14651858.CD014884.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD014884-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014884-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014884-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014884-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014884-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD014884-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014884-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD014884-abs-0001" lang="en"> <section id="CD014884-sec-0001"> <h3 class="title" id="CD014884-sec-0001">Background</h3> <p>Kawasaki disease (KD) is an acute systemic vasculitis (inflammation of the blood vessels) that mainly affects children. Symptoms include fever, chapped lips, strawberry tongue, red eyes (bulbar conjunctival injection), rash, redness, swollen hands and feet or skin peeling; and enlarged cervical lymph nodes. High fevers and systemic inflammation characterise the acute phase. Inflammation of the coronary arteries causes the most serious complication of the disease, coronary artery abnormalities (CAAs). The primary treatment is intravenous immunoglobulin (IVIG) and acetylsalicylic acid (ASA/aspirin), with doses and regimens differing between institutions. It is important to know which regimens are the safest and most effective in preventing complications. </p> </section> <section id="CD014884-sec-0002"> <h3 class="title" id="CD014884-sec-0002">Objectives</h3> <p>To evaluate the efficacy and safety of IVIG in treating and preventing cardiac consequences of Kawasaki disease. </p> </section> <section id="CD014884-sec-0003"> <h3 class="title" id="CD014884-sec-0003">Search methods</h3> <p>The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL databases, and the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 26 April 2022. </p> </section> <section id="CD014884-sec-0004"> <h3 class="title" id="CD014884-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) investigating the use of IVIG for the treatment of KD. We included studies involving treatment for initial or refractory KD, or both. </p> </section> <section id="CD014884-sec-0005"> <h3 class="title" id="CD014884-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcomes were incidence of CAAs and incidence of any adverse effects after treatment. Our secondary outcomes were acute coronary syndromes, duration of fever, need for additional treatment, length of hospital stay, and mortality. We used GRADE to assess the certainty of the evidence for each outcome. </p> </section> <section id="CD014884-sec-0006"> <h3 class="title" id="CD014884-sec-0006">Main results</h3> <p>We identified 31 RCTs involving a total of 4609 participants with KD. Studies compared IVIG with ASA, another dose or regimen of IVIG, prednisolone, or infliximab. The majority of studies reported on primary treatment, so those results are reported below. A limited number of studies investigated secondary or tertiary treatment in IVIG‐resistant patients. Doses and regimens of IVIG infusion varied between studies, and all studies had some concerns related to risk of bias. </p> <p><b>Primary treatment with IVIG compared to ASA for people with KD</b> </p> <p>Compared to ASA treatment, IVIG probably reduces the incidence of CAAs in people with KD up to 30 days (odds ratio (OR) 0.60, 95% confidence interval (CI) 0.41 to 0.87; 11 studies, 1437 participants; moderate‐certainty evidence). The individual studies reported a range of adverse effects, but there was little to no difference in numbers of adverse effects between treatment groups (OR 0.57, 95% CI 0.17 to 1.89; 10 studies, 1376 participants; very low‐certainty evidence). There was limited evidence for the incidence of acute coronary syndromes, so we are uncertain of any effects. Duration of fever days from treatment onset was probably shorter in the IVIG group (mean difference (MD) −4.00 days, 95% CI −5.06 to −2.93; 3 studies, 307 participants; moderate‐certainty evidence). There was little or no difference between groups in need for additional treatment (OR 0.27, 95% CI 0.05 to 1.57; 3 studies, 272 participants; low‐certainty evidence). No study reported length of hospital stay, and no deaths were reported in either group. </p> <p><b>Primary treatment with IVIG compared to different infusion regimens of IVIG for people with KD</b> </p> <p>Higher‐dose regimens of IVIG probably reduce the incidence of CAAs compared to medium‐ or lower‐dose regimens of IVIG up to 30 days (OR 0.60, 95% CI 0.40 to 0.89; 8 studies, 1824 participants; moderate‐certainty evidence). There was little to no difference in the number of adverse effects between groups (OR 1.11, 95% CI 0.52 to 2.37; 6 studies, 1659 participants; low‐certainty evidence). No study reported on acute coronary syndromes. Higher‐dose IVIG may reduce the duration of fever compared to medium‐ or lower‐dose regimens (MD −0.71 days, 95% CI −1.36 to −0.06; 4 studies, 992 participants; low‐certainty evidence). Higher‐dose regimens may reduce the need for additional treatment (OR 0.29, 95% CI 0.10 to 0.88; 4 studies, 1125 participants; low‐certainty evidence). We did not detect a clear difference in length of hospital stay between infusion regimens (MD −0.24, 95% CI −0.78 to 0.30; 3 studies, 752 participants; low‐certainty evidence). One study reported mortality, and there was little to no difference detected between regimens (moderate‐certainty evidence). </p> <p><b>Primary treatment with IVIG compared to prednisolone for people with KD</b> </p> <p>The evidence comparing IVIG with prednisolone on incidence of CAA is very uncertain (OR 0.60, 95% CI 0.24 to 1.48; 2 studies, 140 participants; very low‐certainty evidence), and there was little to no difference between groups in adverse effects (OR 4.18, 95% CI 0.19 to 89.48; 1 study; 90 participants; low‐certainty evidence). We are very uncertain of the impact on duration of fever, as two studies reported this outcome differently and showed conflicting results. One study reported on acute coronary syndromes and mortality, finding little or no difference between groups (low‐certainty evidence). No study reported the need for additional treatment or length of hospital stay. </p> </section> <section id="CD014884-sec-0007"> <h3 class="title" id="CD014884-sec-0007">Authors' conclusions</h3> <p>The included RCTs investigated a variety of comparisons, and the small number of events observed during the study periods limited detection of effects. The certainty of the evidence ranged from moderate to very low due to concerns related to risk of bias, imprecision, and inconsistency. The available evidence indicated that high‐dose IVIG regimens are probably associated with a reduced risk of CAA formation compared to ASA or medium‐ or low‐dose IVIG regimens. There were no clinically significant differences in incidence of adverse effects, which suggests there is little concern about the safety of IVIG. Compared to ASA, high‐dose IVIG probably reduced the duration of fever, but there was little or no difference detected in the need for additional treatment. Compared to medium‐ or low‐dose IVIG, there may be reduced duration of fever and reduced need for additional treatment. We were unable to draw any conclusions regarding acute coronary syndromes, mortality, or length of hospital stay, or for the comparison IVIG versus prednisolone. Our findings are in keeping with current guideline recommendations and evidence from long‐term epidemiology studies. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD014884-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014884-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014884-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014884-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014884-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD014884-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD014884-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD014884-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD014884-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014884-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD014884-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD014884-abs-0002" lang="en"> <h3>Immunoglobulin treatment for Kawasaki disease</h3> <p><b>Key message</b> </p> <p>In children with Kawasaki disease, high‐dose intravenous immunoglobulin (IVIG) regimens:<br/>• probably reduce the risk of coronary artery abnormalities formation compared to aspirin or medium‐ or low‐dose IVIG regimens;<br/>• show no clear safety concerns;<br/>• probably reduce the duration of fever, but there was little or no difference detected in the need for additional treatment compared to aspirin;<br/>• may reduce the duration of fever and need for additional treatment compared to medium‐ or low‐dose IVIG. </p> <p><b>Why is this question important?</b> </p> <p>Kawasaki disease is a condition that causes blood vessels to become swollen and inflamed. Symptoms include high temperature (fever) along with chapped lips, strawberry tongue (swollen, bumpy red tongue), red eyes, a rash, redness and swelling of hands and feet or skin peeling; and swollen glands in the neck. It is most often seen in young children. Swelling and inflammation of the vessels which supply blood to the heart (coronary arteries) is the most serious complication of the disease, causing coronary artery abnormalities. These abnormalities can result in acquired heart disease and sometimes death. Fast diagnosis and treatment can prevent these complications. Intravenous immunoglobulin and aspirin are the main medicines used to treat Kawasaki disease. Different combinations, doses, or timings (regimens) of these medicines are used to treat patients. It is important to know which treatments and regimens are the safest and most effective in preventing heart complications. </p> <p><b>What did we do?</b> </p> <p>We searched for randomised controlled trials (a type of study where participants are randomly assigned to one of two or more treatment groups) that compared treatment of Kawasaki disease with IVIG to treatment with another medicine or regimen. We found 31 studies with a total of 4609 participants. The studies compared IVIG with aspirin, another regimen of IVIG, infliximab, or prednisolone. All studies reported on coronary artery abnormalities, but they did not all report on our other outcomes of interest: adverse effects, acute coronary syndromes (such as a heart attack), duration of fever, need for additional treatment, length of hospital stay, and mortality. Where appropriate, we combined data from the included studies. </p> <p><b>What did we find?</b> </p> <p>We looked at studies that compared IVIG with aspirin. Our results showed that children who received IVIG probably developed fewer coronary artery abnormalities than children treated with aspirin alone. Reporting of adverse effects varied between studies, but there was little or no difference in the number of adverse effects between groups. Acute coronary syndromes were poorly reported, so we cannot say if IVIG affected this. IVIG treatment probably reduced the duration of fever compared to aspirin alone. There was little or no difference in the need for additional treatment between IVIG and aspirin groups, and no study reported on the length of hospital stay. No deaths were reported in either group. </p> <p>We looked at studies that compared high‐dose IVIG regimens with medium‐ or low‐dose regimens. Our results showed that children who received high‐dose regimens probably developed fewer abnormalities. There was no apparent difference in the number of adverse effects between the high and medium‐ or low‐dose groups. Acute coronary syndromes were poorly reported, with little or no difference seen between groups. Higher‐dose regimens may reduce the duration of fever and need for additional treatment compared to medium‐ and lower‐dose regimens. We did not find a clear difference between regimens in length of hospital stay. One death was reported in one study, so we cannot say for sure if one regimen was better than another for this outcome. </p> <p>We also looked at studies that compared IVIG with prednisolone. The evidence was very uncertain for number of coronary artery abnormalities and duration of fever, and there was little or no difference between groups in adverse effects, acute coronary syndromes, and deaths. Results for all outcomes were limited by the small number of children with Kawasaki disease involved. No study reported on need for additional treatment or length of hospital stay. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the evidence provided from the included studies differed between outcomes and ranged from very low to moderate, due to concerns about how some of the studies were carried out, differences in the regimens used, and there were often only small numbers of events and participants providing data. Our findings are in keeping with current guideline recommendations and evidence from long‐term studies involving large numbers of people. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>The evidence is current to April 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD014884-sec-0122" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD014884-sec-0122"></div> <h3 class="title" id="CD014884-sec-0123">Implications for practice</h3> <section id="CD014884-sec-0123"> <p>Our findings are in keeping with current guideline recommendations. The strength of our conclusions is limited by restricting to randomised controlled trial (RCT) data. The included RCTs investigated a variety of comparisons, and the small number of events observed during the study periods limited the detection of effects. The available evidence indicated that high‐dose intravenous immunoglobulin (IVIG) regimens are probably associated with a reduced risk of coronary artery abnormalities (CAAs) formation compared to acetylsalicylic acid (ASA) or medium‐ or low‐dose IVIG regimens. Incidence of adverse events did not show clinically significant differences, which suggests there is little concern about the safety of IVIG. Compared to ASA, high‐dose IVIG probably reduced duration of fever, but there was little or no difference detected in the need for additional treatment. Compared to medium‐ or low‐dose IVIG, there may be reduced duration of fever and reduced need for additional treatment. We were unable to draw any conclusions regarding acute coronary syndromes, mortality, and length of hospital stay. We were also unable to determine any effects when comparing IVIG treatment with tumour necrosis factor (TNF)‐blockers or corticosteroids, or in people who were resistant to initial IVIG treatment. </p> </section> <h3 class="title" id="CD014884-sec-0124">Implications for research</h3> <section id="CD014884-sec-0124"> <p>Although we included 31 RCTs in the review, we found limited short‐ and long‐term RCT evidence for most outcomes, especially acute coronary syndromes, mortality, and length of hospital stay. Further well‐designed RCTs would both provide missing evidence and strengthen our certainty in the effects detected. This is the case for IVIG compared to ASA, other IVIG regimens, and other treatments for Kawasaki disease including TNF‐blockers and corticosteroids. Any such studies should report clinically relevant, clearly defined outcomes in a standardised way and report both short‐ and long‐term follow‐up periods. In order to assess these outcomes appropriately, randomised trials would need to include very large numbers of people. However, as large epidemiological studies are ongoing, it is unlikely that new RCTs investigating different IVIG regimens or comparing IVIG with ASA will begin. Ongoing RCTs identified in our searches compare IVIG with newer treatments (interleukin‐1 receptor antagonists) or are focused on IVIG‐resistant patients. Evidence from RCTs comparing IVIG with other treatments is important for the proportion of patients who fail to respond to initial IVIG treatment, as they are at most risk of serious complications from Kawasaki disease. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD014884-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD014884-sec-0008"></div> <div class="table" id="CD014884-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Primary treatment with intravenous immunoglobulin (IVIG) compared to acetylsalicylic acid (ASA) for people with Kawasaki disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous immunoglobulin (IVIG) versus acetylsalicylic acid (ASA) for the primary treatment of Kawasaki disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people undergoing initial treatment for KD </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> IVIG<sup>a</sup> </p> <p><b>Comparison:</b> ASA<sup>b</sup> </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ASA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with IVIG</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of CAAs</b> </p> <p>(up to 30 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.60</b> (0.41 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1437</p> <p>(11 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is likely that the incidence of CAA was reduced in the IVIG group compared to the ASA group. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>295 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b><br/>(147 to 267) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of any adverse effects after treatment initiation</b> </p> <p>(from 30 days to 30 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.57</b> (0.17 to 1.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1376</p> <p>(10 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There was little or no difference in the numbers of adverse effects detected. See <a href="./full#CD014884-tbl-0002">Table 1</a> for adverse effects reported by study. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b><br/>(12 to 120) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute coronary syndrome</b> (such as MI or coronary thrombus) </p> <p>(to 30 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>202</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a> reported acute coronary syndromes: 30 months 2/17 participants in the ASA group had coronary thrombus compared to 0/7 in the IVIG group. <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a> confirmed no acute coronary events occurred. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of fever</b> (days) </p> <p>(acute phase)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of fever from treatment onset across ASA group ranged from <b>6 to 7.9 days</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of fever from treatment onset in the IVIG group was <b>4 days lower</b> (5.06 lower to 2.93 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>307</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is likely that duration of fever was reduced in the IVIG group compared to the ASA group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Need for additional treatment</b> </p> <p>(up to 30 or 60 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.27</b> (0.05 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>272</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There was little or no difference in the need for additional treatment between groups.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> <p>(2 to 55)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of hospital stay</b> (days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies comparing IVIG with ASA reported on length of hospital stay.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality (all‐cause)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Details on the incidence of mortality were reported by 2 studies, with no deaths occurring in either study. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ASA:</b> acetylsalicylic acid; <b>CAA:</b> coronary artery abnormality; <b>CI:</b> confidence interval; <b>IVIG:</b> intravenous immunoglobulin; <b>KD:</b> Kawasaki disease; <b>MI:</b> myocardial infarction; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>IVIG total dose ranged from 100 mg/kg to 2 g/kg, via either single infusion or multiple infusions over three to five days. See <a href="./references#CD014884-sec-0139" title="">Characteristics of included studies</a> tables for specific details. All studies administered ASA to both arms, except for <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>, where one of two IVIG study arms did not receive ASA.<br/><sup>b</sup>Most studies administered ASA initially at 30 mg/kg/day, except for <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>, who used 100 mg/kg/day every 6 hours to day 14 of illness, and <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>, <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>, and <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>, who used 50 mg/kg/day.<br/><sup>c</sup>We downgraded by one level due to concerns related to risk of bias.<br/><sup>d</sup>We downgraded by one level due to concerns related to risk of bias, one level for inconsistency (I<sup>2</sup> = 73%), and one level for imprecision (small number of events, and confidence intervals include appreciable benefit or harm).<br/><sup>e</sup>We downgraded by one level due to concerns related to risk of bias and one level for imprecision (small numbers of participants and events).<br/><sup>f</sup>We downgraded by a total of one level due to concerns related to risk of bias and imprecision (small number of participants).<br/><sup>g</sup>We downgraded by one level due to concerns related to risk of bias and one level for imprecision (small numbers of participants and events, and confidence intervals include appreciable benefit or harm). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014884-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">1.</span> <span class="table-title">Adverse events ‐ primary treatment with IVIG versus ASA</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>IVIG<sup>a</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ASA<sup>a</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. "><b>Furusho 1984</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/46 chills and fever</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/47 liver disorder</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIG discontinued, and ASA changed to IVIG.</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. "><b>Furusho 1991B</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reports no SAE, AE not detailed</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. "><b>Matsushima 1985</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/17 pericardial effusion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/15 pericardial effusion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. "><b>Nagashima 1987</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/69 chills and fever</p> <p>1/69 urticaria</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In all cases, symptoms were transient and disappeared in a short time.</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. "><b>Newburger 1986</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 SAE</p> <p>3/84 mild congestive heart failure</p> <p>1/84 shaking/itching</p> <p>1/84 sepsis</p> <p>1/84 rash, fever, lymphadenopathy and splenomegaly</p> <p>1/84 neutropenia and splenomegaly</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/84 mild congestive heart failure</p> <p>1/84 neutropenia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. "><b>Ogawa 1987</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/63 liver disorder</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/54 liver disorder</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. "><b>Ogino 1987</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/42 liver disorder</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. "><b>Okuni 1987A</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. "><b>Okuni 1987B</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/196</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/99</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. "><b>Onouchi 1988</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/97 erythema (200 mg/kg arm)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/48 liver disorder</p> <p>1/48 nasal haemorrhage</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. "><b>Yabiku 1989</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/48 liver disorder</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/36 liver disorder</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>AE: adverse event<br/>ASA: acetylsalicylic acid<br/>IVIG: intravenous immunoglobulin<br/>SAE: serious adverse event<br/><sup>a</sup>See <a href="./references#CD014884-sec-0139" title="">Characteristics of included studies</a> tables for doses given. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014884-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Primary treatment with intravenous immunoglobulin (IVIG) compared to different infusion regimens of IVIG for people with Kawasaki disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>High‐dose versus medium‐ or low‐dose intravenous immunoglobulin infusion (IVIG) regimens for the primary treatment of Kawasaki disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people undergoing initial treatment for KD </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> IVIG high‐dose regimens<sup>a</sup> </p> <p><b>Comparison:</b> IVIG medium‐ or low‐dose regimens<sup>b</sup> </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with medium‐ or low‐dose IVIG</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with high‐dose IVIG</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of CAAs</b> </p> <p>(up to 30 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.60</b><br/>(0.40 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1824</p> <p>(8 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is likely that the incidence of CAAs is reduced in the high‐dose infusion regimens compared to the medium‐ or low‐dose regimens. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b><br/>(93 to 186) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of any adverse effects after treatment initiation</b> </p> <p>(follow‐up ranged from 30 days to 5 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.11</b><br/>(0.52 to 2.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1659</p> <p>(6 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There was little or no difference in the number of adverse effects detected. See <a href="./full#CD014884-tbl-0004">Table 2</a> for adverse effects reported by study. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b><br/>(10 to 44) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute coronary syndrome</b> (such as MI or coronary thrombus) </p> <p>(up to 7 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of fever</b> (days) </p> <p>(acute phase)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of fever in the medium‐ or low‐dose infusion regimens ranged from<br/><b>5 days to 10.3 days</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of fever was <b>0.71 days lower</b><br/>(1.36 lower to<br/>0.06 lower) in the high‐dose infusion regimens. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>992</p> <p>(4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of fever may be slightly reduced in the high‐dose regimens compared to the medium‐ or low‐dose regimens. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Need for additional treatment</b> </p> <p>(up to 6 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.29</b><br/>(0.10 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1125</p> <p>(4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Need for additional treatment may be slightly reduced in the high‐dose regimens compared to the medium‐ or low‐dose regimens. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>116 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b><br/>(13 to 103) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of hospital stay</b> (days) </p> <p>(up to 28 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay<br/>(days) ranged from <b>8.3 days to 18.95 days</b> across medium‐ and low‐dose infusion regimens. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay was <b>0.24 days lower</b><br/>(0.78 lower to<br/>0.3 higher) in the high‐dose infusion regimens. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>752</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was little to no difference detected in the length of hospital stay between regimens. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality (all‐cause)</b> </p> <p>(up to 7 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>549</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a> reported 1 death in the subacute phase of the 400 mg/kg/day for 4 days group. The cause of death was a giant aneurysm. The remaining studies did not report mortalities. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CAA:</b> coronary artery abnormality; <b>CI:</b> confidence interval; <b>IVIG:</b> intravenous immunoglobulin; <b>KD:</b> Kawasaki disease; <b>MI:</b> myocardial infarction; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We included studies that compared different doses or infusion regimens of IVIG for the primary treatment of KD. We defined high dose as single‐ or multiple‐infusion regimens of over 1600 mg/kg total IVIG.<br/><sup>b</sup>We defined medium dose to be single‐ or multiple‐infusion regimens of 1600 mg/kg to 1000 mg/kg total IVIG, and low dose to be single‐ or multiple‐infusion regimens of less than 1000 mg/kg total IVIG.<br/><sup>c</sup>We downgraded by one level due to concerns related to risk of bias.<br/><sup>d</sup>We downgraded by one level due to concerns related to risk of bias and one level for imprecision (small numbers of events, and confidence intervals include appreciable benefit or harm).<br/><sup>e</sup>We downgraded by one level due to concerns related to risk of bias and one level for inconsistency (I<sup>2</sup> = 71%).<br/><sup>f</sup>We downgraded by one level due to concerns related to risk of bias and one level for inconsistency (I<sup>2</sup> = 69%).<br/><sup>g</sup>We downgraded by a total of two levels due to concerns related to risk of bias and imprecision (confidence intervals include appreciable benefit or harm).<br/><sup>h</sup>We downgraded by one level for imprecision (small number of events reported). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014884-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">2.</span> <span class="table-title">Adverse events ‐ primary treatment with IVIG versus IVIG</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>IVIG</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>IVIG</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>IVIG</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. "><b>Barron 1990</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/22</p> <p>1 g/kg single</p> <p>4 mild flushing, chills, and nausea and vomiting, mild hypotension, morbilliform rash</p> <p>6/22 pericardial effusion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/22</p> <p>400 mg/kg/day for 4 days</p> <p>3 shaking chills, chills and noisy breathing, headache, flushing, and abdominal cramping</p> <p>3/22 pericardial effusion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Numbers of participants with pericardial effusion added separately to other AE, as it is not clear from text if these were different participants to those reporting other AE. </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]"><b>Furusho 1991A</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/41</p> <p>100 mg/kg/day for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/51</p> <p>200 mg/kg/day for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/53</p> <p>400 mg/kg/day for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE were detected. Unclear if this means no AE or not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. "><b>Harada 1989</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/125</p> <p>100 mg/kg/day for 5 days</p> <p>rash, mild hypotension</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/117</p> <p>400 mg/kg/day for 5 days</p> <p>anaphylactic shock</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). "><b>He 2021</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/129</p> <p>1 g/kg/day for 2 days</p> <p>chickenpox</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/132</p> <p>2 g/kg single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/138</p> <p>1 g/kg single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/129 recovered without complications.</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. "><b>Morikawa 1994</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/310</p> <p>200 mg/kg/day for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/156</p> <p>400 mg/kg/day for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All reported AE were mild to moderate and included fever, rash, shivering, peripheral cyanosis, hepatic dysfunction. </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. "><b>Newburger 1991</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/273</p> <p>2 g/kg single</p> <p>6/273 new or worsening congestive heart failure</p> <p>1/273 infusion was SC not IV – oedema and blistering</p> <p>1/273 generalised oedema</p> <p>1/273 nasal congestion, cough, nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/276</p> <p>400 mg/kg/day for 4 days</p> <p>3/276 new or worsening congestive heart failure</p> <p>2/276 had pruritis</p> <p>1/276 had generalised oedema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. "><b>Nishihara 1988</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not report</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. "><b>Onouchi 1988</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/49</p> <p>200 mg/kg/day for 3 days</p> <p>erythema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/48</p> <p>400 mg/kg/day for 3 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. "><b>Onouchi 1992</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/57</p> <p>100 mg/kg/day for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52</p> <p>200 mg/kg/day for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/56</p> <p>400 mg/kg/day for 5 days</p> <p>nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. "><b>Qin 2006</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/122</p> <p>2 g/kg single</p> <p>2 cases of rash, nausea, and abdominal pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/120</p> <p>1 g/kg single</p> <p>2 cases of rash, nausea, and abdominal pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Related to an allergic reaction to IVIG</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. "><b>Sakata 2007</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not report</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. "><b>Sato 1995</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/72</p> <p>2 g/kg single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/73</p> <p>400 mg/kg/day for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported that there were no AE to IVIG treatment in either group</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>AE: adverse effects<br/>IV: intravenous<br/>IVIG: intravenous immunoglobulin<br/>SC: subcutaneous </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014884-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Primary treatment with intravenous immunoglobulin (IVIG) compared to prednisolone for people with Kawasaki disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous immunoglobulin (IVIG) versus prednisolone for the primary treatment of Kawasaki disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people undergoing initial treatment for KD </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> IVIG<sup>a</sup> </p> <p><b>Comparison:</b> prednisolone<sup>b</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with prednisolone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with IVIG</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of CAAs</b> </p> <p>(acute phase)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.60</b> (0.24 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>140</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b><br/>(57 to 270) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of any adverse effects after treatment initiation</b> </p> <p>(up to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 4.18</b> (0.19 to 89.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>90</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There is little to no difference in the incidence of adverse effects.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0/40 in prednisolone group</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute coronary syndrome</b> (such as MI or coronary thrombus) </p> <p>(up to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>90</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a> reported an MI in the IVIG group (1/50 vs 0/40 in the prednisolone group). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of fever</b> (days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not pool, as considerable heterogeneity was detected.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Need for additional treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neither study comparing IVIG with prednisolone reported on the need for additional treatment. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of hospital stay</b> (days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither study comparing IVIG with prednisolone reported on length of hospital stay.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality (all‐cause)</b> </p> <p>(up to 30 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>90</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>e</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a> reported 1/50 deaths in the IVIG group compared to 0/40 in the prednisolone group. Cause of death was a giant aneurysm, intracranial bleeding, and MI. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CAA:</b> coronary artery abnormality; <b>CI:</b> confidence interval; <b>IVIG:</b> intravenous immunoglobulin; <b>KD:</b> Kawasaki disease; <b>MI:</b> myocardial infarction; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>IVIG dose was 400 mg/kg/day IVIG for 3 days, <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>, and 1 g/kg/day IVIG for 2 days, <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>. See <a href="./references#CD014884-sec-0139" title="">Characteristics of included studies</a> tables for specific details.<br/><sup>b</sup>Prednisolone dose was 2 mg/kg/day for 5 days, <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>, or 2 mg/kg/day intravenous methylprednisolone for 5 days, <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>, then oral prednisolone until C‐reactive protein‐negative. This group did not receive IVIG.<br/><sup>c</sup>We downgraded by two levels due to concerns related to risk of bias and one level for imprecision (small numbers of events and participants).<br/><sup>d</sup>We downgraded by one level due to concerns related to risk of bias and one level for imprecision (small numbers of events and participants, very wide confidence interval).<br/><sup>e</sup>We downgraded by one level due to concerns related to risk of bias and one level for imprecision (small numbers of events and participants).<br/><sup>f</sup>We downgraded by one level due to concerns related to risk of bias, one level for inconsistency (I<sup>2</sup> = 82%), and one level for imprecision (small numbers of participants). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD014884-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD014884-sec-0009"></div> <section id="CD014884-sec-0010"> <h3 class="title" id="CD014884-sec-0010">Description of the condition</h3> <p>Kawasaki disease (KD) is an acute systemic vasculitis (inflammation of the blood vessels) first described in 1967 by Japanese paediatrician Tomisaku Kawasaki that mainly affects children (<a href="./references#CD014884-bbs2-0096" title="KawasakiT . Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi1967;16(3):178–222.">Kawasaki 1967</a>; <a href="./references#CD014884-bbs2-0125" title="YamajiN , da Silva LopesK , ShodaT , IshitsukaK , KobayashiT , OtaE , et al. TNF-α blockers for the treatment of Kawasaki disease in children. Cochrane Database of Systematic Reviews2019, Issue 8. Art. No: CD012448. [DOI: 10.1002/14651858.CD012448.pub2]">Yamaji 2019</a>). The majority of cases are seen in children between six months and five years old, and more often in males than females (21 per 100,000 compared to 15 per 100,000, respectively) (<a href="./references#CD014884-bbs2-0105" title="MakinoN , NakamuraY , YashiroM , KosamiK , MatsubaraY , AeR , et al. The nationwide epidemiologic survey of Kawasaki disease in Japan, 2015-2016. Pediatrics International2019;61(4):397–403. [DOI: 10.1111/ped.13809]">Makino 2019</a>). There is substantial ethnic variation, with the lowest rates seen amongst white children (13.7 per 100,000 children under five) and the highest rates seen in children of Asian descent (29.8 per 100,000 children under five) (<a href="./references#CD014884-bbs2-0105" title="MakinoN , NakamuraY , YashiroM , KosamiK , MatsubaraY , AeR , et al. The nationwide epidemiologic survey of Kawasaki disease in Japan, 2015-2016. Pediatrics International2019;61(4):397–403. [DOI: 10.1111/ped.13809]">Makino 2019</a>), although a Japan‐wide survey reported that KD had increased between 2008 and 2015 (<a href="./references#CD014884-bbs2-0104" title="MakinoN , NakamuraY , YashiroM , AeR , TsuboiS , AoyamaY , et al. Descriptive epidemiology of Kawasaki disease in Japan, 2011-2012: from the results of the 22nd nationwide survey. Journal of Epidemiology2015;25(3):239–45.">Makino 2015</a>). Data are lacking for black/Hispanic ethnic groups due to too few cases being reported (<a href="./references#CD014884-bbs2-0094" title="HolmanRC , ChristensenKY , BelayED , SteinerCA , EfflerPV , MiyamuraJ , et al. Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii. Hawaii Medical Journal2010;69:194–7.">Holman 2010</a>; <a href="./references#CD014884-bbs2-0103" title="MaddoxRA , PersonMK , LindsayJL , BaherlingDL , SteinerCA , SchonbergerLB , et al. Monitoring the occurrence of Kawasaki syndrome in the United States. Circulation2015;131(Suppl 2):Abstract 0.03.">Maddox 2015</a>). </p> <p>There is no specific diagnostic test for KD, with diagnosis being made using clinical criteria and excluding other possible diagnoses. To be diagnosed with KD, individuals must have five or more days of fever as well as four or more of the five principal clinical features (chapped lips, strawberry tongue; bulbar conjunctival injection; rash, redness, and swelling of hands and feet or skin peeling; and enlarged cervical lymph nodes) (see <a href="#CD014884-tbl-0006">Table 3</a>) (<a href="./references#CD014884-bbs2-0118" title="RifeE , GedaliaA . Kawasaki disease: an update. Current Rheumatology Reports2020;22:75. [DOI: 10.1007/s11926-020-00941-4]">Rife 2020</a>). Individuals who meet the criteria are said to have complete KD (also known as typical or classic KD). Individuals who do not meet all the criteria may be diagnosed as having incomplete KD (also known as atypical KD) (<a href="./references#CD014884-bbs2-0098" title="KobayashiT , AyusawaM , SuzukiH , AbeJ , ItoS , KatoT , et al. Revision of diagnostic guidelines for Kawasaki disease (6th revised edition). Pediatrics International2020;62(10):1135-8. [DOI: 10.1111/ped.14326] [PMID: 33001522]">Kobayashi 2020</a>; <a href="./references#CD014884-bbs2-0106" title="McCrindleBW , RowleyAH , NewburgerJW , BurnsJC , BolgerAF , GewitzM , American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, and Council on Epidemiology and Prevention, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation2017;135(17):e927-99. [DOI: 10.1161/CIR.0000000000000484]">McCrindle 2017</a>). </p> <div class="table" id="CD014884-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Diagnosis of classic Kawasaki disease*</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Diagnosis of classic Kawasaki disease</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Classic KD is diagnosed in the presence of fever for at least 5 days (the day of fever onset is taken to be the first day of fever) together with at least 4 of the 5 following principal clinical features. In the presence of ≥ 4 principal clinical features, particularly when redness and swelling of the hands and feet are present, the diagnosis of KD can be made with 4 days of fever, although in rare cases experienced clinicians who have treated many patients with KD may establish the diagnosis with 3 days of fever. </p> <p> <ol id="CD014884-list-0001"> <li> <p>Erythema and cracking of lips, strawberry tongue, and/or erythema of oral and pharyngeal mucosa </p> </li> <li> <p>Bilateral bulbar conjunctival injection without exudate</p> </li> <li> <p>Rash: maculopapular, diffuse erythroderma, or erythema multiforme‐like</p> </li> <li> <p>Erythema and oedema of the hands and feet in acute phase and/or periungual desquamation in subacute phase </p> </li> <li> <p>Cervical lymphadenopathy (≥ 1.5‐centimetre diameter), usually unilateral</p> </li> </ol> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A careful history may reveal that ≥ 1 principal clinical features were present during the illness but had resolved by the time of presentation. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who lack full clinical features of classic KD are often evaluated for incomplete KD. If coronary artery abnormalities are detected, the diagnosis of KD is considered confirmed in most cases. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laboratory tests typically reveal normal or elevated white blood cell count with neutrophil predominance and elevated acute phase reactants such as C‐reactive protein and erythrocyte sedimentation rate during the acute phase. Low serum sodium and albumin levels, elevated serum liver enzymes, and sterile pyuria can be present. In the second week after fever onset, thrombocytosis is common. </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Other clinical findings may include the following:</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myocarditis, pericarditis, valvular regurgitation, shock</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coronary artery abnormalities</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aneurysms of medium‐sized non‐coronary arteries</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peripheral gangrene</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aortic root enlargement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Respiratory</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peribronchial and interstitial infiltrates on chest x‐ray</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary nodules</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Musculoskeletal</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arthritis, arthralgia (pleocytosis of synovial fluid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gastrointestinal</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea, vomiting, abdominal pain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hepatitis, jaundice</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gallbladder hydrops</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pancreatitis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nervous system</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Extreme irritability</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aseptic meningitis (pleocytosis of cerebrospinal fluid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Facial nerve palsy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sensorineural hearing loss</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Genitourinary</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urethritis/meatitis, hydrocele</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Desquamating rash in groin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retropharyngeal phlegmon</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anterior uveitis by slit lamp examination</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erythema and induration at BCG inoculation site</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>The differential diagnosis includes other infectious and non‐infectious conditions, including the following:</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measles</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other viral infections (e.g. adenovirus, enterovirus)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Staphylococcal and streptococcal toxin‐mediated diseases (e.g. scarlet fever and toxic shock syndrome) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drug hypersensitivity reactions, including Stevens‐Johnson syndrome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systemic onset juvenile idiopathic arthritis</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>With epidemiologic risk factors:</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rocky Mountain spotted fever or other rickettsial infections</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leptospirosis</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*American Heart Association guidelines (<a href="./references#CD014884-bbs2-0106" title="McCrindleBW , RowleyAH , NewburgerJW , BurnsJC , BolgerAF , GewitzM , American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, and Council on Epidemiology and Prevention, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation2017;135(17):e927-99. [DOI: 10.1161/CIR.0000000000000484]">McCrindle 2017</a>). </p> <p>BCG: Bacillus Calmette–Guérin (used in vaccine for prevention of tuberculosis)<br/>KD: Kawasaki disease </p> </div> </div> <p>Kawasaki disease is usually triphasic with an acute, subacute, and convalescent phase. The acute phase is characterised by high fevers (lasting from seven to 14 days if untreated), and systemic inflammation in the medium‐sized arteries, multiple organs, and tissues, resulting in the following common clinical findings: liver (hepatocyte damage), lung (interstitial pneumonitis), gastrointestinal tract (abdominal pain, vomiting, diarrhoea, gallbladder hydrops), meninges (aseptic meningitis, irritability), heart (myocarditis, pericarditis, valvulitis), urinary tract (pyuria), pancreas (pancreatitis), and lymph nodes (lymphadenopathy) (<a href="./references#CD014884-bbs2-0106" title="McCrindleBW , RowleyAH , NewburgerJW , BurnsJC , BolgerAF , GewitzM , American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, and Council on Epidemiology and Prevention, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation2017;135(17):e927-99. [DOI: 10.1161/CIR.0000000000000484]">McCrindle 2017</a>). Inflammation of the coronary arteries causes the most serious complication of the disease, that is coronary artery abnormalities (CAAs), which include dilatations and aneurysms. Close monitoring of CAA is important, as ischaemic symptoms or myocardial infarction (MI) due to thrombosis or stenosis can occur. In Japan between 2017 and 2018, coronary artery dilatation, aneurysm, and giant aneurysm (lumen size ≥ 8 mm) within 30 days after KD onset were reported to occur in 7.64%, 0.95%, and 0.11% of patients, respectively (<a href="./references#CD014884-bbs2-0070" title="AeR , MakinoN , KosamiK , KuwabaraM , MatsubaraY , NakamuraY . Epidemiology, treatments and cardiac complications in patients with Kawasaki disease: the nationwide survey in Japan, 2017-2018. Journal of Pediatrics2020;225:23-9.e2. [DOI: 10.1016/j.jpeds.2020.05.034]">Ae 2020</a>). Kawasaki disease is believed to be a leading cause of acquired heart disease in children from high‐income countries, with male patients or those resistant to initial intravenous immunoglobulin (IVIG) treatment at increased risk of CAAs (<a href="./references#CD014884-bbs2-0111" title="NewburgerJW , TakahashiM , GerberMA , GewitzMH , TaniLY , BurnsJC , et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics2004;114(6):1708–33. [DOI: 10.1542/peds.2004-2182]">Newburger 2004</a>; <a href="./references#CD014884-bbs2-0123" title="UeharaR , YashiroM , NakamuraY , YanagawaH . Kawasaki disease in parents and children. Acta Paediatrica2003;92:694–7. [DOI: 10.1111/j.1651-2227.2003.tb00602.x]">Uehara 2003</a>). </p> <p>The subacute phase is often asymptomatic, lasting approximately four weeks. During this time there may be peeling of the skin of the hands and feet, joint pain, and abnormal clinical findings such as thrombocytosis (increase in the number of platelets) or joint pain. This is also when the patient is at greatest risk of developing a coronary artery aneurysm. The convalescent phase is typically asymptomatic, four to eight weeks after onset. </p> <p>Echocardiography is the standard imaging technique used to evaluate coronary abnormalities, with coronary arteries classified according to size. In children less than five years old, a coronary artery lumen diameter of 3 mm or more is abnormal, whilst in children five years or older, 4 mm or more is considered to be abnormal (<a href="./references#CD014884-bbs2-0095" title="Research Committee on Kawasaki Disease. Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease. Tokyo: Japanese Ministry of Health and Welfare; 1984.">JMHW 1984</a>). Coronary artery lesions (CAL) are classified using Z scores (the coronary artery dimensions adjusted for body surface area, as dimensions will change with the size of the child) (<a href="./references#CD014884-bbs2-0080" title="DallaireF , DahdahN . New equations and a critical appraisal of coronary artery Z scores in healthy children. Journal of the American Society of Echocardiography2011;24(1):60-74. [DOI: 10.1016/j.echo.2010.10.004] [PMID: 21074965]">Dallaire 2010</a>; <a href="./references#CD014884-bbs2-0095" title="Research Committee on Kawasaki Disease. Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease. Tokyo: Japanese Ministry of Health and Welfare; 1984.">JMHW 1984</a>; <a href="./references#CD014884-bbs2-0097" title="KobayashiT , FuseS , SakamotoN , MikamiM , OgawaS , HamaokaK , Z Score Project Investigators. A new Z score curve of the coronary arterial internal diameter using the lambda-mu-sigma method in a pediatric population. Journal of the American Society of Echocardiography2016;29(8):794-801.e29. [DOI: 10.1016/j.echo.2016.03.017] [PMID: 27288089]">Kobayashi 2016</a>; <a href="./references#CD014884-bbs2-0113" title="OlivieriL , ArlingB , FribergM , SableC . Coronary artery Z score regression equations and calculators derived from a large heterogeneous population of children undergoing echocardiography. Journal of the American Society of Echocardiography2009;22(2):159-64. [DOI: 10.1016/j.echo.2008.11.003] [PMID: 19084373]">Olivieri 2008</a>). </p> <p>The prognosis for children with KD is highly dependent on the severity of coronary artery involvement. The fatality rate in the USA and Japan is reported as less than 0.2%, with MI from coronary occlusion being the main cause of death (<a href="./references#CD014884-bbs2-0090" title="HayasakaS , NakamuraY , YashiroM , UeharaR , OkiI , TajimiM , et al. Analysis of fatal cases of Kawasaki disease in Japan using vital statistical data over 27 years. Journal of Epidemiology2003;13:246–50.">Hayasaka 2003</a>). </p> </section> <section id="CD014884-sec-0011"> <h3 class="title" id="CD014884-sec-0011">Description of the intervention</h3> <p>It is thought that KD may be caused by activation of the immune system after infection with an unknown agent, such as a virus, in a genetically susceptible child. This results in an inflammatory cascade where both the innate and adaptive arms of the immune system are activated (<a href="./references#CD014884-bbs2-0084" title="FrancoA , ShimizuC , TremouletAH , BurnsJC . Memory T-cells and characterization of peripheral T-cell clones in acute Kawasaki disease. Autoimmunity2010;43(4):317–24. [DOI: 10.3109/08916930903405891]">Franco 2010</a>; <a href="./references#CD014884-bbs2-0085" title="GedaliaA . Kawasaki disease: 40 years after the original report. Current Rheumatology Reports2007;9(4):336–41.">Gedalia 2007</a>; <a href="./references#CD014884-bbs2-0119" title="RowleyAH , EckerleyCA , JäckHM , ShulmanST , BakerSC . IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. Journal of Immunology1997;159(12):5946–55.">Rowley 1997</a>). However, no infectious cause has yet been identified. A genetic role is indicated by the ethnic relationships and by increased incidence in children whose parents or siblings have also had KD (<a href="./references#CD014884-bbs2-0123" title="UeharaR , YashiroM , NakamuraY , YanagawaH . Kawasaki disease in parents and children. Acta Paediatrica2003;92:694–7. [DOI: 10.1111/j.1651-2227.2003.tb00602.x]">Uehara 2003</a>; <a href="./references#CD014884-bbs2-0126" title="YashiroM , NakamuraY , YanagawaH . Clinical features of patients with Kawasaki disease whose parents had the same disease. Archives of Pediatrics and Adolescent Medicine2004;158:1166–9.">Yashiro 2004</a>), as well as by polymorphisms identified in different genes and gene regions by family linkage and genome studies (<a href="./references#CD014884-bbs2-0114" title="OnouchiY , GunjiT , BurnsJC , ShimizuC , NewburgerJW , YashiroM , et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nature Genetics2008;40(1):35–42. [DOI: 10.1038/ng.2007.59]">Onouchi 2008</a>; <a href="./references#CD014884-bbs2-0115" title="OnouchiY , OzakiK , BunsJC , ShimizuC , HamadaH , HondaT , et al. Common variants in CASP3 confer susceptibility to Kawasaki disease. Human Molecular Genetics2010;19(14):2898–906. [DOI: 10.1093/hmg/ddq176]">Onouchi 2010</a>; <a href="./references#CD014884-bbs2-0116" title="OnouchiY , OzakiK , BurnsJC , ShimizuC , TeraiT , HamadaH , et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nature Genetics2012;44(5):517–21. [DOI: 10.1038/ng.2220]">Onouchi 2012</a>). </p> <p>The primary treatments for KD are IVIG and acetylsalicylic acid (ASA) (<a href="./references#CD014884-bbs2-0111" title="NewburgerJW , TakahashiM , GerberMA , GewitzMH , TaniLY , BurnsJC , et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics2004;114(6):1708–33. [DOI: 10.1542/peds.2004-2182]">Newburger 2004</a>; <a href="./references#CD014884-bbs2-0118" title="RifeE , GedaliaA . Kawasaki disease: an update. Current Rheumatology Reports2020;22:75. [DOI: 10.1007/s11926-020-00941-4]">Rife 2020</a>). Standard regimen of the primary treatment consists of a single infusion of high‐dose IVIG (2 g/kg) together with ASA (<a href="./references#CD014884-bbs2-0110" title="NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324:1633–9. [DOI: 10.1056/NEJM199106063242305]">Newburger 1991</a>). IVIG is most effective when administered within 10 days of the onset of fever, and has been reported to reduce the risk of coronary artery aneurysm formation from 20% to 25%, to 3% to 5% (<a href="./references#CD014884-bbs2-0109" title="NewburgerJW , TakahashiM , BurnsJC , BeiserAS , ChungKJ , DuffyCE , et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341–7.">Newburger 1986</a>). As many as 20% of children are considered to be IVIG resistant (or refractory), as they develop recurrent or persistent fevers after primary treatment (<a href="./references#CD014884-bbs2-0072" title="AshouriN , TakahashiM , DoreyF , MasonW . Risk factors for non response to therapy in Kawasaki disease. Journal of Pediatrics2008;153(3):3.">Ashouri 2008</a>; <a href="./references#CD014884-bbs2-0108" title="MoriM , MiyamaeT , ImagawaT , KatakuraS , KimuraK , YokotaS . Meta-analysis of the results of intravenous gamma globulin treatment of coronary artery lesions in Kawasaki disease. Modern Rheumatology2004;14(5):361–6. [DOI: 10.1007/s10165-004-0324-3]">Mori 2004</a>; <a href="./references#CD014884-bbs2-0111" title="NewburgerJW , TakahashiM , GerberMA , GewitzMH , TaniLY , BurnsJC , et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics2004;114(6):1708–33. [DOI: 10.1542/peds.2004-2182]">Newburger 2004</a>). Adjunctive therapy may benefit those patients who are at higher risk of coronary artery aneurysms. Adjuvant treatments may include the use of corticosteroids and tumour necrosis factor‐alpha (TNF‐alpha) blockers such as etanercept and infliximab. Corticosteroids have been shown to reduce the incidence of CALs in KD and decrease fever, duration of hospitalisation, and time to normalisation of C‐reactive protein (CRP) levels (<a href="./references#CD014884-bbs2-0087" title="GreenJ , WardleAJ , TullohRM . Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database of Systematic Reviews2022, Issue 5. Art. No: CD011188. [DOI: 10.1002/14651858.CD011188.pub3]">Green 2022</a>). Recent American Heart Association (AHA) guidelines state that giving high‐risk or IVIG‐resistant patients a longer course of corticosteroids should be considered as primary adjunctive therapy (<a href="./references#CD014884-bbs2-0106" title="McCrindleBW , RowleyAH , NewburgerJW , BurnsJC , BolgerAF , GewitzM , American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, and Council on Epidemiology and Prevention, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation2017;135(17):e927-99. [DOI: 10.1161/CIR.0000000000000484]">McCrindle 2017</a>). Compared with no treatment or additional treatment with IVIG, TNF‐alpha blockers may have beneficial effects on treatment resistance and the unwanted 'infusion reaction' after treatment initiation for KD (<a href="./references#CD014884-bbs2-0125" title="YamajiN , da Silva LopesK , ShodaT , IshitsukaK , KobayashiT , OtaE , et al. TNF-α blockers for the treatment of Kawasaki disease in children. Cochrane Database of Systematic Reviews2019, Issue 8. Art. No: CD012448. [DOI: 10.1002/14651858.CD012448.pub2]">Yamaji 2019</a>). </p> <p>Other agents include interleukin‐1 (IL‐1) receptor inhibitors (<a href="./references#CD014884-bbs2-0099" title="Kone-PautI , CimazR , HerbergJ , BatesO , CarbasseA , SaulnierJP , et al. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: a retrospective cases series. Autoimmunity Reviews2018;17(8):768–74. [DOI: 10.1016/j.autrev.2018.01.024]">Kone‐Paut 2018</a>), calcineurin inhibition therapy (ciclosporin) (<a href="./references#CD014884-bbs2-0088" title="HamadaH , SuzukiH , OnouchiY , EbataR , TeraiM , FuseS , et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet2019;393(10176):1128–37.">Hamada 2019</a>), cyclophosphamide, methotrexate (<a href="./references#CD014884-bbs2-0100" title="LeeTJ , KimKH , ChunJK , KimDS . Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Medical Journal2008;49(5):714–8. [DOI: 10.3349/ymj.2008.49.5.714]">Lee 2008</a>), rituximab (<a href="./references#CD014884-bbs2-0120" title="SauvagetE , BonelloB , DavidM , ChabrolB , DubusJC , BosdureE . Resistant Kawasaki disease treated with anti-CD20. Journal of Pediatrics2012;160(5):875-6. [DOI: 10.1016/j.jpeds.2012.01.018] [PMID: 22341587]">Sauvaget 2012</a>), and plasma exchange (<a href="./references#CD014884-bbs2-0093" title="HokosakiT , MoriM , NishizawaT , NakamuraT , ImagawaT , IwamotoM , et al. Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatrics International2012;54(1):99-103. [DOI: 10.1111/j.1442-200X.2011.03487.x]">Hokosaki 2012</a>), but their use is not widespread due to a lack of evidence (<a href="./references#CD014884-bbs2-0118" title="RifeE , GedaliaA . Kawasaki disease: an update. Current Rheumatology Reports2020;22:75. [DOI: 10.1007/s11926-020-00941-4]">Rife 2020</a>). Statins are also undergoing investigation due to their effects on inflammation, platelet aggregation, coagulation, and endothelial function (<a href="./references#CD014884-bbs2-0122" title="TremouletAH , JainS , JonePN , BestBM , DuxburyEH , FrancoA , et al. Phase I/IIa trial of atorvastatin in patients with acute Kawasaki disease with coronary artery aneurysm. Journal of Pediatrics2019;215:107–17.e12. [DOI: 10.1016/j.jpeds.2019.07.064]">Tremoulet 2019</a>). </p> </section> <section id="CD014884-sec-0012"> <h3 class="title" id="CD014884-sec-0012">How the intervention might work</h3> <p>Exactly how IVIG works as a treatment of KD is unknown, but it has a general anti‐inflammatory effect, probably by modulating cytokine and antibody production and by increasing regulatory T‐cell activity (<a href="./references#CD014884-bbs2-0077" title="BurnsJC , FrancoA . The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. Expert Reviews of Clinical Immunology2015;11:819–25. [DOI: 10.1586/1744666X.2015.1044980]">Burns 2015</a>). Acetylsalicylic acid has anti‐inflammatory activity in high dose or antiplatelet activity in low dose, but it does not appear to prevent the development of coronary abnormalities (<a href="./references#CD014884-bbs2-0075" title="BaumerJH , LoveS , GuptaA , HainesL , MaconochieIK , DuaJS . Salicylate for the treatment of Kawasaki disease in children. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD004175. [DOI: 10.1002/14651858.CD004175.pub2]">Baumer 2006</a>). The remaining adjunctive and additional therapeutic agents also act by suppressing the widespread immune response characterised in KD with the aim of minimising symptoms and preventing cardiac abnormalities (<a href="./references#CD014884-bbs2-0127" title="ZhangRL , LoHH , LeiC , IpN , ChenJ , LawBYK . Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease. Current Opinion in Pharmacology2020;54:1–10.">Zhang 2020</a>). </p> </section> <section id="CD014884-sec-0013"> <h3 class="title" id="CD014884-sec-0013">Why it is important to do this review</h3> <p>Kawasaki disease is an important cause of acquired heart disease in children in high‐income countries, with the majority of deaths resulting from damage to the coronary arteries. In addition, unexpected death from MI can happen many years later, with incidences of non‐fatal and fatal MI in young adults sometimes thought to result from 'missed' KD in childhood (<a href="./references#CD014884-bbs2-0076" title="BurnsJC , ShikeH , GordonJB , MalhotraA , SchoenwetterM , KawasakiT . Sequelae of Kawasaki disease in adolescents and young adults. Journal of the American College of Cardiology1996;28:253–7.">Burns 1996</a>; <a href="./references#CD014884-bbs2-0081" title="DanielsLB , TjajadiMS , WalfordHH , Jimenez-FernandezS , TrofimenkoV , Fick DB Jr, et al. Prevalence of Kawasaki disease in young adults with suspected myocardial ischemia. Circulation2012;125:2447–53. [DOI: 10.1161/CIRCULATIONAHA.111.082107]">Daniels 2012</a>). The primary aim of an accurate diagnosis is to help prevent these complications with quick and effective treatment, and IVIG is widely used for this purpose. In 2020, with the SARS‐CoV‐2 pandemic, increased numbers of KD symptoms have been reported (<a href="./references#CD014884-bbs2-0124" title="VerdoniL , MazzaA , GervasoniA , MartelliL , RuggeriM , CiuffredaM , et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet2020;395:1771-8.">Verdoni 2020</a>). This review will replace an earlier Cochrane Review on the same topic (<a href="./references#CD014884-bbs2-0112" title="Oates-WhiteheadRM , BaumerJH , HainesL , LoveS , MaconochieIK , GuptaA , et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD004000. [DOI: 10.1002/14651858.CD004000]">Oates‐Whitehead 2003</a>). A new review is planned due to significant changes in Cochrane methodology since the previous review was published. We also aim to include all currently available evidence for IVIG for the treatment of KD in children to aid decision‐making for healthcare providers internationally. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD014884-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD014884-sec-0014"></div> <p>To evaluate the efficacy and safety of intravenous immunoglobulin (IVIG) in treating and preventing cardiac consequences of Kawasaki disease. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD014884-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD014884-sec-0015"></div> <section id="CD014884-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD014884-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included all randomised controlled trials (RCTs) investigating the use of IVIG for the treatment of KD. We planned to include studies involving treatment for initial or refractory KD, or both. We excluded studies that did not investigate any of our outcomes of interest. </p> </section> <section id="CD014884-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies involving participants diagnosed with KD using Japanese or AHA guidelines (see <a href="#CD014884-tbl-0006">Table 3</a>) (<a href="./references#CD014884-bbs2-0074" title="AyusawaM , SonobeT , UemuraS , OgawaS , NakamuraY , KiyosawaN , Kawasaki Disease Research Committee. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatrics International2005;47(2):232-4.">Ayusawa 2005</a>; <a href="./references#CD014884-bbs2-0106" title="McCrindleBW , RowleyAH , NewburgerJW , BurnsJC , BolgerAF , GewitzM , American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, and Council on Epidemiology and Prevention, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation2017;135(17):e927-99. [DOI: 10.1161/CIR.0000000000000484]">McCrindle 2017</a>). </p> </section> <section id="CD014884-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies using IVIG to treat participants with KD. We included all doses and types of IVIG. We included studies with the following comparisons. </p> <p> <ul id="CD014884-list-0002"> <li> <p>IVIG versus placebo or no treatment.</p> </li> <li> <p>IVIG versus ASA.</p> </li> <li> <p>IVIG versus TNF‐alpha blockers.</p> </li> <li> <p>IVIG versus corticosteroids.</p> </li> <li> <p>IVIG versus IVIG (i.e. dose versus dose).</p> </li> <li> <p>IVIG versus any combination of the above providing IVIG was the only difference between the groups, and any treatment effect was not confounded with another co‐treatment. </p> </li> </ul> </p> <p>We excluded studies comparing infusion speed when the same dose was used. We excluded studies that compared one type of IVIG versus another (i.e. different manufacturer or separated/sulphonated). </p> </section> <section id="CD014884-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We recorded the time points of outcomes reported by the included studies. We were interested in the acute phase (up to two weeks) and convalescent phase (four weeks or later after initial treatment). </p> <section id="CD014884-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD014884-list-0003"> <li> <p>Incidence of CAAs diagnosed by echocardiography or coronary angiography defined by absolute diameter, <a href="./references#CD014884-bbs2-0095" title="Research Committee on Kawasaki Disease. Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease. Tokyo: Japanese Ministry of Health and Welfare; 1984.">JMHW 1984</a>, or Z‐scores. </p> </li> <li> <p>Incidence of any adverse effects after treatment initiation.</p> </li> </ul> </p> </section> <section id="CD014884-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD014884-list-0004"> <li> <p>Acute coronary syndromes, such as MI or coronary thrombus.</p> </li> <li> <p>Duration of fever (days).</p> </li> <li> <p>Need for additional treatment.</p> </li> <li> <p>Length of hospital stay (days).</p> </li> <li> <p>Mortality (all‐cause).</p> </li> </ul> </p> </section> </section> </section> <section id="CD014884-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD014884-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Vascular Information Specialist conducted systematic searches of the following databases for RCTs and controlled clinical trials with no language, publication year, or publication status restrictions: </p> <p> <ul id="CD014884-list-0005"> <li> <p>Cochrane Vascular Specialised Register via the Cochrane Register of Studies (CRS‐Web; searched 26 April 2022); </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; Issue 3, 2022) via the Cochrane Register of Studies Online (CRSO); </p> </li> <li> <p>MEDLINE (Ovid MEDLINE Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE) 1946 to 26 April 2022; </p> </li> <li> <p>Embase Ovid (1974 to 26 April 2022);</p> </li> <li> <p>CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature) (1982 to 26 April 2022). </p> </li> </ul> </p> <p>We developed search strategies for other databases from the search strategy designed for MEDLINE. Where appropriate, these were combined with adaptations of the Highly Sensitive Search Strategy designed by the Cochrane for identifying RCTs and controlled clinical trials (as described in Chapter 4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, <a href="./references#CD014884-bbs2-0101" title="LefebvreC , GlanvilleJ , BriscoeS , FeatherstoneR , LittlewoodA , MarshallC , et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Lefebvre 2022</a>). Search strategies for the major databases are provided in <a href="./appendices#CD014884-sec-0128">Appendix 1</a>. </p> <p>We searched the following trials registries:</p> <p> <ul id="CD014884-list-0006"> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://who.int/trialsearch" target="_blank">who.int/trialsearch</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>). </p> </li> </ul> </p> <p>The most recent searches were carried out on 26 April 2022.</p> </section> <section id="CD014884-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of included studies and relevant review articles to identify other ongoing or published studies. We contacted relevant manufacturers for trial information (Baxter Healthcare, Teijin Ltd, Mitsubishi Pharma Corp, Japan Blood Products Organization, Nihon Pharmaceutical Co Ltd, N‐Bayer Yakuhin Ltd, KM Biologics, and Takeda Pharmaceuticals). </p> </section> </section> <section id="CD014884-sec-0026"> <h3 class="title" id="CD014884-sec-0026">Data collection and analysis</h3> <section id="CD014884-sec-0027"> <h4 class="title">Selection of studies</h4> <p>We used Covidence software to screen all reports identified by the Information Specialist (<a href="./references#CD014884-bbs2-0079" title="Covidence. Version accessed 15 June 2021. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a>). One of two review authors assessed reports by title or abstract (CB, SK), with any articles clearly not meeting the inclusion criteria (e.g. non‐RCTs) considered as 'not relevant'. We obtained the full‐text reports of all studies deemed potentially relevant. Two of three review authors (CB, SK, MS) independently assessed the full‐text reports for inclusion in the review. Any disagreements were resolved by discussion. We collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We illustrated the study selection process in a PRISMA diagram (<a href="./references#CD014884-bbs2-0102" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Medicine2009;6:e1000100.">Liberati 2009</a>). We listed all articles excluded after full‐text assessment in the <a href="./references#CD014884-sec-0140" title="">Characteristics of excluded studies</a> tables and provided the reasons for their exclusion. </p> </section> <section id="CD014884-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form based on the form provided by Cochrane Vascular to record study characteristics and outcome data. One of three review authors (CB, SK, MS) extracted the following study characteristics from the included studies. </p> <p> <ul id="CD014884-list-0007"> <li> <p>Methods (study design, number of participants, exclusions postrandomisation, losses to follow‐up, intention‐to‐treat analysis, duration of study). </p> </li> <li> <p>Participants (country, setting, age, sex, inclusion and exclusion criteria).</p> </li> <li> <p>Interventions (intervention, comparison, concomitant medications).</p> </li> <li> <p>Outcomes (primary and secondary outcomes specified and collected, and time points reported). </p> </li> <li> <p>Funding source and declaration of interest of the study authors.</p> </li> </ul> </p> <p>One of three review authors (CB, SK, MS) independently extracted outcome data from the included studies, which a second review author (CB, SK, or MS) checked. When multiple trial arms were reported in a single trial, we included only the relevant arms. Any disagreements were resolved by consensus or by involving a third review author (TK, SI). One review author (CB) transferred data into Review Manager Web (<a href="./references#CD014884-bbs2-0117" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). We double‐checked that data were entered correctly. In the case of unclear or incomplete information or data, we contacted the study authors to request clarification. Additional information was provided for <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>. </p> </section> <section id="CD014884-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two of three review authors (CB, SK, MS) independently assessed the risk of bias of each included study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014884-bbs2-0091" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). Any disagreements were resolved by discussion or by involving another review author (TK). We assessed risk of bias according to the following domains. </p> <p> <ul id="CD014884-list-0008"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other bias</p> </li> </ul> </p> <p>We graded each domain as low, high, or unclear risk of bias, and provided a statement to justify our judgement in the risk of bias table. We summarised the risk of bias judgements across different studies for each of the domains listed. Where necessary, we considered blinding separately for cardiac outcomes and non‐cardiac outcomes. </p> </section> <section id="CD014884-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as odds ratios (OR) with 95% confidence intervals (CI), and continuous data as mean difference (MD) with 95% CI. We planned to use standardised mean difference (SMD) if outcomes were reported using different measurement scales, but this was not necessary. </p> </section> <section id="CD014884-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was each individual participant. Some papers reported multiple studies. We entered the separate studies into the <a href="./references#CD014884-sec-0139" title="">Characteristics of included studies</a> tables by author, followed by date, followed by either A, B, or C (where A is the earliest of the trials documented) (i.e. Smith 1990A, Smith 1990B, Smith 1990C). Some studies reported three comparison arms. We were careful there were no unit of analysis issues with double‐counting of participants if included studies used multiple intervention arms. If two comparisons (e.g. drug A versus control and drug B versus control) were combined in the same meta‐analysis, we halved the control group to avoid double‐counting. We used intention‐to‐treat analysis when possible. </p> </section> <section id="CD014884-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors to obtain missing study characteristics or outcome data when necessary. When this was not possible, and the missing data were considered sufficient to introduce bias, we would explore the impact of including these studies by sensitivity analysis. We considered missing data sufficient to introduce bias if the missing data were imbalanced between study arms or were potentially a result of the intervention. </p> </section> <section id="CD014884-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity visually by inspecting forest plots. We also used the Chi<sup>2</sup> and I<sup>2</sup> statistics and Tau<sup>2</sup> in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014884-bbs2-0092" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021</a>). We interpreted the I<sup>2</sup> value approximately as follows: </p> <p> <ul id="CD014884-list-0009"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>When assessing the importance of the observed value of I<sup>2</sup>, we considered (i) the magnitude and direction of effects and (ii) the strength of evidence for heterogeneity (e.g. P value from the Chi<sup>2</sup> test, or a CI for I<sup>2</sup>) in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014884-bbs2-0092" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021</a>). If we detected heterogeneity, we explored the reasons for it through subgroup analysis. </p> </section> <section id="CD014884-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned that when more than 10 studies were pooled for a given outcome, we would create a funnel plot to explore possible small‐study and publication biases. </p> </section> <section id="CD014884-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We carried out data synthesis using Review Manager Web (<a href="./references#CD014884-bbs2-0117" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). We planned to use a fixed‐effect model when there were no concerns about heterogeneity. As there were differences between many of the studies (doses, infusion regimen, concomitant medications, etc.), we used a random‐effects model for all analyses, not just in the case of substantial heterogeneity (I<sup>2</sup> &gt; 50%). We only undertook meta‐analyses where this was meaningful, that is if the treatments, participants, and the underlying clinical question were similar enough for pooling to make sense. When meta‐analysis was not possible, we reported the results using a narrative synthesis. </p> </section> <section id="CD014884-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had planned to undertake subgroup analyses by initial or refractory (secondary) IVIG treatment and by single‐ or multiple‐dose regimens. Given the range of regimens involved in the included studies, it was clinically more appropriate to present initial versus secondary IVIG treatment, and single versus multiple doses as separate comparisons and subgroup by the total dose administered. We investigated any impact on the geographical distribution of participants by subgrouping by trial country setting when possible. When only limited data were available, we considered whether it was appropriate to conduct subgroup analysis, as in such cases results may reflect a lack of information rather than a true effect (<a href="./references#CD014884-bbs2-0082" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Deeks 2021</a>). We used the formal test for subgroup interactions in Review Manager Web (<a href="./references#CD014884-bbs2-0117" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). </p> <p>We had planned to undertake subgroup analyses on the day of IVIG treatment, age, and weight/body mass index (BMI), but these analyses were precluded by insufficient information. We investigated any impact of study risk of bias using sensitivity analysis (see below). </p> </section> <section id="CD014884-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We undertook sensitivity analyses to check if the results were robust by excluding studies at high risk of bias from the analysis. We considered studies to be at high risk of bias when assessed as being at high risk of selection bias (i.e. high risk for either random sequence generation or allocation sequence concealment), or at high risk of detection bias for cardiac outcomes. We also undertook sensitivity analysis when it was not clear what KD diagnostic criteria had been used. We further undertook sensitivity analysis when we identified substantial heterogeneity by removing studies from the analyses to assess the individual impact of studies on the results. </p> </section> <section id="CD014884-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created a summary of findings table to present the evidence in the review for the following outcomes. </p> <p> <ul id="CD014884-list-0010"> <li> <p>Incidence of CAAs.</p> </li> <li> <p>Incidence of any adverse effects after treatment initiation.</p> </li> <li> <p>Acute coronary syndrome such as MI or coronary thrombus.</p> </li> <li> <p>Duration of fever.</p> </li> <li> <p>Need for additional treatment.</p> </li> <li> <p>Length of hospital stay.</p> </li> <li> <p>Mortality (all‐cause).</p> </li> </ul> </p> <p>We included a table for the most clinically relevant comparisons. These were: primary treatment with IVIG compared to ASA (see <a href="./full#CD014884-tbl-0001">summary of findings Table 1</a>); primary treatment with IVIG compared to different infusion regimens of IVIG (see <a href="./full#CD014884-tbl-0003">summary of findings Table 2</a>); and primary treatment with IVIG compared to prednisolone (see <a href="./full#CD014884-tbl-0005">summary of findings Table 3</a>). We used the five GRADE considerations (risk of bias, inconsistency, imprecision, indirectness, and publication bias) to assess the certainty of the evidence as it relates to the studies which contributed data to the meta‐analyses for each prespecified outcome (<a href="./references#CD014884-bbs2-0073" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490-4.">Atkins 2004</a>). We used the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014884-bbs2-0092" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021</a>; <a href="./references#CD014884-bbs2-0121" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Schünemann 2021</a>), employing GRADEpro GDT software (<a href="./references#CD014884-bbs2-0086" title="GRADEpro GDT. Version accessed 6 November 2020. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). We explained all decisions to downgrade the certainty of evidence using footnotes and added comments to aid the reader's understanding of the review when needed. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD014884-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD014884-sec-0039"></div> <section id="CD014884-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD014884-sec-0041"> <h4 class="title">Results of the search</h4> <p>The searches identified a total of 2679 articles. An additional 23 records were identified from citation screening. After deduplication, we screened 1957 articles by title and abstract. We assessed 237 full‐text articles for eligibility. We included 31 studies (49 records). Several records reported on more than one study. We excluded 13 studies (16 records) with reasons provided. We identified two ongoing studies (three records) and 23 studies as awaiting classification. See <a href="#CD014884-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD014884-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram." data-id="CD014884-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram.</p> </div> </div> </div> </section> <section id="CD014884-sec-0042"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD014884-sec-0139" title="">Characteristics of included studies</a> tables. </p> <p>We included 31 studies with a total of 4609 participants that investigated IVIG treatment for KD (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>; <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>). The majority of studies (21) were carried out in Japan (<a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>). Five were carried out in the USA or the USA and Canada (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>), four in China (<a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>; <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>), and one in Korea (<a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>). </p> <p>The size of the included studies varied, with the smallest having 17 participants, <a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a>, and the largest 549 participants, <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>. <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a> did not report the numbers of male and female participants. As expected, clinically all studies reported a larger proportion of males overall, with one exception being <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>, which reported equal numbers of males and females in the control group. </p> <p>The age of participants ranged from two months, <a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a>, to 14 years, <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>, with the majority of participants aged between 18 and 30 months (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>). Four studies included some older participants (<a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>; <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>). </p> <p>The majority of studies reported on the primary treatment of KD (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>; <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>). One study reported on primary plus additional treatment (<a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>). Six studies reported on secondary or refractory treatment for KD (<a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>), and one study reported on tertiary treatment (<a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a>). </p> <p>For those studies reporting on primary treatment, treatment was initiated within seven days of onset in 12 studies (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>), and 10 days in eight studies (<a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>). Initiation of treatment was not clear in <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a> and <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>. </p> <p>All studies investigating secondary treatment used IVIG as the initial treatment. Secondary treatment was initiated when fever did not decrease within 36 hours to seven days after initial treatment (<a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>), or 24 to 48 hours after initial treatment (<a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>). </p> <p>Some studies reported three arms (<a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>). When necessary, to be able to report these in analyses using Review Manager Web, we split one of the comparison arms between the other two arms to prevent double‐counting of participants. </p> <p>We identified and included studies with the following comparisons:</p> <p> <ul id="CD014884-list-0011"> <li> <p>IVIG compared to ASA;</p> </li> <li> <p>IVIG compared to a different dose of IVIG;</p> </li> <li> <p>IVIG compared to infliximab;</p> </li> <li> <p>IVIG compared to methylprednisolone.</p> </li> </ul> </p> <p>We did not identify any randomised studies comparing IVIG to placebo or no treatment.</p> <p>The total dose and frequency of IVIG treatment varied between studies and ranged from 50 to 100 mg/kg/day to 2 g/kg/day as either a single dose or daily infusions for up to five days. Infusion times ranged from one to 24 hours. The majority of participants received ASA in addition to IVIG. One study also administered dipyridamole (<a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>). In <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>, participants also received paracetamol and diphenhydramine; heparin was infused with methylprednisolone in <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; and <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a> administered flurbiprofen to participants with liver dysfunction. </p> <p>The majority of studies compared initial IVIG to a different dose or regimen of initial IVIG, <a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>, or to ASA alone, <a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>. <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a> and <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a> compared IVIG to prednisolone. Studies investigating secondary treatment compared IVIG to infliximab, <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>, or methylprednisolone, <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>. <a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a> investigated tertiary treatment and compared IVIG with methylprednisolone. For specific details on doses and regimens, see the <a href="./references#CD014884-sec-0139" title="">Characteristics of included studies</a> tables. </p> <p>Coronary artery abnormalities were reported by all included studies, the majority of which described detection and classification of CAA with echocardiography (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>). Seven studies did not describe how they classified CAA (<a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>; <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>). </p> <p>The remaining outcomes of interest were reported by only some studies:</p> <p> <ul id="CD014884-list-0012"> <li> <p>adverse effects (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>); </p> </li> <li> <p>acute coronary syndromes (<a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>); </p> </li> <li> <p>duration of fever (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>; <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>); </p> </li> <li> <p>need for additional treatment (<a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>); </p> </li> <li> <p>length of hospital stay (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>); </p> </li> <li> <p>mortality (<a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>). </p> </li> </ul> </p> <p>Eleven studies reported public or government funding sources (<a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>). Three studies received funding (or additional funding) from pharmaceutical companies that manufacture blood plasma products or immune‐regulating products (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>). Three studies acknowledged pharmaceutical companies for donating gammaglobulin (<a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>). The remaining studies did not report funding sources (<a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>; <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>). See <a href="./references#CD014884-sec-0139" title="">Characteristics of included studies</a>. </p> </section> <section id="CD014884-sec-0043"> <h4 class="title">Excluded studies</h4> <p>We excluded a total of 13 studies based on full‐text assessment (<a href="./references#CD014884-bbs2-0032" title="ChiCTR2000035163. A multicenter clinical trial of a new individualized treatment opinion for Kawasaki disease. chictr.org.cn/showprojen.aspx?proj=57061 (first received 2 August 2020). ">ChiCTR2000035163</a>; <a href="./references#CD014884-bbs2-0033" title="HamadaH , SuzukiH , OnouchiY , EbataR , TeraiM , FuseS , et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet2019;393(10176):1128-37. HamadaH , SuzukiH , OnouchiY , EbataR , TeraiM , FuseS , et al. Efficacy of primary treatment with immunoglobulin plus cyclosporine for prevention of coronary artery abnormalities in Kawasaki disease patients predicted to be at increased risk of IVIG non-response (KAICA study): a controlled, phase 3, randomised, open-label, blinded-endpoints trial. Rheumatology2019;58(Suppl 2):kez063-031. [DOI: 10.1093/rheumatology/kez063.031]">Hamada 2019</a>; <a href="./references#CD014884-bbs2-0034" title="ISRCTN71987471. Corticosteroids plus standard of care treatment versus standard of care treatment alone to prevent heart complications in Kawasaki disease. isrctn.com/ISRCTN71987471 (first received 31 March 2020). ">ISRCTN71987471</a>; <a href="./references#CD014884-bbs2-0035" title="JPRN-UMIN000014665. The investigation of the therapeutic efficacy of rapid intravenous immunoglobulin injection for acute phase Kawasaki disease. trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000014665 (first received 30 October 2014). ">JPRN‐UMIN000014665</a>; <a href="./references#CD014884-bbs2-0036" title="LeeHK , KimDS , NohGW , LeeKY . Effects of intravenous immune globulin on the peripheral lymphocyte phenotypes in Kawasaki disease. Yonsei Medical Journal1996;37(5):357-63. ">Lee 1996</a>; <a href="./references#CD014884-bbs2-0037" title="LinSY , HeL , XieLP , WangY , LinYX , CaoYY , et al. Effects of immunoglobulin plus prednisolone in reducing coronary artery lesions in patients with Kawasaki disease: study protocol for a phase III multicenter, open-label, blinded-endpoints randomized controlled trial. Trials2021;22(2):898. ">Lin 2021</a>; <a href="./references#CD014884-bbs2-0038" title="MutaH , IshiiM , HiroseA , FuruiJ , SugaharaY , HimenoW , et al. Randomized prospective controlled study of intravenous gamma-globulin products in treatment of Kawasaki disease. Journal of the Japan Pediatric Society2002;106(6):742-6. MutaH , IshiiM , SugaharaY , AkagiT , KatoH . Randomized controlled study of intravenous gamma-globulin products in treatment of Kawasaki disease. Pediatric Research2003;53(1):181. ">Muta 2002</a>; <a href="./references#CD014884-bbs2-0039" title="NanishiE , NishioH , TakadaH , YamamuraK , FukazawaM , FurunoK , et al. Clarithromycin plus intravenous immunoglobulin therapy can reduce the relapse rate of Kawasaki disease: a phase 2, open-label, randomized control study. Journal of the American Heart Association2017;6(7):e005370. ">Nanishi 2017</a>; <a href="./references#CD014884-bbs2-0040" title="NCT02298062. Infliximab for Kawasaki disease patients resistant to IVIG: a multicentre, prospective, randomised trial. clinicaltrials.gov/ct2/show/NCT02298062 (first received 21 November 2014). ">NCT02298062</a>; <a href="./references#CD014884-bbs2-0041" title="PortmanMA , DahdahN , OlsonAK , SleeA , ChoueiterN , AltmanC . Multicenter, randomized, double-blind trial of etanercept in acute Kawasaki disease. Circulation2017;136:A15447. PortmanMA , DahdahNS , SleeA , OlsonAK , ChoueiterNF , SorianoBD , et al. Etanercept with IVIg for acute Kawasaki disease: a randomized controlled trial. Pediatrics2019;143:6. [DOI: 10.1542/peds.2018-3675]">Portman 2019</a>; <a href="./references#CD014884-bbs2-0042" title="KobayashiT , SajiT , OtaniT , TakeuchiK , NakamuraT , ArakawaH , et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet2012;379(9826):1613-20. [DOI: 10.1016/S0140-6736(11)61930-2]">RAISE 2012</a>; <a href="./references#CD014884-bbs2-0043" title="SanatiF , BagheriM , EslamiS , KhalooeiA . Evaluation of high-dose aspirin elimination in the treatment of Kawasaki disease in the incidence of coronary artery aneurysm. Annals of Pediatric Cardiology2021;14(2):146-51. ">Sanati 2021</a>; <a href="./references#CD014884-bbs2-0044" title="SekiM , MinamiT , OkaK , YokomizoA , MatsubaraD , SatoT , et al. Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial. Pediatric Rheumatology2021;19(1):107. ">Seki 2021</a>). The reasons for exclusion were as follows: </p> <p> <ul id="CD014884-list-0013"> <li> <p>IVIG was not the differentiating intervention (<a href="./references#CD014884-bbs2-0032" title="ChiCTR2000035163. A multicenter clinical trial of a new individualized treatment opinion for Kawasaki disease. chictr.org.cn/showprojen.aspx?proj=57061 (first received 2 August 2020). ">ChiCTR2000035163</a>; <a href="./references#CD014884-bbs2-0033" title="HamadaH , SuzukiH , OnouchiY , EbataR , TeraiM , FuseS , et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet2019;393(10176):1128-37. HamadaH , SuzukiH , OnouchiY , EbataR , TeraiM , FuseS , et al. Efficacy of primary treatment with immunoglobulin plus cyclosporine for prevention of coronary artery abnormalities in Kawasaki disease patients predicted to be at increased risk of IVIG non-response (KAICA study): a controlled, phase 3, randomised, open-label, blinded-endpoints trial. Rheumatology2019;58(Suppl 2):kez063-031. [DOI: 10.1093/rheumatology/kez063.031]">Hamada 2019</a>; <a href="./references#CD014884-bbs2-0037" title="LinSY , HeL , XieLP , WangY , LinYX , CaoYY , et al. Effects of immunoglobulin plus prednisolone in reducing coronary artery lesions in patients with Kawasaki disease: study protocol for a phase III multicenter, open-label, blinded-endpoints randomized controlled trial. Trials2021;22(2):898. ">Lin 2021</a>; <a href="./references#CD014884-bbs2-0039" title="NanishiE , NishioH , TakadaH , YamamuraK , FukazawaM , FurunoK , et al. Clarithromycin plus intravenous immunoglobulin therapy can reduce the relapse rate of Kawasaki disease: a phase 2, open-label, randomized control study. Journal of the American Heart Association2017;6(7):e005370. ">Nanishi 2017</a>; <a href="./references#CD014884-bbs2-0042" title="KobayashiT , SajiT , OtaniT , TakeuchiK , NakamuraT , ArakawaH , et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet2012;379(9826):1613-20. [DOI: 10.1016/S0140-6736(11)61930-2]">RAISE 2012</a>; <a href="./references#CD014884-bbs2-0043" title="SanatiF , BagheriM , EslamiS , KhalooeiA . Evaluation of high-dose aspirin elimination in the treatment of Kawasaki disease in the incidence of coronary artery aneurysm. Annals of Pediatric Cardiology2021;14(2):146-51. ">Sanati 2021</a>); </p> </li> <li> <p>study compared injection or infusion speed of IVIG (<a href="./references#CD014884-bbs2-0035" title="JPRN-UMIN000014665. The investigation of the therapeutic efficacy of rapid intravenous immunoglobulin injection for acute phase Kawasaki disease. trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000014665 (first received 30 October 2014). ">JPRN‐UMIN000014665</a>; <a href="./references#CD014884-bbs2-0044" title="SekiM , MinamiT , OkaK , YokomizoA , MatsubaraD , SatoT , et al. Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial. Pediatric Rheumatology2021;19(1):107. ">Seki 2021</a>); </p> </li> <li> <p>study only reported surrogate outcomes (lymphocyte phenotypes), and so did not meet our inclusion criteria (<a href="./references#CD014884-bbs2-0036" title="LeeHK , KimDS , NohGW , LeeKY . Effects of intravenous immune globulin on the peripheral lymphocyte phenotypes in Kawasaki disease. Yonsei Medical Journal1996;37(5):357-63. ">Lee 1996</a>); </p> </li> <li> <p>study compared different types of IVIG, and dosage was determined by KD severity (<a href="./references#CD014884-bbs2-0038" title="MutaH , IshiiM , HiroseA , FuruiJ , SugaharaY , HimenoW , et al. Randomized prospective controlled study of intravenous gamma-globulin products in treatment of Kawasaki disease. Journal of the Japan Pediatric Society2002;106(6):742-6. MutaH , IshiiM , SugaharaY , AkagiT , KatoH . Randomized controlled study of intravenous gamma-globulin products in treatment of Kawasaki disease. Pediatric Research2003;53(1):181. ">Muta 2002</a>); </p> </li> <li> <p>study randomised to treatment (not IVIG) after initial IVIG treatment (<a href="./references#CD014884-bbs2-0034" title="ISRCTN71987471. Corticosteroids plus standard of care treatment versus standard of care treatment alone to prevent heart complications in Kawasaki disease. isrctn.com/ISRCTN71987471 (first received 31 March 2020). ">ISRCTN71987471</a>; <a href="./references#CD014884-bbs2-0041" title="PortmanMA , DahdahN , OlsonAK , SleeA , ChoueiterN , AltmanC . Multicenter, randomized, double-blind trial of etanercept in acute Kawasaki disease. Circulation2017;136:A15447. PortmanMA , DahdahNS , SleeA , OlsonAK , ChoueiterNF , SorianoBD , et al. Etanercept with IVIg for acute Kawasaki disease: a randomized controlled trial. Pediatrics2019;143:6. [DOI: 10.1542/peds.2018-3675]">Portman 2019</a>); </p> </li> <li> <p>study not completed due to limited participants and COVID‐19 (<a href="./references#CD014884-bbs2-0040" title="NCT02298062. Infliximab for Kawasaki disease patients resistant to IVIG: a multicentre, prospective, randomised trial. clinicaltrials.gov/ct2/show/NCT02298062 (first received 21 November 2014). ">NCT02298062</a>). </p> </li> </ul> </p> <p>For details of the excluded studies, see <a href="./references#CD014884-sec-0140" title="">Characteristics of excluded studies</a> tables. </p> </section> <section id="CD014884-sec-0044"> <h4 class="title">Ongoing studies</h4> <p>We identified two ongoing studies (<a href="./references#CD014884-bbs2-0068" title="ChiCTR1900027954. Effecacy of infliximab on IVIG-unresponsive Kawasaki disease: a single center prospective randamized controlled study. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR1900027954 (first received 7 December 2019). ">ChiCTR1900027954</a>; <a href="./references#CD014884-bbs2-0069" title="EUCTR2020-003194-22-FR. A randomized phase III multicentre trial comparing the efficacy and safety of Anakinra versus intravenous immunoglobulin (IVIG) retreatment, in patients with Kawasaki disease who failed to respond to initial standard IVIG treatment (ANACOMP) [Essai multicentrique randomisé de phase III comparant l'efficacité et la sécurité de l'anakinra au retraitement par immunoglobulines intraveineuses (IVIG), chez des patients atteints de la maladie de Kawasaki qui n'ont pas répondu au traitement initial standard par IVIG]. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-003194-22-FR (first received 7 September 2020). NCT04656184. A randomized phase III multicenter trial comparing the efficacy and safety of anakinra versus intravenous immunoglobulin (IVIG) retreatment, in patients with Kawasaki disease who failed to respond to initial standard IVIG treatment. clinicaltrials.gov/show/NCT04656184 (first received 7 December 2020). ">EUCTR2020‐003194‐22‐FR</a>). For details, see <a href="./references#CD014884-sec-0142" title="">Characteristics of ongoing studies</a> tables. </p> </section> <section id="CD014884-sec-0045"> <h4 class="title">Studies awaiting classification</h4> <p>We assessed 23 reports as awaiting classification (<a href="./references#CD014884-bbs2-0045" title="ChangYC . Two different large dosage of gamma-immunoglobulin for the treatment of Kawasaki disease. Sichuan Medical Journal2007;28(7):801. ">Chang 2007</a>; <a href="./references#CD014884-bbs2-0046" title="ChangWH . The different dosage of gamma-immunoglobulin in treating of Kawasaki disease - a clinical study. Journal of Jilin Medical College2008;29(4):199-201. ">Chang 2008</a>; <a href="./references#CD014884-bbs2-0047" title="ChenPC , ShiWZ . Medium dose of gamma-immunoglobulin for the treatment of Kawasaki disease - a clinical observation. Zhejiang Clinical Medicine2006;8(3):308. ">Chen 2006</a>; <a href="./references#CD014884-bbs2-0048" title="FuCN , ChenHP . Comparison of the therapeutic effects of different dose intravenous gamma-immunoglobulin in Kawasaki disease. China Modern Drug Application2010;4(7):121-2. ">Fu 2010</a>; <a href="./references#CD014884-bbs2-0049" title="HoHH , ChangQ , LeeJY . Different dosage of intravenous immunoglobulin for the treatment of Kawasaki disease - the observation of therapeutic effect. FJ Medical Journal2003;25(2):49-50. ">Ho 2003</a>; <a href="./references#CD014884-bbs2-0050" title="HoC . Comparison of therapeutic efficacy of two intravenous gamma-immunoglobulin regimen in acute Kawasaki disease. Hebei Medicine2004;26(4):323. ">Ho 2004</a>; <a href="./references#CD014884-bbs2-0051" title="JuanHL , XiangRL , LiangGA , LuHP . The effect of different IVIG dosage on CD4+ /CD8+ of children with Kawasaki disease. Pediatric Pharmacological Magazine2003;9(3):18-9. ">Juan 2003</a>; <a href="./references#CD014884-bbs2-0052" title="JuanC , YangHB , JuanJ , HoXL . Comparison of therapeutic efficacy of two large dosage intravenous gamma-immunoglobulin regimens in pediatric Kawasaki disease. Practical Clinical Medicine2005;8(3):48-9. ">Juan 2005</a>; <a href="./references#CD014884-bbs2-0053" title="JuanC , CaiXJ . Comparison of therapeutic efficacy of two gamma-immunoglobulin regimens in acute Kawasaki disease. Qingdao Medicine and Health2006;38(3):175-6. ">Juan 2006</a>; <a href="./references#CD014884-bbs2-0054" title="KuoL , ChangHY , DouJL , XuFX , ZhaiYL . Different dosage of intravenous gamma-immunoglobulin for the treatment of Kawasaki disease. The observation of therapeutic effect and nursing experience. China Practical Clinical Medicine2009;3(7):116-7. ">Kuo 2009</a>; <a href="./references#CD014884-bbs2-0055" title="LiHL , LiaoY . Analysis of the therapeutic efficacy of a single dose gamma-immunoglobulin for the treatment of Kawasaki disease in thirty three children. Journal of Gannan Medical University2008;28(1):36-8. ">Li 2008</a>; <a href="./references#CD014884-bbs2-0056" title="LiCK . Two different intravenous gamma-immunoglobulin regimens in the treatment acute Kawasaki disease - an observation of therapeutic efficacy. Practical Clinical Medicine2009;10(12):60-2. ">Li 2009</a>; <a href="./references#CD014884-bbs2-0057" title="LiaoJ , HeKJ . The clinical study of different dosage immune globulin in treating Kawasaki in intravenous injection. China Healthcare Innovation2007;2(22):8-9. ">Liao 2007</a>; <a href="./references#CD014884-bbs2-0058" title="LiuHM . The exploration of intravenous immunoglobulin dosage for the treatment of Kawasaki disease. Shantung Medicine2000;40(8):23-4. ">Liu 2000</a>; <a href="./references#CD014884-bbs2-0059" title="LiuTC . The observation of therapeutic effect of intravenous gamma-immunoglobulin in Kawasaki disease. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(4):451. ">Liu 2004</a>; <a href="./references#CD014884-bbs2-0060" title="LiuM , ChengJ , LuoQ . Comparison of therapeutic efficacy of two intravenous gamma-immunoglobulin regimens in children with Kawasaki disease. China Eugenics and Hereditary Magazine2009;17(2):117-8. ">Liu 2009</a>; <a href="./references#CD014884-bbs2-0061" title="LuJX , ZhengZL . Therapeutic effects of intravenous immune globulin on Kawasaki disease. Oinghai Medical Magazine2003;33(5):16-8. ">Lu 2003</a>; <a href="./references#CD014884-bbs2-0062" title="PengCM , XiaoQ , ChenYL , SuY . A study on different dose of intravenous immunoglobulins for treating Kawasaki disease. Journal of Nanhua University (Medical Edition)2001;29(6):581-3. ">Peng 2001</a>; <a href="./references#CD014884-bbs2-0063" title="TengMY . Comparison of therapeutic efficacy of two gamma-immunoglobulin regimens in Kawasaki disease. International Medical Health Reports2005;11(2):33-4. ">Teng 2005</a>; <a href="./references#CD014884-bbs2-0064" title="YaoSH . The observation of therapeutic efficacy of different intravenous gamma-immunoglobulin for the treatment in sixty-four children with Kawasaki disease. China Community Physician2009;11(213):68-9. ">Yao 2009</a>; <a href="./references#CD014884-bbs2-0065" title="YenP . The observation of therapeutic efficacy of different intravenous gamma-immunoglobulin for the treatment in Kawasaki disease. Community Medical Magazine2007;5(23):11. ">Yen 2007</a>; <a href="./references#CD014884-bbs2-0066" title="YuanYF , KuaiWX . The application of gamma-immunoglobulin for pediatric Kawasaki disease. Shanxi Medical Magazine2009;38(4):365-6. ">Yuan 2009</a>; <a href="./references#CD014884-bbs2-0067" title="YuehAH , TianQL , LiH . The observation of therapeutic efficacy of intravenous gamma-immunoglobulin for the treatment in fifty-six children with Kawasaki disease. Clinical Gathering2006;21(13):962-3. ">Yueh 2006</a>), which were identified by citation screening from published reviews and not by our database searches. We are currently unable to verify if they meet our inclusion criteria. </p> </section> </section> <section id="CD014884-sec-0046"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias of each included study based on the seven domains of the Cochrane risk of bias tool (RoB 1). An overall summary of bias present within each of the included studies is presented in <a href="#CD014884-fig-0002">Figure 2</a> and <a href="#CD014884-fig-0003">Figure 3</a>. No studies were at low risk of bias in all domains. Of the 31 included studies, 24 studies had at least one domain at high risk of bias. No study was at high risk of bias in all domains. All studies were at unclear risk of bias in at least one domain. </p> <div class="figure" id="CD014884-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD014884-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD014884-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD014884-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD014884-sec-0047"> <h4 class="title">Allocation</h4> <p>We selected only RCTs for this review. However, we judged only eight studies to be at low risk of bias for both random sequence generation and allocation concealment domains (<a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>). We judged <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a> to be at high risk for both random sequence generation and allocation concealment domains, as hospital numbers were used to assign treatment. We judged <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a> and <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a> to be at high risk for both random sequence generation and allocation concealment domains, as odd and even numbers were used to assign treatment. Four studies provided sufficient details to be assessed as at low risk for random sequence generation, but insufficient information to be assessed as low or high risk for allocation concealment, and were therefore judged as unclear (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>). Four studies stated that randomisation was arranged centrally, but did not provide details, so were assessed as unclear for random sequence generation and low for allocation concealment (<a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>). Twelve studies did not describe the method of randomisation and allocation at all or did not describe their methods in sufficient detail to permit an assessment, so were assessed as at unclear risk of bias for both domains (<a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a>; <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>). </p> </section> <section id="CD014884-sec-0048"> <h4 class="title">Blinding</h4> <section id="CD014884-sec-0049"> <h5 class="title">Performance bias</h5> <p>We assessed one study to be at low risk of performance bias, as blinding of clinicians was described (<a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>). We judged nine studies to be at high risk of performance bias, as it was clearly stated that no blinding of participants and personnel had been undertaken (<a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>). We assessed the remaining 21 studies as at unclear risk because they did not provide sufficient details to be assessed as at either low or high risk of performance bias. We acknowledge that given the different infusion times between some of the treatments, blinding of participants and personnel would have been difficult. </p> </section> <section id="CD014884-sec-0050"> <h5 class="title">Detection bias</h5> <p>We assessed each study for detection bias for both cardiac abnormality outcomes and non‐cardiac abnormality outcomes. This was because blinding of cardiac outcome assessment was possible even in situations where blinding of personnel or participants was not. </p> <p>Fourteen studies provided a clear description of blinding for evaluating cardiac abnormalities and so were judged to be at low risk of detection bias (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>). This was generally achieved by echocardiogram (ECG) recordings being assessed by clinicians who were not aware of the participant's identity. We judged 12 studies to be at high risk of detection bias for cardiac outcomes because there were no blinding measures, and the outcome could have been influenced by a lack of blinding (<a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>; <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>). When blinding of outcome assessors was insufficiently described, we judged the risk of detection bias as unclear (<a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>). </p> <p>For non‐cardiac outcomes, <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a> and <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a> reported that independent assessors were used for non‐cardiac outcomes, therefore we judged these studies to be at low risk of detection bias. We judged 24 studies to be at high risk of bias, as a lack of blinding was likely to influence outcomes (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>; <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>). We judged four studies to be at unclear risk of detection bias for non‐cardiac outcomes because insufficient details on how these outcomes were assessed were provided, or none of the outcomes measured was likely to be impacted by a lack of blinding (<a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>). One study did not report on non‐cardiac outcomes, preventing a judgement of detection bias (<a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>). </p> </section> </section> <section id="CD014884-sec-0051"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed no studies as being at high risk of attrition bias. The majority of included studies were at low risk of attrition bias, as data were all reported or accounted for (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>). Nine studies were at unclear risk of attrition bias because missing data were sufficient to potentially impact the results (<a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>), or the reasons for missing data were unclear (<a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>). </p> </section> <section id="CD014884-sec-0052"> <h4 class="title">Selective reporting</h4> <p>We assessed <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a> and <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a> as being at high risk of reporting bias, as no description of outcomes or measurements was provided in a methods section. Seven studies were at low risk of reporting bias, as all expected or planned outcomes per study protocols or trial databases were reported in the results (<a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>). We assessed the majority of included studies (22) as at unclear risk of reporting bias, as no protocol was available, or it was not clear what the planned outcomes were (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>; <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>). </p> </section> <section id="CD014884-sec-0053"> <h4 class="title">Other potential sources of bias</h4> <p>We had no concerns about other potential biases in 21 studies (<a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>). No studies were at high risk of other bias. We assessed the remaining studies as at unclear risk of other bias. Reasons for this included an imbalance in gender or ages between groups, and we were not sure if this could have affected the results (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>); study was halted prematurely (<a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>); inconsistencies in reporting (<a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>); treatments were switched at physician's discretion because of worsening KD in a substantial proportion of participants in both groups (<a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>); and results were published as a letter or abstract and likely not peer reviewed (<a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>). </p> </section> </section> <section id="CD014884-sec-0054"> <h3 class="title" id="CD014884-sec-0054">Effects of interventions</h3> <p>See: <a href="./full#CD014884-tbl-0001"><b>Summary of findings 1</b> Primary treatment with intravenous immunoglobulin (IVIG) compared to acetylsalicylic acid (ASA) for people with Kawasaki disease</a>; <a href="./full#CD014884-tbl-0003"><b>Summary of findings 2</b> Primary treatment with intravenous immunoglobulin (IVIG) compared to different infusion regimens of IVIG for people with Kawasaki disease</a>; <a href="./full#CD014884-tbl-0005"><b>Summary of findings 3</b> Primary treatment with intravenous immunoglobulin (IVIG) compared to prednisolone for people with Kawasaki disease</a> </p> <p>We have presented the results of the studies by each comparison and outcome of interest as pre‐planned. For the comparison of IVIG versus IVIG, the studies were heterogeneous in the dose of IVIG used and their infusion regimens. The total dose and frequency of IVIG treatment ranged from 50 to 100 mg/kg/day to 2 g/kg/day as either a single dose or daily infusions for up to five days. In order to present this information as clearly and as usefully as possible, we have indicated the dose and if this was over multiple days (e.g. 200 mg/kg/day for five days), as this is the most clinically familiar way. In the analysis tables, we presented the doses as the total IVIG received and indicated if this was on single or multiple days (e.g. 1000 mg/kg in five days). This was to facilitate a clearer comparison of regimens. We used a random‐effects model for all analyses due to the differences between studies. For specific details on interventions and concomitant medications, please see <a href="./references#CD014884-sec-0139" title="">Characteristics of included studies</a>. </p> <section id="CD014884-sec-0055"> <h4 class="title">Primary treatment ‐ intravenous immunoglobulin (IVIG) versus acetylsalicylic acid (ASA) </h4> <p>See <a href="./full#CD014884-tbl-0001">summary of findings Table 1</a>. </p> <p>Eleven studies involving 1396 participants compared IVIG treatment with ASA (<a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>). All studies compared IVIG plus ASA versus ASA. One of two IVIG study arms in <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a> was not given ASA. Most studies administered ASA initially at 30 mg/kg/day, except for <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>, who used 100 mg/kg/day every 6 hours to day 14 of illness, and <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>, <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>, and <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>, who used 50 mg/kg/day in both groups. Studies differed in total IVIG dose administered, number of doses, and time points measured. </p> <section id="CD014884-sec-0056"> <h5 class="title">Incidence of coronary artery abnormalities (CAAs)</h5> <p>All 11 studies reported on the incidence of CAA (<a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>). Where possible, we have presented numbers of CAA excluding any CAA present at enrolment. </p> <p>Overall, there were fewer CAA detected up to 30 days in the IVIG treatment group compared to the ASA group (odds ratio (OR) 0.60, 95% confidence interval (CI) 0.41 to 0.87; P = 0.008; 11 studies, 1437 participants; moderate‐certainty evidence). See <a href="./references#CD014884-fig-0005" title="">Analysis 1.1</a>. </p> <p>Seven studies reported CAA at 60 days or 1 year (<a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>). There was no clear difference detected at 60 days and over in the IVIG treatment group compared to the ASA group (OR 0.79, 95% CI 0.45 to 1.38; P = 0.41; 7 studies, 679 participants). See <a href="./references#CD014884-fig-0006" title="">Analysis 1.2</a>. </p> <p><a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a> reported 6/40 (15%) CAA in the IVIG group at 30 days, compared to 19/45 (42%) in the ASA group. No new lesions were detected between day 30 and 60; 14 CAA persisted in the ASA group compared to three CAA in the IVIG group. At day 60, 1/6 CAA were detected in the IVIG group compared to 11/19 CAA in the ASA group. </p> <p><a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a> investigated three groups: ASA, ASA + IVIG 200 mg/kg/day, and IVIG 200 mg/kg/day for five days. Before day 30, CAA was reported in 9/49, 10/53, and 19/49 participants respectively. At day 30, CAA was detected in 5/49, 4/51, and 9/47 participants respectively. We halved the ASA group data between subgroup analysis to prevent double‐counting. </p> <p><a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a> compared IVIG 400 mg/kg over 5 days with ASA. This study reported CAA incidence (dilations and aneurysms) at 1, 2, 3, and 4 weeks: 0/17, 3/17, 1/17, and 1/17 versus 0/17, 6/17, 6/17, and 3/17 in the IVIG and ASA groups, respectively. </p> <p><a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a> compared IVIG 400 mg/kg over three days with ASA. This study reported the number of CAA (dilations and aneurysms) at 1, 2, 3, and 4 weeks, and up to day 30, where 11/69 CAA were detected in the IVIG group compared to 25/67 in the ASA group. </p> <p><a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a> compared IVIG 400 mg/kg over four days with ASA. They reported the number of CAA at enrolment, 2 and 7 weeks, and 1‐year follow‐up. At enrolment, 2/84 participants in the IVIG group and 4/84 in the ASA group had CAA. At 2 and 7 weeks, excluding those at enrolment, there were 5/74 versus 15/75 and 2/77 versus 11/75 CAA in the IVIG and ASA groups, respectively. At 2 and 7 weeks and 1 year, including those at enrolment, there were 6/75 versus 18/78, 3/79 versus 14/79, and 2/7 versus 9/17 CAA in the IVIG and ASA groups, respectively. </p> <p><a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a> compared IVIG (400 mg/kg/day for 3 consecutive days) with ASA (30 mg/kg/day) versus ASA (30 mg/kg/day). The reported number of CAA at enrolment (1 to 10 days), under 11 to 25 days, 30 days, and 60 days were: 5/63, 11/63, 6/63, and 3/63 in the IVIG with ASA group versus 2/54, 17/54, 9/54, and 7/54 in the ASA group. </p> <p><a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a> compared IVIG (200 mg/kg/day for 3 consecutive days) with ASA (30 mg/kg/day) versus ASA (30 mg/kg/day). The reported number of CAA at enrolment (1 to 10 days), under 11 to 25 days, 30 days, 60 days, and 1 year were: 3/50, 15/50, 13/50, 9/50, and 4/50 in the IVIG with ASA group versus 5/42, 13/42, 10/42, 6/42, and 3/42 in the ASA group. </p> <p><a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a> compared single 100 mg/kg of IVIG (either pepsin treated or intact) versus ASA. We combined the two types of IVIG used. They reported CAA at enrolment, under 30 days, 30 days, 60 days, 6 months, and 1 year: 13/139, 55/136, 31/139, 24/139, 15/139, and 9/138 in the IVIG group versus 7/75, 29/75, 15/74, 11/74, 8/74, and 3/73 in the ASA group. The study authors reported no difference between groups if CAA numbers at enrolment were excluded, but we do not have those data. </p> <p><a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a> compared 100 mg/kg of IVIG for five days (either pepsin treated or intact) versus ASA. We combined the two types of IVIG used. They reported CAA at enrolment, under 30 days, 30 days, 60 days, 6 months, and 1 year: 17/196, 78/192, 36/188, and 21/186 in the IVIG group versus 11/99, 50/97, 30/95, and 20/90 in the ASA group. They also reported the data excluding those present at enrolment for under 30 days, 30 days, 60 days, 6 months, and 1 year: 61/175, 27/171, and 15/169 in the IVIG group versus 39/86, 21/85, and 13/81 in the ASA group. </p> <p><a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a> compared three arms: 200 mg/kg IVIG for 3 days, 400 mg/kg IVIG for 3 days, and ASA. They reported CAA detected before treatment, and at days 15, 30, and 60: IVIG 200 mg/kg: 6/38, 15/38, 10/38, and 7/38 versus IVIG 400 mg/kg: 5/42, 16/42, 10/42, and 6/42 versus ASA: 7/46, 19/46, 14/46, and 6/46. We included the day 15 data in the analysis. We split the ASA group between the analysis to prevent double‐counting. </p> <p><a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a> compared a single dose of IVIG 1 g/kg with ASA versus ASA. They reported the number of CAA at enrolment (1 to 10 days), under 11 to 25 days, 30 days, and 60 days: 4/48, 13/48, 8/48, and 3/48 in the IVIG with ASA group versus 4/36, 12/36, 6/36, and 3/36 in the ASA group, respectively. </p> </section> <section id="CD014884-sec-0057"> <h5 class="title">Incidence of any adverse effects after treatment initiation</h5> <p>See <a href="./references#CD014884-fig-0007" title="">Analysis 1.3</a> and <a href="./full#CD014884-tbl-0002">Table 1</a>. </p> <p>Ten studies reported a wide range of adverse effects, including: liver disorder, chills and fever, pericardial effusion, urticaria, mild congestive heart failure, shaking/itching, sepsis, lymphadenopathy, splenomegaly, neutropenia, and nasal haemorrhage (<a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>). No serious adverse events were reported. <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a> did not report adverse effects. </p> <p>We combined the data in a meta‐analysis and described specific adverse effects by study in <a href="./full#CD014884-tbl-0002">Table 1</a>. Overall, there was no clear difference in the number of adverse effects between the IVIG and ASA groups (OR 0.57, 95% CI 0.17 to 1.89; P = 0.35; 10 studies, 1376 participants; very low‐certainty evidence). See <a href="./references#CD014884-fig-0007" title="">Analysis 1.3</a>. We detected substantial heterogeneity (I<sup>2</sup> = 73%). This may have been due to the different adverse effects reported by each study. The test for subgroup differences did not detect a difference in adverse effects between the different total IVIG doses used (P = 0.10). </p> </section> <section id="CD014884-sec-0058"> <h5 class="title">Acute coronary syndromes, such as myocardial infarction (MI) or coronary thrombus</h5> <p>Only <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a> reported the incidence of acute coronary syndromes. At 30 months, no adverse sequelae were reported in the 7 participants in the IVIG group followed up to this point. Two of 17 participants in the ASA group had a coronary artery thrombus. <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a> provided additional information upon request and confirmed that no acute coronary events had occurred. No other studies reported this outcome. We assessed this evidence to be of low certainty. </p> </section> <section id="CD014884-sec-0059"> <h5 class="title">Duration of fever (days)</h5> <p>Eight studies reported duration of fever (<a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>). Four studies reported duration from onset of disease (<a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>). Three studies reported duration both from disease onset and onset of treatment (<a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>). <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a> reported the average fall in temperature and maximum temperature in hospitalised children. </p> <p>We combined the data from studies reporting duration of fever from treatment onset. Overall, the duration of fever in the IVIG group was shorter than in the ASA group (mean difference (MD) −4.00 days, 95% CI −5.06 to −2.93; P &lt; 0.001; 3 studies, 307 participants; moderate‐certainty evidence). See <a href="./references#CD014884-fig-0008" title="">Analysis 1.4</a>. </p> <p>We also combined the data from studies reporting duration from disease onset. Overall, the duration of fever in the IVIG group was shorter than in the ASA group (MD −1.60 days, 95% CI −2.69 to −0.52; P = 0.004; 7 studies, 693 participants). See <a href="./references#CD014884-fig-0009" title="">Analysis 1.5</a>. </p> <p><a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a> also reported data from centres where participants were hospitalised for at least two days to prevent bias from home reporting. Between day 1 and 2, the average temperature (± standard error, SE) of the IVIG group fell by 1.3 ± 0.16 ˚C compared to 0.42 ± 0.11 ˚C in the ASA group. At day 2, the number of participants with a maximum temperature ≥ 38 ˚C was 16/35 in IVIG group compared to 30/35 in the ASA group. </p> </section> <section id="CD014884-sec-0060"> <h5 class="title">Need for additional treatment</h5> <p>Details on the need for additional treatment were limited, with three studies reporting this outcome. <a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a> reported that one IVIG participant was retreated with IVIG and one ASA participant was treated with IVIG because of worsening symptoms. <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a> reported that no participants needed retreatment. <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a> reported that three ASA participants were retreated, but did not provide details about the medication given. Overall, there was no clear difference in need for additional retreatment between IVIG and ASA groups (OR 0.27, 95% CI 0.05 to 1.57; P = 0.15; 3 studies, 272 participants; low‐certainty evidence). See <a href="./references#CD014884-fig-0010" title="">Analysis 1.6</a>. </p> <p><a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a> mentions that 1/69 participants in the IVIG group received additional IVIG, but it is unclear if this was the only participant to do so. The need for additional treatment was not clearly reported in the remaining studies in this comparison, and no further information was available upon contacting study authors (<a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>). </p> </section> <section id="CD014884-sec-0061"> <h5 class="title">Length of hospital stay (days)</h5> <p>None of the studies comparing IVIG with ASA reported on length of hospital stay (<a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>). </p> </section> <section id="CD014884-sec-0062"> <h5 class="title">Mortality (all‐cause)</h5> <p>Two studies reported details on mortality incidence, with no deaths occurring in either study (<a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>; <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>). The remaining studies did not mention mortality, and although it is likely this means there were no deaths, we cannot be sure about this (<a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>; <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>; <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>; <a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. ">Ogawa 1987</a>; <a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. ">Ogino 1987</a>; <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>; <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. ">Yabiku 1989</a>). We assessed this evidence to be of low certainty. </p> </section> </section> <section id="CD014884-sec-0063"> <h4 class="title">Primary treatment ‐ IVIG versus IVIG</h4> <p>See <a href="./full#CD014884-tbl-0003">summary of findings Table 2</a>. </p> <p>Twelve studies compared IVIG with a different dose of IVIG or single versus multiple infusions, or multiple versus multiple infusions (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>). </p> <p>Eight studies with a total of 1824 participants compared a high‐dose regimen versus a medium‐ or low‐dose regimen (<a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>). <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a> administered additional IVIG if needed after the first dose. We included data from the first infusion only in this analysis. We considered a high dose to be more than 1900 mg/kg total IVIG; medium to be 1900 mg/kg to 900 mg/kg total IVIG; and low to be less than 900 mg/kg total IVIG. These dose categories are the same as the nationwide survey in Japan (<a href="./references#CD014884-bbs2-0070" title="AeR , MakinoN , KosamiK , KuwabaraM , MatsubaraY , NakamuraY . Epidemiology, treatments and cardiac complications in patients with Kawasaki disease: the nationwide survey in Japan, 2017-2018. Journal of Pediatrics2020;225:23-9.e2. [DOI: 10.1016/j.jpeds.2020.05.034]">Ae 2020</a>; <a href="./references#CD014884-bbs2-0071" title="AeR , YashiroM , MatsubaraY , OsamiM , MakinoS , NakamuraY . Results of the 26th nationwide survey of Kawasaki disease in Japan. jichi.ac.jp/dph/wp-dph/wp-content/uploads/2022/04/a19b047d4b9e6fbb84b6b187236779c8.pdf.">Ae 2021</a>). Some studies reported on three groups (<a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>). Where appropriate, we split the data between subgroups to prevent double‐counting. </p> <p>All eight studies infused a total of 2 g/kg using either a single infusion, <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>, or multiple infusions over two days, <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>, or five days, <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>. The medium and low doses ranged from 1000 mg/kg to 500 mg/kg total IVIG by single, <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>, or multiple infusions over five days, <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>. </p> <section id="CD014884-sec-0064"> <h5 class="title">Incidence of CAAs</h5> <p>Meta‐analysis showed that fewer CAA were reported in the higher infusion regimens compared to the medium or lower regimens (OR 0.60, 95% CI 0.40 to 0.89; P = 0.01; 8 studies, 1824 participants; moderate‐certainty evidence). See <a href="./references#CD014884-fig-0011" title="">Analysis 2.1</a>. No differences were detected between subgroups (test for subgroup differences P = 0.07). </p> <p>Three studies compared higher‐dose single‐infusion regimens with medium‐dose single infusion (<a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>). No clear difference in incidence of CAA was detected between these regimens (OR 0.88, 95% CI 0.59 to 1.32; P = 0.53; 3 studies, 621 participants). See <a href="./references#CD014884-fig-0012" title="">Analysis 2.2</a>. </p> <p>Six studies investigated higher‐dose multiple‐infusion versus lower‐dose multiple‐infusion regimens (<a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>). Higher multiple‐infusion doses were 2 g/kg, <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>, or 1000 mg/kg total, <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>, over five days. Overall, fewer CAA were detected in groups receiving the higher‐dose multiple infusions (OR 0.46, 95% CI 0.32 to 0.66; P &lt; 0.001; 6 studies, 1154 participants). See <a href="./references#CD014884-fig-0013" title="">Analysis 2.3</a>. No differences were detected between subgroups (test for subgroup differences P = 0.32). </p> <p>Four studies investigated single‐infusion regimens versus multiple‐infusion regimens (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>). <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a> only included participants scoring ≥ 4 on Harada score. Single doses ranged from 2 g/kg, <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>, to 1000 mg/kg, <a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>, total dose of IVIG. Multiple doses ranged from 2 g/kg total over two days, <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>, or five days, <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>, and 1600 mg/kg total over four days (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>). Overall, there was no clear difference in incidence of CAA between the single‐infusion and multiple‐infusion groups (OR 0.61, 95% CI 0.28 to 1.34; P = 0.22; 4 studies, 962 participants). See <a href="./references#CD014884-fig-0014" title="">Analysis 2.4</a>. No differences were detected between subgroups (test for subgroup differences P = 0.31). </p> <p>When splitting participants between subgroup analyses, if groups contained an uneven number of participants so that numbers could not be equally divided, we carried out the analysis in both ways to detect possible differences in the results caused by an unequal division of the numerator and denominator. This did not cause a significant change in size or direction of effect in any of the analyses. </p> </section> <section id="CD014884-sec-0065"> <h5 class="title">Incidence of any adverse effects after treatment initiation</h5> <p>Ten studies reported adverse effects (or lack of) after treatment initiation (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>). These included a range of reactions such as mild flushing, chills, nausea and vomiting, mild hypotension, rash, pericardial effusion, chills and noisy breathing, headache, flushing, abdominal cramping, fever, shivering, anaphylactic shock, peripheral cyanosis, hepatic dysfunction, new or worsening congestive heart failure or aortic insufficiency, pruritis, oedema and blistering, nasal congestion, cough, and erythema. No serious adverse events related to treatment were reported. </p> <p>As above, we have combined data from studies following similar infusion regimens and presented all adverse effects by study in <a href="./full#CD014884-tbl-0004">Table 2</a>. </p> <p>Two studies did not report adverse reactions (<a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>). We cannot be sure if none occurred, or if they were not recorded. </p> <p>Six studies with a total of 1659 participants compared a high‐dose regimen versus a medium‐ or low‐dose regimen (described above) and reported adverse effects (<a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>). Overall, no clear difference in the number of adverse effects was detected between regimens (OR 1.11, 95% CI 0.52 to 2.37; P = 0.78; 6 studies, 1659 participants; low‐certainty evidence). See <a href="./references#CD014884-fig-0015" title="">Analysis 2.5</a>. No differences were detected between subgroups (test for subgroup differences P = 0.93). </p> <p>Two studies compared higher‐dose single‐infusion with lower‐dose single‐infusion regimens (<a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>). No clear difference in incidence of adverse effects was detected between regimens (OR 1.02, 95% CI 0.14 to 7.34; P = 0.99; 2 studies, 512 participants). See <a href="./references#CD014884-fig-0016" title="">Analysis 2.6</a>. </p> <p>Five studies investigated higher‐dose multiple‐infusion versus lower‐dose multiple‐infusion regimens as described above and reported adverse effects (<a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>). Overall, there was no clear difference detected between regimens (OR 0.98, 95% CI 0.43 to 2.22; P = 0.96; 5 studies, 1115 participants). See <a href="./references#CD014884-fig-0017" title="">Analysis 2.7</a>. No differences were detected between subgroups (test for subgroup differences P = 0.67). </p> <p>Four studies investigated single‐infusion regimens versus multiple‐infusion regimens as described above and reported adverse effects (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>). Overall, there was no clear difference detected between regimens (OR 1.61, 95% CI 0.74 to 3.51; P = 0.23; 4 studies, 1005 participants). See <a href="./references#CD014884-fig-0018" title="">Analysis 2.8</a>. No differences were detected between subgroups (test for subgroup differences P = 0.52). </p> </section> <section id="CD014884-sec-0066"> <h5 class="title">Acute coronary syndromes, such as MI or coronary thrombus</h5> <p>No study mentioned acute coronary syndromes, and we cannot be sure if this means none occurred, or if they were not reported (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>). </p> </section> <section id="CD014884-sec-0067"> <h5 class="title">Duration of fever (days)</h5> <p>Four studies comparing a high‐dose regimen versus a medium‐ or low‐dose regimen (as described above) reported on duration of fever such that data could be pooled (<a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>). All studies reported the mean duration of fever days (± standard deviation (SD)). <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a> reported the duration of fever from treatment onset in days (± SD). The remaining three studies reported mean duration of fever days (± SD) from disease onset (<a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>). </p> <p>Overall, duration of fever was slightly reduced with higher‐dose regimens (MD −0.71, 95% CI −1.36 to −0.06; P = 0.03; 4 studies, 992 participants; low‐certainty evidence). Heterogeneity was detected (I<sup>2</sup> = 71%), which was reduced (I<sup>2</sup> = 0%) following sensitivity analysis to exclude <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a> (which measured duration from treatment onset) and <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a> (study protocol was to administer different additional treatments depending on the group). No differences were detected between subgroups (test for subgroup differences P = 0.10). See <a href="./references#CD014884-fig-0019" title="">Analysis 2.9</a>. </p> <p><a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a> reported that 194/300 (65%) participants were afebrile by 72 hours in the 200 mg/kg/day for 5 days groups compared to 121/152 (80%) in the 400 mg/kg/day for 5 days group. <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a> did not provide data, but stated that duration of febrile stages was similar between groups during treatment. <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a> reported that more than 50% of participants in the 200 mg/kg/day for 5 days and 400 mg/kg/day for 5 days groups were afebrile by day 2. The 100 mg/kg/day for 5 days group did not reach 50% afebrile until day 4. </p> <p><a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a> did not report duration of fever. </p> <p>Two studies compared higher‐dose single‐infusion with lower‐dose single‐infusion regimens and reported mean duration of fever days (± SD) from disease onset (<a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>). No clear difference in incidence of adverse effects was detected between regimens (MD −0.12, 95% CI −0.68 to 0.45; P = 0.69; 2 studies, 512 participants). See <a href="./references#CD014884-fig-0020" title="">Analysis 2.10</a>. </p> <p>Two studies investigated higher‐dose multiple‐infusion versus lower‐dose multiple‐infusion regimens (described above) and reported mean duration of fever days (± SD) from treatment onset (<a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>). Overall, no clear difference was detected between regimens (MD −0.64, 95% CI −2.88 to 1.61; P = 0.58; 2 studies, 322 participants). Heterogeneity was detected (I<sup>2</sup> = 80%), and a difference was detected between subgroups (test for subgroup differences P = 0.02); this was likely due to the different infusion regimen doses compared in the subgroups. See <a href="./references#CD014884-fig-0021" title="">Analysis 2.11</a>. </p> <p>Four studies investigated single‐infusion regimens versus multiple‐infusion regimens (described above) and reported on duration of fever. <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a> and <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a> reported mean duration of fever from enrolment (days ± SD) and treatment onset (days ± SD), respectively. <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a> reported mean duration of fever from disease onset (days ± SD). <a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a> did not report the total duration of fever, instead reporting that the maximum temperature fell an average of 1.41 ˚C in the 1 g/kg single‐infusion group compared to 0.78 ˚C in the 400 mg/kg/day multiple‐infusion group between day 1 and day 2 of treatment. For <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>, we calculated SD from SE using the RevMan Web calculator. Overall, there was no clear difference between regimens (MD −0.49, 95% CI −1.42 to 0.44; P = 0.30; 3 studies, 961 participants). Heterogeneity was detected (I<sup>2</sup> = 87%), which was not reduced by sensitivity analysis to remove each study in turn. See <a href="./references#CD014884-fig-0022" title="">Analysis 2.12</a>. </p> </section> <section id="CD014884-sec-0068"> <h5 class="title">Need for additional treatment</h5> <p>Four studies compared a high‐dose regimen versus a medium‐ or low‐dose regimen and reported on the need for additional treatment (<a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>). In <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>, resistant participants (fever persisting for more than 24 hours after completion of IVIG infusion or recrudescent fever associated with at least two symptoms of KD after an afebrile period) received a second dose of IVIG at 2 g/kg. The numbers of participants who received a second IVIG dose were 14/141 in the 2 g/kg group compared to 12/132 in the 1000 mg/kg group. In <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>, 17/299 participants in the 200 mg/kg/day for 5 days group compared to 2/151 in the 400 mg/kg/day for 5 days group required additional treatment with further IVIG due to recrudescent or persistent fever. In <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>, 6/57 participants in the 500 mg/kg group and 2/52 participants in the 1000 mg/kg group received additional IVIG (based on two‐dimensional echocardiography data). No participants in the 2 g/kg group received additional IVIG. In <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>, resistant participants in the 2 g/kg group were given an additional 2 g/kg of IVIG (4/54). Participants in the 1 g/kg group were given an additional 1 g/kg (26/55), then a further 2 g/kg if required (6/55). <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>, <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>, <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>, and <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a> did not report additional treatment. We cannot be sure if this means no participants needed additional treatment, or if this was not recorded. </p> <p>Pooling of data from the four studies showed a reduced need for additional treatment with the high‐dose regimens compared to the medium‐ or low‐dose regimens (OR 0.29, 95% CI 0.10 to 0.88; P = 0.03; 4 studies, 1125 participants; low‐certainty evidence). No difference was detected between subgroups (test for subgroup differences P = 0.69). Heterogeneity was detected (I<sup>2</sup> = 69%), which was no longer detected (I<sup>2</sup> = 8%) when sensitivity analysis was undertaken by removing <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a> from the analysis, suggesting the heterogeneity was caused by including data from this study. See <a href="./references#CD014884-fig-0023" title="">Analysis 2.13</a>. </p> <p>Two studies compared higher‐dose single‐infusion with lower‐dose single‐infusion regimens (<a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>). No clear difference was detected between groups (OR 0.26, 95% CI 0.01 to 4.80; P = 0.36; 2 studies, 382 participants). Heterogeneity was again detected (I<sup>2</sup> = 94%), likely for the reason described above. We were unable to undertake sensitivity analysis, as only two studies were included in the analysis. See <a href="./references#CD014884-fig-0024" title="">Analysis 2.14</a>. </p> <p>Two studies comparing higher‐dose multiple‐infusion versus lower‐dose multiple‐infusion regimens reported on the need for additional treatment (<a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>). Our analysis showed a reduced need for additional treatment in the higher‐dose multiple‐infusion compared to the lower‐dose multiple‐infusion regimens (OR 0.24, 95% CI 0.08 to 0.70; P = 0.009; 2 studies, 615 participants). No differences were detected between subgroups (test for subgroup differences P = 0.88). See <a href="./references#CD014884-fig-0025" title="">Analysis 2.15</a>. </p> <p><a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a> compared 200 mg/kg versus 400 mg/kg regimens and reported that no additional treatment was needed in either group. </p> <p>Two studies comparing single‐infusion regimens versus multiple‐infusion regimens reported on the need for additional treatment (<a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>). In <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>, 5/273 participants in the 2 g/kg single‐infusion group had additional infusion compared to 8/276 in the 400 mg/kg for 4 days group. Our analysis did not detect a clear difference in the need for additional treatment between groups (OR 1.14, 95% CI 0.38 to 3.39; P = 0.81; 2 studies, 818 participants). See <a href="./references#CD014884-fig-0026" title="">Analysis 2.16</a>. </p> <p><a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a> and <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a> did not report on additional treatment. We cannot be sure if this means no participants needed additional treatment, or if this was not recorded. </p> </section> <section id="CD014884-sec-0069"> <h5 class="title">Length of hospital stay (days)</h5> <p>Three studies compared a high‐dose regimen versus a medium‐ or low‐dose regimen and reported on hospital stay in days (± SD) (<a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>). Our analysis did not detect a clear difference in the length of hospital stay between groups (MD −0.24, 95% CI −0.78 to 0.30; P = 0.39; 3 studies, 752 participants; low‐certainty evidence). No differences were detected between subgroups (test for subgroup differences P = 0.40). See <a href="./references#CD014884-fig-0027" title="">Analysis 2.17</a>. </p> <p><a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>, <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>, <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>, <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>, and <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a> did not report this outcome. </p> <p>Three studies compared higher‐dose single‐infusion with lower‐dose single‐infusion regimens (<a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>). Our analysis did not detect a clear difference in the length of hospital stay between groups (MD −0.36, 95% CI −1.09 to 0.37; P = 0.33; 3 studies, 621 participants). See <a href="./references#CD014884-fig-0028" title="">Analysis 2.18</a>. </p> <p><a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a> did not report length of hospital stay, so we have no data to compare higher‐dose multiple‐infusion versus lower‐dose multiple‐infusion regimens that are not already reported above. </p> <p>Four studies investigated single‐infusion regimens versus multiple‐infusion regimens, ranging from 1000 mg/kg to 2 g/kg single IVIG versus 1600 mg/kg to 2 g/kg IVIG over 2 or 4 days, and reported on hospital stay (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>). </p> <p><a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a> reported that participants were discharged at a median of 4 days after entry into the study in the 1 g/kg group, and at a median of 5 days in the 400 mg/kg group (P = 0.01, study author calculation). This difference at least partially reflects the fact that participants receiving the four doses required a minimum of four days of hospitalisation. </p> <p><a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a> recorded that although the study protocol described 4 days of hospitalisation, 6% of participants in the 2 g/kg single‐infusion group compared to 1% of the 400 mg/kg/day for 4 days group were discharged early, the majority at day 3. Again, this must reflect that four doses required a minimum of four days of hospitalisation. </p> <p><a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a> only included participants scoring ≥ 4 on the Harada score and reported that the mean duration of hospital stay was 13.1 ± 6.0 days in the 2 g/kg single‐infusion group compared to 15.9 ± 7.2 days in the 400 mg/kg/day for 5 days group. It was not clear if the study authors reported SE or SD, but we have assumed these numbers to be SD. <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a> reported that the mean ± SD of hospital stay in the 2 g/kg single‐infusion group was 8.3 ± 2.7 days compared to 8.4 ± 2.5 days in the 1000 mg/kg/day for 2 days group. We combined the data, and found no clear overall difference between single and multiple IVIG infusions (MD −1.24, 95% CI −3.86 to 1.37; P = 0.35; 2 studies, 414 participants). Heterogeneity was detected (I<sup>2</sup> = 82%), which was likely due to the different participant characteristics (≥ 4 on Harada score). We were unable to undertake sensitivity analysis, as only two studies were included in the analysis. See <a href="./references#CD014884-fig-0029" title="">Analysis 2.19</a>. </p> </section> <section id="CD014884-sec-0070"> <h5 class="title">Mortality (all‐cause)</h5> <p><a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a> reported details on incidence of mortality, with one death in the subacute phase of the 400 mg/kg/day for 4 days group. The cause of death was a giant aneurysm. The remaining studies did not mention mortality, and although it is likely this means there were no deaths, we cannot be sure of this (<a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. ">Barron 1990</a>; <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>; <a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. ">Harada 1989</a>; <a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). ">He 2021</a>; <a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. ">Morikawa 1994</a>; <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>; <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>; <a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. ">Onouchi 1992</a>; <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>; <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>; <a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. ">Sato 1995</a>). We assessed this evidence to be of moderate certainty. </p> </section> </section> <section id="CD014884-sec-0071"> <h4 class="title">Primary treatment ‐ IVIG versus prednisolone</h4> <p>See <a href="./full#CD014884-tbl-0005">summary of findings Table 3</a>. </p> <p>Two studies compared IVIG with prednisolone for the treatment of KD (<a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>; <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>). <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a> randomised participants to 400 mg/kg/day IVIG for 3 days or 2 mg/kg/day of prednisolone for 5 days then 2 mg/kg/day orally until C‐reactive protein (CRP) fell to negative. <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a> randomised participants to 1 g/kg/day IVIG for 2 days or 2 mg/kg/day intravenous methylprednisolone (IVMP) for 5 days then 2 mg/kg/day orally until CRP negative. Oral dipyridamole was administered if CAA was detected. </p> <section id="CD014884-sec-0072"> <h5 class="title">Incidence of CAAs</h5> <p>Both studies reported CAAs. <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a> reported CAA in the acute period, 30 days, and 3 months: 7/50, 6/50, 3/41 in the IVIG group versus 10/40, 3/31, 3/31 in the prednisolone group. </p> <p><a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a> reported CAA at 2 weeks, 3, 6, 9 months, and 1‐year post‐treatment: 3/25, 2/25, 1/25, 0/25 in the IVIG group versus 3/25, 1/25, 0/25, 0/25 in the IVMP group. </p> <p>Overall, there was no clear difference in the incidence of CAA in the acute phase (OR 0.60, 95% CI 0.24 to 1.48; P = 0.27; 2 studies, 140 participants; very low‐certainty evidence). See <a href="./references#CD014884-fig-0030" title="">Analysis 3.1</a>. No difference was detected by the test for subgroup differences (P = 0.49). </p> </section> <section id="CD014884-sec-0073"> <h5 class="title">Incidence of any adverse effects after treatment initiation</h5> <p><a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a> reported that no adverse effects occurred in the prednisolone group (0/40). There was one report of mild shock and one death (2/50) in the IVIG group (OR 4.18, 95% CI 0.19 to 89.48; P = 0.36; 1 study; 90 participants; low‐certainty evidence). See <a href="./references#CD014884-fig-0031" title="">Analysis 3.2</a>. <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a> did not report adverse effects. We assessed this evidence to be of low certainty. </p> </section> <section id="CD014884-sec-0074"> <h5 class="title">Acute coronary syndromes, such as MI or coronary thrombus</h5> <p><a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a> reported one MI in the IVIG group (1/50) as a cause of death. <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a> did not report any acute coronary syndromes, but we are not certain whether none occurred or if these were not reported. We assessed this evidence to be of low certainty. </p> </section> <section id="CD014884-sec-0075"> <h5 class="title">Duration of fever (days)</h5> <p><a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a> reported the time to return to normal temperature after treatment started and the overall febrile period from KD onset and found a benefit of prednisolone treatment. <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a> reported the duration of fever from treatment and found no difference between groups. We pooled the time to return to normal/duration of fever from treatment onset. Overall, there was no clear difference in duration of fever (days) after treatment was started (MD 0.68, 95% CI −0.59 to 1.94; P = 0.29; 2 studies, 140 participants; very low‐certainty evidence). Considerable heterogeneity was detected (I<sup>2</sup> = 82%), likely due to differences in study design. A difference was detected by the test for subgroup differences, but given the size of the subgroups, this should be interpreted with caution (P = 0.02). See <a href="./references#CD014884-fig-0032" title="">Analysis 3.3</a>. </p> </section> <section id="CD014884-sec-0076"> <h5 class="title">Need for additional treatment</h5> <p>Neither <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a> nor <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a> reported this outcome. </p> </section> <section id="CD014884-sec-0077"> <h5 class="title">Length of hospital stay (days)</h5> <p>Neither <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a> nor <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a> reported this outcome. </p> </section> <section id="CD014884-sec-0078"> <h5 class="title">Mortality (all‐cause)</h5> <p><a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a> reported one death in the IVIG group. Cause of death was a giant aneurysm, intracranial bleeding, and MI. <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a> did not report any deaths, but we are not certain whether none occurred or if these were not reported. We assessed this evidence to be of low certainty. </p> </section> </section> <section id="CD014884-sec-0079"> <h4 class="title">Secondary treatment ‐ IVIG versus infliximab</h4> <p>Four studies compared IVIG with infliximab as a secondary treatment for KD (<a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>). All participants had received primary treatment of 2 g/kg IVIG but were resistant. Resistance was described as persistent fever 48 hours to 7 days, 36 to 48 hours, 24 to 36 hours, and 36 to 48 hours respectively, after initial treatment. Participants were then randomised to treatment with further IVIG (2 g/kg) or infliximab at 5 mg/kg, <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>, or 10 mg/kg, <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>. </p> <section id="CD014884-sec-0080"> <h5 class="title">Incidence of CAAs</h5> <p>All four studies reported incidence of CAA, but results were difficult to interpret as many participants had CAA at start of secondary treatment. </p> <p>In <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>, 24 participants were resistant to initial IVIG treatment, and 12 were randomised to 5 mg/kg infliximab and 12 to further IVIG. At baseline (start of second treatment), 3/12 in the infliximab group had CAA compared to 1/12 in the IVIG group. In total, 4/12 CAA were detected in the infliximab group compared to 1/12 in the IVIG group. </p> <p>In <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>, IVIG‐resistant KD patients were randomised to either further treatment with a second IVIG or 10 mg/kg infliximab. At baseline (start of second treatment), 1/50 participants in the infliximab group had CAA compared to 7/49 in the IVIG group. In total, 4/50 CAA were detected in the infliximab group compared to 1/49 in the IVIG group before receiving cross‐over treatment (or third treatment). </p> <p>In <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>, the number of CAA detected at the start of the second treatment was unclear. They report that CAAs were found in 1/16 participants receiving 5 mg/kg infliximab (6.3%) and 3/15 participants receiving IVIG (20.0%) through to day 21. No participant had a new CAA after day 21. <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a> reports that no difference in the Z max score (largest of the right coronary artery, left main coronary artery, left anterior descending artery, and left circumflex coronary artery internal diameters) was detected in participants who were evaluated for coronary artery internal diameters (Z‐score) after the start of treatment to day 56 between the infliximab group and the IVIG group. </p> <p>In <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>, 43 patients who were resistant to initial IVIG treatment were randomised to either a further 2 g/kg IVIG or 5 mg/kg infliximab. No CAA was detected at the start of the second treatment. CAAs developed in 4/32 participants retreated with IVIG and in 1/11 participants treated with infliximab. </p> <p>Overall, there was no clear difference in the incidence of CAA between the IVIG and infliximab groups (OR 1.31, 95% CI 0.46 to 3.74; P = 0.62; 4 studies, 197 participants). See <a href="./references#CD014884-fig-0033" title="">Analysis 4.1</a>. We have presented data by the total infliximab dose as subgroups. No difference was detected by the test for subgroup differences (P = 0.60). </p> </section> <section id="CD014884-sec-0081"> <h5 class="title">Incidence of any adverse effects after treatment initiation</h5> <p>All four studies reported adverse effects (<a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>). </p> <p><a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a> reported that 5 participants (3 infliximab, 2 IVIG) experienced one or more serious adverse events (SAEs). No SAEs were related to the study medication. Eighteen participants (9 infliximab, 4 IVIG, 1 infliximab cross‐over to IVIG, and 4 IVIG cross‐overs to infliximab) experienced one or more adverse events (AEs) attributable to KD (including eczema, CAA, diastolic dysfunction, and pericardial effusion), but it was not clear in which group these occurred. Ten participants experienced 18 AE not attributable to KD: 5 participants were treated with infliximab, 1 with IVIG, 3 with IVIG followed by infliximab, and 1 with infliximab followed by IVIG. Of these AEs, only transient hepatomegaly was deemed possibly related to study drug infusion; 5/12 participants who received infliximab and 1/12 who received IVIG experienced this AE. </p> <p><a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a> reported 45 adverse events in the infliximab group and 65 adverse events in the second IVIG group: 24/54 participants in the infliximab group and 33/49 participants in the second IVIG group experienced at least one adverse event. There were a total of 51 SAEs: 15/54 in the infliximab group and 36/49 in second IVIG group; 10/54 participants in the infliximab group and 27/49 in the second IVIG group experienced at least one SAE. SAEs that were deemed definitely or likely related to study treatment were experienced by 0/54 participants who received only infliximab and 9/58 participants who received IVIG as either their first or second study treatment; in all nine participants the SAE experienced was haemolytic anaemia. </p> <p><a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a> reported that AEs occurred in 15/16 participants in the infliximab group and 15/15 participants in the IVIG group. Adverse drug reactions (anti‐double stranded DNA (anti‐dsDNA), rash, and neuralgia) occurred in 11/16 participants in the infliximab group and 10/15 participants in the IVIG group. There were no discontinuations due to AEs. There was one serious AE (relapse of KD) in an IVIG‐treated participant. Infusion reactions were reported in 0/16 infliximab and 2/15 IVIG‐treated participants. In participants with elevated anti‐dsDNA antibodies, this decreased to normal levels by the end of the trial and in participants who were followed after completion of the trial. Lupus‐like syndrome was not observed in any participant. </p> <p><a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a> reported that no serious AEs such as anaphylactoid reaction, severe infections, or heart failure were observed. In the IVIG group, 5/32 participants experienced infusion reaction defined as fever with or without chill that requires transient interruption of infusion. In the infliximab group, 1/11 participants experienced skin rash developed during infusion. </p> <p>Overall, there was no clear difference in the incidence of AE between the IVIG and infliximab groups (OR 1.13, 95% CI 0.35 to 3.61; P = 0.84; 4 studies, 201 participants). See <a href="./references#CD014884-fig-0034" title="">Analysis 4.2</a>. We have presented data by the total infliximab dose as subgroups. No difference was detected by the test for subgroup differences (P = 0.09). </p> </section> <section id="CD014884-sec-0082"> <h5 class="title">Acute coronary syndromes, such as MI or coronary thrombus</h5> <p><a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>, <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>, and <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a> did not report acute coronary syndromes, and <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a> stated that no SAEs such as heart failure were observed. </p> </section> <section id="CD014884-sec-0083"> <h5 class="title">Duration of fever (days)</h5> <p>All four studies reported on duration of fever but in different ways (<a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>), preventing data pooling. We have reported the results narratively below. </p> <p><a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a> reported the median area (and range) under temperature curve (AUC) as 1331 (1286 to 1367) in the IVIG group compared to 1333 (1313 to 1354) in the infliximab group. The study authors reported that 1/12 participants had 2 days of fever in the infliximab‐treated group; 2/12 participants had 2 days of fever in the second IVIG‐treated group; and 2/12 participants had &gt; 2 days of fever post‐study drug administration. Participants who did not respond to treatment were crossed over to receive the second treatment. The study authors reported that the participants who crossed over had a higher AUC than those who did not cross over (P = 0.003). </p> <p><a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a> reported the mean (± SD) days of fever from enrolment as 1.5 (± 1.4) days in the infliximab group versus 2.5 (± 2.5) days in the IVIG group (P = 0.014). They also reported resolution of fever within 24 hours of treatment and no recurrence within 7 days in 40/52 (77%) participants in the infliximab group compared to 25/49 (51%) in the IVIG group. </p> <p><a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a> reported the median febrile period from start of treatment was 16 hours in the infliximab group compared to 56.1 hours in the IVIG group (no range provided). They also reported that the defervescence rate within 48 hours was greater in the infliximab group (76.7%, 95% CI 56.6 to 96.7%) compared to the IVIG group (37.0%, 95% CI 11.9 to 62.1%; P = 0.02). </p> <p><a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a> reported the median duration of fever and range was 6 hours (1 to 30 hours) in the infliximab group compared to 17 hours (1 to 154 hours) in the IVIG group (P = 0.044). Defervescence occurred within 24 hours in 9/11 (81.8%) participants treated with infliximab and in 18/32 (56.3%) retreated with IVIG (P = 0.098). </p> </section> <section id="CD014884-sec-0084"> <h5 class="title">Need for additional treatment</h5> <p>All four studies reported on the need for additional treatment (<a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>; <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>; <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>; <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>). </p> <p>In <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>, fever resolved in 1/12 participants who did not respond to infliximab after crossing over to IVIG. From the IVIG group, 4/12 participants required additional infliximab, and two of these went on to receive further treatment with steroids. </p> <p>In <a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a>, 9/52 participants in the infliximab group crossed over to IVIG, and 22/49 in the IVIG group crossed over to the infliximab group. Six participants with persistent fever (4/22 who received infliximab and 2/9 who received second IVIG as their cross‐over treatment) were then further treated with either ciclosporin or steroids at the discretion of the treating physician. </p> <p><a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a> reported that 5/16 participants in the infliximab group and 9/15 in the IVIG group were switched to another treatment (at physician's discretion) due to worsening KD. </p> <p><a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a> reported that 11/32 participants in the IVIG group required additional treatment (7 IVMP and 4 crossed to infliximab) compared to 1/11 in the infliximab group who crossed over to IVIG. </p> <p>We were able to combine these data. Overall, fewer participants receiving infliximab required further (tertiary) treatment (OR 3.99, 95% CI 1.98 to 8.02; P &lt; 0.001; 4 studies, 199 participants). See <a href="./references#CD014884-fig-0035" title="">Analysis 4.3</a>. We have presented data by the total infliximab dose as subgroups. No difference was detected by the test for subgroup differences (P = 0.94). </p> </section> <section id="CD014884-sec-0085"> <h5 class="title">Length of hospital stay (days)</h5> <p>Presentation of the data for this outcome in the different studies precluded data pooling. We have reported the results narratively below. </p> <p><a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a> reported the mean ± SD days in hospital from randomisation in the infliximab group as 3.2 ± 2.1 days compared to 4.5 ± 2.5 days in the IVIG group (P &lt; 0.001). </p> <p><a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a> reported the median number (and range) of days in hospital as 8 days (6 to 12) in the infliximab group compared to 10 days (6 to 14) in the IVIG group (P = 0.046). </p> <p>Length of hospital stay was not reported by <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a> or <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>. </p> </section> <section id="CD014884-sec-0086"> <h5 class="title">Mortality (all‐cause)</h5> <p><a href="./references#CD014884-bbs2-0003" title="BurnsJC , RobertsSC , TremouletAH , HeF , PrintzBF , AshouriN , et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child and Adolescent Health2021;5(12):852-61. NCT03065244. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial). clinicaltrials.gov/show/NCT03065244 (first received 27 February 2017). RobertsSC , JainS , TremouletAH , KimKK , BurnsJC , KIDCARE Multicenter Study Group. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: a phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemporary Clinical Trials2019;79:98-103. ">Burns 2021</a> reported that no deaths occurred. <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>, <a href="./references#CD014884-bbs2-0012" title="MoriM , HaraT , KikuchiM , ShimizuH , MiyamotoT , IwashimaS , et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports2018;8(1):1994. MoriM . Clinical trial of the infliximab for Kawasaki disease that an effect is inadequate for by existing treatment in Japan. Rheumatology (United Kingdom)2017;56(Suppl 3):P1-67. NCT01596335. Clinical study of TA-650 in patients with refractory Kawasaki disease. clinicaltrials.gov/ct2/show/NCT01596335 (first received 26 September 2018). ">Mori 2017</a>, and <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a> did not report incidence of mortality; although this likely means there were no deaths, we cannot be sure of this. </p> </section> </section> <section id="CD014884-sec-0087"> <h4 class="title">Secondary treatment ‐ IVIG versus prednisolone</h4> <p>Two studies compared IVIG with prednisolone as secondary treatment for KD (<a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>). All participants received primary treatment of 2 g/kg IVIG but were resistant. Resistance was described as recrudescent or persistent fever 36 or 48 hours after initial IVIG infusion, respectively (<a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>). Participants were then randomised to treatment with further IVIG (2 g/kg) or IVMP at 30 mg/kg/day for 3 days, <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>, or intravenous methylprednisolone pulse therapy (MPT) at 15 mg/kg/day for 3 days, <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>. </p> <section id="CD014884-sec-0088"> <h5 class="title">Incidence of CAAs</h5> <p>Both studies reported incidence of CAA (<a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>; <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>). Results for these studies were difficult to interpret as many participants had CAA at start of secondary treatment. </p> <p>Overall, there was no clear difference in the incidence of CAA between the IVIG and prednisolone groups (OR 0.46, 95% CI 0.02 to 9.18; P = 0.61; 2 studies, 75 participants). See <a href="./references#CD014884-fig-0036" title="">Analysis 5.1</a>. We have presented data by the total prednisolone dose as subgroups. No difference was detected by the test for subgroup differences (P = 0.1). </p> <p>In <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>, 22 participants resistant to initial IVIG treatment received secondary treatment with either IVIG or IVMP. Coronary artery dimensions and the prevalence of CAA were similar in the two groups (IVMP 2/11 versus IVIG 3/11). It is not clear at what time point the CAAs were assessed or if they were present at baseline. <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a> was halted prematurely due to adverse events following IVMP infusion. </p> <p>In <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>, 80 IVIG‐resistant patients were randomised to either IVIG or MPT, and 33/80 had CAA before secondary treatment. They reported CAA at 7 days and 1, 3, 6, 12, and 24 months. No dropouts were CAA‐positive. The numbers of CAA in the IVIG group compared to the MPT group at each time point were as follows: 7 days: 15/40 versus 18/40; 1 month: 8/39 versus 10/40; 3 months: 4/39 versus 3/39; 6 months: 2/35 versus 4/36; 12 months: 0/28 versus 4/25; 24 months: 0/18 versus 4/15). Fewer participants returned for follow‐up ECGs as time progressed. </p> </section> <section id="CD014884-sec-0089"> <h5 class="title">Incidence of any adverse effects after treatment initiation</h5> <p>Presentation of the data for this outcome in the different studies precluded data pooling. We have reported the results narratively below. </p> <p><a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a> was halted prematurely due to adverse events following IVMP infusion. The study authors reported increased sinus bradycardia (P = 0.01) and hyperglycaemia (P = 0.01) in the IVMP group. All adverse effects were transient. There were no convulsions, gastrointestinal symptoms, infection, or malignant arrhythmia. </p> <p><a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a> reported that 5/40 participants in the MPT group developed bradycardia and that there were no adverse reactions in the IVIG group (0/40) (OR 0.08, 95% CI 0.00 to 1.49; P = 0.09; 1 study, 80 participants). See <a href="./references#CD014884-fig-0037" title="">Analysis 5.2</a>. </p> </section> <section id="CD014884-sec-0090"> <h5 class="title">Acute coronary syndromes, such as MI or coronary thrombus</h5> <p><a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a> reported that there were no embolisms in either group. <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a> did not report any acute coronary syndromes, meaning it is likely that none occurred. </p> </section> <section id="CD014884-sec-0091"> <h5 class="title">Duration of fever (days)</h5> <p>Presentation of the data for this outcome in the different studies precluded data pooling. We have reported the results narratively below. </p> <p><a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a> reported that the proportion of febrile participants was lower in the IVMP group compared to the IVIG group until day 3 (1/11 versus 8/11; P &lt; 0.001), but not on or after day 4 (6/11 versus 6/11). <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a> also reported that the mean (SD) minimum body temperature (˚C) at 72 hours after treatment started in IVMP was 35.4˚C (± 0.4) compared to 36.1˚C (± 0.5) in the IVIG group (P = 0.002). Given the data on the proportion of febrile participants, it is likely this difference disappeared after 72 hours. </p> <p><a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a> reported that the mean (± SD) duration of fever (≥ 38˚C) after additional treatment was 11 ± 6.3 hours in the MPT group compared to 18 ± 4.4 hours in the IVIG group (P &lt; 0.05). </p> </section> <section id="CD014884-sec-0092"> <h5 class="title">Need for additional treatment</h5> <p><a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a> did not report if any participants required additional treatment. <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a> reported that 4/40 participants in the IVIG group required readmission compared to 11/40 in the MPT group. The same four participants resistant to second IVIG crossed over to MPT or received third‐line IVIG. Those not responsive to MPT received either oral methylprednisolone or IVIG. </p> </section> <section id="CD014884-sec-0093"> <h5 class="title">Length of hospital stay (days)</h5> <p>Length of hospital stay was not reported by <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a> or <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>. </p> </section> <section id="CD014884-sec-0094"> <h5 class="title">Mortality (all‐cause)</h5> <p><a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a> reported that there were no sudden deaths in either group. <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a> did not report any deaths, meaning it is likely that none occurred. </p> </section> </section> <section id="CD014884-sec-0095"> <h4 class="title">Tertiary treatment ‐ IVIG versus prednisolone</h4> <p>One study compared IVIG with prednisolone for the tertiary treatment of KD (<a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a>). <a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a> randomised 17 participants who did not respond to initial IVIG 2 g/kg or secondary IVIG 1 g/kg treatment for KD to either a third dose of IVIG 1 g/kg or IVMP at 20 mg/kg/day for 3 days within the acute phase. </p> <section id="CD014884-sec-0096"> <h5 class="title">Incidence of CAAs</h5> <p>At baseline (before third‐line therapy), 4/17 participants had CAA (2 in each group). During the acute phase, CAA was detected in 5/8 participants in the IVIG group (2 giant aneurysms, 3 small aneurysms, 3 intact coronary arteries) and 7/9 in the IVMP group (2 giant aneurysms, 2 small aneurysms, 3 transient dilations, 2 intact coronary arteries). Given the small numbers in each group, our analysis detected no difference (OR 0.48, 95% CI 0.06 to 3.99; P = 0.49; 1 study, 17 participants). See <a href="./references#CD014884-fig-0038" title="">Analysis 6.1</a>. </p> </section> <section id="CD014884-sec-0097"> <h5 class="title">Incidence of any adverse effects after treatment initiation</h5> <p><a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a> did not report adverse events, so we cannot be certain whether any occurred. </p> </section> <section id="CD014884-sec-0098"> <h5 class="title">Acute coronary syndromes, such as MI or coronary thrombus</h5> <p><a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a> did not report acute coronary syndromes, so we cannot be certain whether any occurred. </p> </section> <section id="CD014884-sec-0099"> <h5 class="title">Duration of fever (days)</h5> <p><a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a> reported the duration of fever (&gt; 38.5 °C) after retreatment. In the IVIG group, the mean (± SD) duration was 4.8 ± 0.7 days compared to 1.4 ± 0.7 days in the IVMP group. Analysis suggests fever duration is reduced with IVMP treatment compared to a third dose of IVIG (MD 3.40, 95% CI 2.73 to 4.07; P &lt; 0.001; 1 study, 17 participants). See <a href="./references#CD014884-fig-0039" title="">Analysis 6.2</a>. </p> </section> <section id="CD014884-sec-0100"> <h5 class="title">Need for additional treatment</h5> <p><a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a> did not report on additional treatment. </p> </section> <section id="CD014884-sec-0101"> <h5 class="title">Length of hospital stay (days)</h5> <p><a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a> did not report on the length of hospital stay. </p> </section> <section id="CD014884-sec-0102"> <h5 class="title">Mortality (all‐cause)</h5> <p><a href="./references#CD014884-bbs2-0008" title="HashinoK , IshiiM , IemuraM , AkagiT , KatoH . Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International2001;43(3):211-7. ">Hashino 2001</a> did not report on mortality. </p> </section> </section> <section id="CD014884-sec-0103"> <h4 class="title">Additional subgroup analyses</h4> <p>We performed additional analyses to investigate CAA incidence by geographic distribution unless data for CAA incidence were only provided by studies from one country. Using the test for subgroup differences, we found no differences between countries for CAA incidence for the comparisons IVIG versus ASA (P = 0.17, see <a href="./references#CD014884-fig-0040" title="">Analysis 7.1</a>). For IVIG versus IVIG CAA: high‐dose versus medium‐ or low‐dose regimens (<a href="./references#CD014884-fig-0011" title="">Analysis 2.1</a>) included Chinese and Japanese studies, and subgrouping by geographical distribution did not indicate any differences (P = 0.66, see <a href="./references#CD014884-fig-0041" title="">Analysis 8.1</a>). For high‐dose single‐infusion versus lower‐dose single‐infusion regimens, subgrouping <a href="./references#CD014884-fig-0012" title="">Analysis 2.2</a> by geographical distribution did not indicate any differences (P = 0.61, see <a href="./references#CD014884-fig-0042" title="">Analysis 8.2</a>). For higher‐dose multiple‐infusion versus lower‐dose multiple‐infusion regimens, only Japanese studies provided data, and no further subgrouping was carried out. For single‐infusion versus multiple‐infusion regimens, subgrouping <a href="./references#CD014884-fig-0014" title="">Analysis 2.4</a> by geographical distribution did not indicate any difference (P = 0.15, see <a href="./references#CD014884-fig-0043" title="">Analysis 8.3</a>). </p> <p>When splitting participants between subgroup analyses, if groups contained an uneven number of participants so that numbers could not be equally divided, we carried out the analysis in both ways to detect possible differences in the results caused by an unequal division of the numerator and denominator. This did not cause a significant change in size or direction of effect in any analysis. </p> </section> <section id="CD014884-sec-0104"> <h4 class="title">Sensitivity analysis</h4> <p>As planned, we undertook sensitivity analyses to exclude studies at high risk of selection bias. This included analyses with data provided by <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>, <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>, or <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>. </p> <p><a href="./references#CD014884-fig-0005" title="">Analysis 1.1</a>: there was no change in overall direction or size of effect for CAA incidence (up to 30 days) in IVIG versus ASA (OR 0.66, 95% CI 0.44 to 0.98; P = 0.04). </p> <p><a href="./references#CD014884-fig-0007" title="">Analysis 1.3</a>: there was no change in overall direction or size of effect for adverse events in IVIG versus ASA (OR 0.48, 95% CI 0.13 to 1.73; P = 0.26). </p> <p><a href="./references#CD014884-fig-0008" title="">Analysis 1.4</a>: there was no change in overall direction or size of effect for duration of fever from treatment in IVIG versus ASA (MD −2.60, 95% CI −4.48 to −0.73; P = 0.007). </p> <p><a href="./references#CD014884-fig-0009" title="">Analysis 1.5</a>: there was no change in overall direction or size of effect for duration of fever from KD onset in IVIG versus ASA (MD −0.80, 95% CI −1.50 to −0.11; P = 0.02). </p> <p><a href="./references#CD014884-fig-0030" title="">Analysis 3.1</a>: there was no change in overall direction or size of effect for CAA incidence in IVIG versus prednisolone (OR 0.49, 95% CI 0.17 to 1.43; P = 0.19). </p> <p><a href="./references#CD014884-fig-0032" title="">Analysis 3.3</a>: there was a change in effect to show a possible benefit of prednisolone for duration of fever in IVIG versus prednisolone (MD 1.40, 95% CI 0.42 to −2.38; P = 0.005). </p> <p>We carried out sensitivity analysis on incidence of CAA where analyses included data from studies that were at high risk of detection bias (cardiac outcomes). This included analyses with data from <a href="./references#CD014884-bbs2-0002" title="BurnsJC , ConnorJD , CapparelliEV , BestBM , MejiasA , MahonyL , et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics2008;153(6):833-8. NCT00271570. Infliximab (Remicade) for patients with acute Kawasaki disease. clinicaltrials.gov/show/NCT00271570 (first received 2 January 2006). ">Burns 2008</a>, <a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. ">Furusho 1984</a>, <a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]">Furusho 1991A</a>, <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>, <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a>, <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>, <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>, <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>, <a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. ">Qin 2006</a>, <a href="./references#CD014884-bbs2-0028" title="ChiCTR-EOC-17013266. The mechanism of coronary artery lesions and effect of treatment in children with Kawasaki disease: a clinical cohort study. chictr.org.cn/showproj.aspx?proj=22637 (first received 11 June 2017). WangZ , WangY , LiW , XieX , LiuP , ZhangX , et al. Methylprednisolone pulse therapy or additional IVIG for patients with IVIG-resistant Kawasaki disease. Journal of Immunology Research2020;2020:4175821. [DOI: 10.1155/2020/4175821]">Wang 2020</a>, <a href="./references#CD014884-bbs2-0030" title="YounY , KimJ , HongYM , SohnS . Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatric Infectious Disease Journal2016;35(4):457-9. ">Youn 2016</a>, or <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>. </p> <p><a href="./references#CD014884-fig-0005" title="">Analysis 1.1</a>: there was no longer a difference in incidence of CAA between groups (up to 30 days) in IVIG versus ASA (OR 0.78, 95% CI 0.51 to 1.19; P = 0.24). </p> <p><a href="./references#CD014884-fig-0006" title="">Analysis 1.2</a>: there was no change in overall direction or size of effect for CAA incidence (over 6 months) in IVIG versus ASA (OR 0.88, 95% CI 0.49 to 1.56; P = 0.66). </p> <p><a href="./references#CD014884-fig-0011" title="">Analysis 2.1</a>: there was no change in overall direction or size of effect for CAA incidence high‐dose regimens versus medium‐ or low‐dose regimens (OR 0.5, 95% CI 0.30 to 0.82; P = 0.007). A difference was detected between subgroups (test for subgroup differences P = 0.01). </p> <p><a href="./references#CD014884-fig-0012" title="">Analysis 2.2</a>: there was no change in overall direction or size of effect for CAA incidence higher‐dose single‐infusion versus lower‐dose single‐infusion regimens (OR 1.01, 95% CI 0.58 to 1.79; P = 0.96). </p> <p><a href="./references#CD014884-fig-0013" title="">Analysis 2.3</a>: there was no change in overall direction or size of effect for CAA incidence higher‐dose multiple‐infusion versus lower‐dose multiple‐infusion regimens (OR 0.41, 95% CI 0.28 to 0.61; P &lt; 0.001). </p> <p><a href="./references#CD014884-fig-0030" title="">Analysis 3.1</a>: both studies reporting on CAA incidence after treatment with IVIG versus prednisolone were excluded, so no longer estimable. </p> <p><a href="./references#CD014884-fig-0033" title="">Analysis 4.1</a>: there was no change in overall direction or size of effect for CAA incidence in IVIG versus infliximab (OR 2.04, 95% CI 0.70 to 5.95; P = 0.19). </p> <p><a href="./references#CD014884-fig-0036" title="">Analysis 5.1</a>: both studies reporting on CAA incidence after secondary treatment with IVIG versus prednisolone were excluded, so no longer estimable. </p> <p>We carried out sensitivity analysis on incidence of CAA where analyses included data from studies lacking a clear description of the criteria used to diagnose KD. This included analyses with data from <a href="./references#CD014884-bbs2-0011" title="MiuraM , KohnoK , OhkiH , YoshibaS , SugayaA , SatohM . Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics2008;167(10):1119-23. MiuraM , OhkiH , YoshibaS , UedaH , SugayaA , SatohM , et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Archives of Disease in Childhood2005;90(10):1096-7. ">Miura 2008</a>, <a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. ">Nagashima 1987</a>, <a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. ">Nishihara 1988</a>, <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>, <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>, <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>, or <a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. ">Sakata 2007</a>. </p> <p><a href="./references#CD014884-fig-0005" title="">Analysis 1.1</a>: there was no change in overall direction or size of effect for CAA incidence (up to 30 days) in IVIG versus ASA (OR 0.60, 95% CI 0.37 to 0.97; P = 0.04). </p> <p><a href="./references#CD014884-fig-0006" title="">Analysis 1.2</a>: there was no change in overall direction or size of effect for CAA incidence (over 6 months) in IVIG versus ASA (OR 0.68, 95% CI 0.37 to 1.26; P = 0.22). </p> <p><a href="./references#CD014884-fig-0011" title="">Analysis 2.1</a>: the overall effect for CAA incidence high‐dose regimens versus medium‐ or low‐dose regimens now includes both possible benefit and harm (OR 0.62, 95% CI 0.38 to 1.02; P = 0.06). </p> <p><a href="./references#CD014884-fig-0012" title="">Analysis 2.2</a>: there was no change in overall direction or size of effect for CAA incidence higher‐dose single‐infusion versus lower‐dose single‐infusion regimens (OR 0.92, 95% CI 0.59 to 1.45; P = 0.72). </p> <p><a href="./references#CD014884-fig-0013" title="">Analysis 2.3</a>: there was no change in overall direction or size of effect for CAA incidence higher‐dose multiple‐infusion versus lower‐dose multiple‐infusion regimens (OR 0.47, 95% CI 0.30 to 0.73; P = 0.001). </p> <p><a href="./references#CD014884-fig-0030" title="">Analysis 3.1</a>: there was no change in overall direction or size of effect for CAA incidence in IVIG versus prednisolone (OR 1.00, 95% CI 0.18 to 5.51; P = 1.00). </p> <p><a href="./references#CD014884-fig-0036" title="">Analysis 5.1</a>: there was no change in overall direction or size of effect for CAA incidence after secondary treatment with IVIG versus prednisolone (OR 0.08, 95% CI 0.00 to 1.64; P = 0.1). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD014884-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD014884-sec-0105"></div> <p>We identified 31 randomised controlled trials (RCTs) involving a total of 4609 participants with Kawasaki disease (KD) that compared intravenous immunoglobulin (IVIG) with either acetylsalicylic acid (ASA), another dose or regimen of IVIG, prednisolone, or infliximab. Most studies had at least one domain at high risk of bias (blinding of participants and personnel, or blinding of outcome assessment (cardiac or non‐cardiac outcomes, or both)), and detailed descriptions of the randomisation process were infrequently provided. See <a href="./full#CD014884-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD014884-tbl-0003">summary of findings Table 2</a>; and <a href="./full#CD014884-tbl-0005">summary of findings Table 3</a>. </p> <section id="CD014884-sec-0106"> <h3 class="title" id="CD014884-sec-0106">Summary of main results</h3> <section id="CD014884-sec-0107"> <h4 class="title">Primary treatment with IVIG compared to ASA for people with KD</h4> <p>Compared to ASA, IVIG probably reduces the incidence of coronary artery abnormalities (CAA) in people with KD. The individual studies reported a range of adverse effects, but there was little to no difference in numbers of these between groups. Evidence for incidence of acute coronary syndromes was limited, so we are uncertain of any effects. Duration of fever was probably shorter in the IVIG group, but there was little or no difference between groups in need for additional treatment. No study reported on length of hospital stay, and there was little to no difference between groups in mortality. </p> </section> <section id="CD014884-sec-0108"> <h4 class="title">Primary treatment with IVIG compared to different infusion regimens of IVIG for people with KD </h4> <p>We considered a high dose to be more than 1900 mg/kg total IVIG; medium to be 1900 mg/kg to 900 mg/kg total IVIG; and low to be less than 900 mg/kg total IVIG (<a href="./references#CD014884-bbs2-0070" title="AeR , MakinoN , KosamiK , KuwabaraM , MatsubaraY , NakamuraY . Epidemiology, treatments and cardiac complications in patients with Kawasaki disease: the nationwide survey in Japan, 2017-2018. Journal of Pediatrics2020;225:23-9.e2. [DOI: 10.1016/j.jpeds.2020.05.034]">Ae 2020</a>; <a href="./references#CD014884-bbs2-0071" title="AeR , YashiroM , MatsubaraY , OsamiM , MakinoS , NakamuraY . Results of the 26th nationwide survey of Kawasaki disease in Japan. jichi.ac.jp/dph/wp-dph/wp-content/uploads/2022/04/a19b047d4b9e6fbb84b6b187236779c8.pdf.">Ae 2021</a>). Probably fewer CAA occurred in participants treated with higher‐dose IVIG regimens compared to medium‐ or lower‐dose IVIG regimens. There was little to no difference in CAA incidence between higher‐dose single‐infusion and lower‐/medium‐dose single‐infusion regimens. Likely fewer CAA were detected in higher‐dose multiple‐infusion regimens compared to lower‐dose multiple‐infusion regimens. No clear differences were detected between single‐infusion and multiple‐infusion regimens. There was little to no difference in number of adverse effects between groups irrespective of the regimens compared. No study reported on acute coronary syndromes. Higher‐dose IVIG may reduce the duration of fever compared to medium‐ or lower‐dose regimens. No differences in duration of fever were detected between high‐dose versus medium‐dose single infusions, multiple infusions, or single‐ versus multiple‐infusion regimens. Higher‐dose regimens may reduce the need for additional treatment. We did not detect a difference in length of hospital stay between infusion regimens, and it is likely that there is little to no difference in mortality. </p> </section> <section id="CD014884-sec-0109"> <h4 class="title">Primary treatment with IVIG compared to prednisolone for people with KD</h4> <p>The evidence for the comparison IVIG versus prednisolone on incidence of CAA is very uncertain, and there was little to no difference between groups in adverse effects, acute coronary syndrome, and mortality. No study reported the need for additional treatment or length of hospital stay. We are very uncertain of the impact on duration of fever, as two studies reported the duration differently and had conflicting results. </p> </section> <section id="CD014884-sec-0110"> <h4 class="title">Secondary treatment with IVIG compared to infliximab for people with KD</h4> <p>We did not detect a clear difference in CAA incidence between groups treated with IVIG or infliximab following resistance to initial treatment with IVIG. Some participants had CAA at the start of secondary treatment. Similarly, no clear differences in the number of adverse effects were detected. Limited data were available for acute coronary syndromes and duration of fever, which prevented us from drawing any conclusions. Analysis indicated that there may be a reduced need for further (tertiary) treatment in the infliximab group. Given that the participants in this analysis were IVIG resistant, this is not surprising. We are unable to draw any conclusions about length of hospital stay because of differences in outcome reporting between studies. It is likely there were no deaths in either group. </p> </section> <section id="CD014884-sec-0111"> <h4 class="title">Secondary treatment with IVIG compared to prednisolone for people with KD</h4> <p>We did not detect a clear difference in CAA incidence between groups treated with IVIG or prednisolone following resistance to initial treatment with IVIG. Some participants had CAA at the start of secondary treatment. One study was halted due to adverse effects in the prednisolone group, and the second study reported increased events in the prednisolone group. Data for acute coronary syndromes were limited, and we could not pool data for duration of fever, though both studies reported a shorter fever duration in the prednisolone group. One study reported that fewer participants required additional (tertiary) treatment in the IVIG group. Length of hospital stay was not reported, and no deaths were reported. </p> </section> <section id="CD014884-sec-0112"> <h4 class="title">Tertiary treatment with IVIG compared to prednisolone for people with KD</h4> <p>One study investigated IVIG compared to prednisolone in participants who were resistant to both initial and secondary IVIG treatment. Evidence was limited, and no clear differences between groups in CAA incidence were detected. The study authors reported that duration of fever was reduced in the prednisolone group; however, this result should be interpreted with caution given the study limitations. No other outcomes of interest were reported. </p> </section> </section> <section id="CD014884-sec-0113"> <h3 class="title" id="CD014884-sec-0113">Overall completeness and applicability of evidence</h3> <p>We have attempted to find all available published and unpublished randomised trials for the use of IVIG in people with KD. We included a total of 31 studies in quantitative synthesis, and we believe that the included trials are comprehensive. However, it should be noted that we were not able to obtain data for all outcomes defined in this systematic review. </p> <p>As we restricted our inclusion criteria to evidence provided by RCTs, the identified studies provided a low overall number of events, and outcomes tended not to be reported for later time points, as study durations were generally short. We identified a variety of comparisons using a range of doses, recording different time points and reporting different outcomes. Specific details on baseline measurements of outcomes, for example CAA, were not always provided. These factors limit the applicability and completeness of our findings, as we are not accounting for the large amount of non‐randomised evidence gathered by long‐term cohort studies such as the Kawasaki Disease Nationwide Survey (<a href="./references#CD014884-bbs2-0071" title="AeR , YashiroM , MatsubaraY , OsamiM , MakinoS , NakamuraY . Results of the 26th nationwide survey of Kawasaki disease in Japan. jichi.ac.jp/dph/wp-dph/wp-content/uploads/2022/04/a19b047d4b9e6fbb84b6b187236779c8.pdf.">Ae 2021</a>). </p> <section id="CD014884-sec-0114"> <h4 class="title">Primary treatment</h4> <p>The available evidence indicates that high‐dose IVIG regimens are associated with a low risk of CAA formation, need for additional therapy, and prolonged duration of fever. This suggests that high‐dose IVIG regimens would be beneficial compared to medium‐ or low‐dose IVIG regimens, which are superior to ASA regimens. There were no clinically significant differences in incidence of adverse events between groups, which suggests there is little concern about the safety of IVIG. Regarding acute coronary syndromes and mortality, we could not find signals of effectiveness because the number of events was rarely observed during the observation period of the trials. </p> </section> <section id="CD014884-sec-0115"> <h4 class="title">Secondary or tertiary treatment</h4> <p>We found no clear evidence to support the effectiveness of IVIG compared to infliximab or prednisolone for the incidence of CAA, adverse effects, duration of fever, length of hospital stay, acute coronary syndrome, or mortality due to lack of sufficient statistical power in the obtained data. </p> </section> </section> <section id="CD014884-sec-0116"> <h3 class="title" id="CD014884-sec-0116">Quality of the evidence</h3> <section id="CD014884-sec-0117"> <h4 class="title">Primary treatment with IVIG compared to ASA for people with KD</h4> <p>See <a href="./full#CD014884-tbl-0001">summary of findings Table 1</a>. </p> <p>For the outcome CAA, we downgraded the certainty of the evidence by one level to moderate, as four studies included in the analysis were at high risk of bias (selection, performance, detection of cardiac outcomes, or reporting bias), and sensitivity analysis to exclude those studies at high risk of detection bias caused a change in effect size. For adverse effects, we downgraded the certainty of the evidence by one level due to concerns related to risk of bias (six studies were at high risk of selection, performance, or detection of non‐cardiac outcomes bias), one level for inconsistency (heterogeneity was high: I<sup>2</sup> = 73%), and one level for imprecision (confidence intervals include appreciable benefit or harm) to very low. For acute coronary syndromes, we downgraded the certainty of the evidence by one level due to concerns related to risk of bias (one study at high risk of selection/detection bias) and one level for imprecision (small numbers of events and participants, and confidence intervals include appreciable benefit or harm) to low. For duration of fever, we downgraded the certainty of the evidence by a total of one level due to concerns related to risk of bias (three studies were at high risk of selection/performance/detection bias) and imprecision (small number of participants) to moderate. For the outcome need for additional treatment, we downgraded the certainty of the evidence by one level due to concerns related to risk of bias (two studies at high risk of selection/detection of non‐cardiac outcomes bias) and one level for imprecision (small numbers of participants and events, and confidence intervals include appreciable benefit or harm) to low. No studies reported length of hospital stay, preventing an assessment of the certainty of the evidence. For mortality, we downgraded the certainty of the evidence by one level due to concerns related to risk of bias (two studies at high risk of selection/detection bias) and one level for imprecision (small numbers of participants and events) to low. </p> </section> <section id="CD014884-sec-0118"> <h4 class="title">Primary treatment with IVIG compared to different infusion regimens of IVIG for people with KD </h4> <p>See <a href="./full#CD014884-tbl-0003">summary of findings Table 2</a>. </p> <p>For CAA, we downgraded the certainty of the evidence by one level due to concerns related to risk of bias (two studies at high risk of detection of cardiac outcomes or performance bias) to moderate. For adverse effects, we downgraded the certainty of the evidence by one level due to concerns related to risk of bias (five studies at high risk of detection of non‐cardiac outcomes or performance bias, or both) and one level for imprecision (small numbers of events, and confidence intervals include appreciable benefit or harm) to low. No studies reported acute coronary syndromes, preventing an assessment of the certainty of the evidence. For duration of fever, we downgraded the certainty of the evidence by one level due to concerns related to risk of bias (three studies at high risk of detection of non‐cardiac outcomes) and one level for inconsistency (I<sup>2</sup> = 71%) to low. Sensitivity analysis indicated that this was explained by study differences (reporting from KD onset or treatment onset). For need for additional treatment, we downgraded the certainty of the evidence by one level due to concerns related to risk of bias (two studies at high risk of detection of cardiac outcomes or performance bias) and one level for inconsistency (I<sup>2</sup> = 69%) to low. For length of hospital stay, we downgraded the certainty of the evidence by a total of two levels to low due to concerns related to risk of bias and imprecision (confidence intervals include appreciable benefit or harm) to low. For mortality, we downgraded the certainty of the evidence by one level due to imprecision (small number of events reported) to moderate. </p> </section> <section id="CD014884-sec-0119"> <h4 class="title">Primary treatment with IVIG compared to prednisolone for people with KD</h4> <p>See <a href="./full#CD014884-tbl-0005">summary of findings Table 3</a>. </p> <p>For CAA, we downgraded the certainty of the evidence by two levels due to concerns related to risk of bias (both studies at high risk of selection/detection bias) and one level for imprecision (small numbers of participants) to very low. For adverse effects, we downgraded the certainty of the evidence by one level due to concerns related to risk of bias (study at risk of detection of non‐cardiac outcome bias) and one level for imprecision (small numbers of events and participants, and wide confidence interval) to low. For acute coronary syndrome, we downgraded the certainty of the evidence by one level due to concerns related to risk of bias (study at high risk of detection bias) and one level for imprecision (small numbers of events and participants) to low. For duration of fever, we downgraded the certainty of the evidence by one level due to concerns related to risk of bias (both studies at high risk of selection or detection bias), one level for inconsistency (I<sup>2</sup> = 82%), and one level for imprecision (small numbers of participants) to very low. Need for additional treatment and length of hospital stay were not reported for this comparison. For mortality, we downgraded the certainty of the evidence by one level for risk of bias and one level for imprecision (small numbers of events and participants) to low. </p> </section> </section> <section id="CD014884-sec-0120"> <h3 class="title" id="CD014884-sec-0120">Potential biases in the review process</h3> <p>We followed standard Cochrane procedures when developing the protocol for this review and in conducting the review. We attempted to contact the study authors where possible to obtain further information. We included studies irrespective of language. We identified additional studies in reference lists of reviews that had not been detected by our searches. These studies have been placed in awaiting classification until we are able to confirm that they meet the inclusion criteria of this Cochrane Review. It is possible that not including data from these studies has impacted the overall review findings. We decided to pool studies that evaluated different doses of treatments using subgroup analysis. We used subgroups for high‐/medium‐/low‐dose IVIG groups, as they represent clinically relevant regimens and allowed important comparisons to be investigated. We decided to include all adverse effects reported by studies in the data analyses, even though studies likely had different definitions of what an adverse effect was. We believe any bias overall would have been minimal, and any differences between treatment groups in individual studies would have been detected. We were limited in only including data from RCTs, and no large‐scale randomised studies have been carried out. This makes detection of rare events unlikely and decreased our confidence in the review findings. As discussed below, further evidence is available from large epidemiological studies. </p> </section> <section id="CD014884-sec-0121"> <h3 class="title" id="CD014884-sec-0121">Agreements and disagreements with other studies or reviews</h3> <p>This review replaces an earlier Cochrane Review (<a href="./references#CD014884-bbs2-0112" title="Oates-WhiteheadRM , BaumerJH , HainesL , LoveS , MaconochieIK , GuptaA , et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD004000. [DOI: 10.1002/14651858.CD004000]">Oates‐Whitehead 2003</a>). Our findings are in agreement with that review. We have included data from more recent studies and widened the scope to include studies also comparing IVIG with tumour necrosis factor‐alpha blockers and corticosteroids, which reflects current clinical options. This review indicates that high‐dose IVIG regimens are probably effective in preventing the formation of CAAs up to 30 days. In Japan, the nationwide survey of Kawasaki disease, which includes more than 90% of new KD patients, has been ongoing since 1970. Based on the latest Kawasaki Disease Nationwide Survey (<a href="./references#CD014884-bbs2-0071" title="AeR , YashiroM , MatsubaraY , OsamiM , MakinoS , NakamuraY . Results of the 26th nationwide survey of Kawasaki disease in Japan. jichi.ac.jp/dph/wp-dph/wp-content/uploads/2022/04/a19b047d4b9e6fbb84b6b187236779c8.pdf.">Ae 2021</a>), chronological changes in the proportion of KD patients treated with IVIG by dose regimens and incidences of CAAs are shown in <a href="#CD014884-fig-0004">Figure 4</a>. The chronological trend based on large epidemiological studies shows clearly an inverse relationship between a decrease in CAAs and an increase in the proportion of IVIG administration, especially IVIG 2 g/kg single‐infusion regimen. In the 1980s, most KD patients were treated with ASA alone, and 16% to 18% of KD patients had CAAs. In the early 1990s, more than 80% of KD patients received low‐ to medium‐dose IVIG multiple‐infusion regimens, and the incidence of CAAs decreased to approximately 12%. Since the late 1990s, IVIG had been replaced by 2 g/kg single infusion, and the incidence of CAAs decreased to approximately 4% in the 2000s. Based on these data, the incidence of CAAs decreased by approximately 30% from the ASA era to the low‐ to medium‐dose IVIG era, and then by approximately 60% in the high‐dose IVIG era. The results from this review showed an odds ratio (OR) of 0.60 (95% confidence interval (CI) 0.41 to 0.87) for ASA regimens versus IVIG regimens and an OR of 0.60 (95% CI 0.40 to 0.89) for high‐dose IVIG regimens versus low‐ or medium‐dose IVIG regimens. Based on these findings, the evidence for the preventive effect of IVIG on CAAs is robust and reproducible in large epidemiological studies. Several recent guidelines recommend high‐dose IVIG single infusion as the primary treatment for acute KD (<a href="./references#CD014884-bbs2-0083" title="deGraeffN , GrootN , OzenS , EleftheriouD , AvcinT , Bader-MeunierB , et al. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease - the SHARE initiative. Rheumatology (OXFORD)2019;58(4):672-82.">de Graeff 2019</a>; <a href="./references#CD014884-bbs2-0106" title="McCrindleBW , RowleyAH , NewburgerJW , BurnsJC , BolgerAF , GewitzM , American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, and Council on Epidemiology and Prevention, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation2017;135(17):e927-99. [DOI: 10.1161/CIR.0000000000000484]">McCrindle 2017</a>; <a href="./references#CD014884-bbs2-0107" title="MiuraM , AyusawaM , FukazawaR , HamadaH , IkedaS , ItoS , et al. Guidelines for medical treatment of acute Kawasaki disease (2020 revised version). Journal of Pediatric Cardiology and Cardiac Surgery2021;5(1):41-73. [DOI: 10.24509/jpccs.0501G1]">Miura 2021</a>). </p> <div class="figure" id="CD014884-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Chronological changes of proportion of intravenous immunoglobulin (IVIG) administration and incidence of coronary artery abnormalities (CAAs) from the Nationwide Survey of Kawasaki Disease in Japan. Created by review author (TK) with data from the Nationwide Survey (with permission from the Director of the Nationwide Survey Kawasaki Disease in Japan)." data-id="CD014884-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-FIG-04.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Chronological changes of proportion of intravenous immunoglobulin (IVIG) administration and incidence of coronary artery abnormalities (CAAs) from the Nationwide Survey of Kawasaki Disease in Japan. Created by review author (TK) with data from the Nationwide Survey (with permission from the Director of the Nationwide Survey Kawasaki Disease in Japan). </p> </div> </div> </div> <p>In this review, we could not show an association between IVIG and mortality because of the short observation period of the clinical trial and the few events that occurred. The National Kawasaki Disease Study has continuously investigated the mortality of people with KD since 1967 and found that mortality was about 2% in the 1960s, 0.8% in the 1970s, 0.2% in the 1980s, 0.1% in the 1990s, 0.04% in the 2000s, and 0.02% in the 2010s (<a href="./references#CD014884-bbs2-0071" title="AeR , YashiroM , MatsubaraY , OsamiM , MakinoS , NakamuraY . Results of the 26th nationwide survey of Kawasaki disease in Japan. jichi.ac.jp/dph/wp-dph/wp-content/uploads/2022/04/a19b047d4b9e6fbb84b6b187236779c8.pdf.">Ae 2021</a>). The rate of death has been declining at a rate of about half a per cent per decade. It is reasonable to assume that the reduction in mortality rates observed in these large observational studies is related to the widespread use of immunoglobulins. </p> <p>With regard to need for additional treatment, adverse effects, and duration of fever, no large‐scale epidemiological studies have been conducted continuously since the 1980s, therefore it is difficult to compare the association between IVIG and these effects on the basis of large studies. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD014884-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram." data-id="CD014884-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD014884-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD014884-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Chronological changes of proportion of intravenous immunoglobulin (IVIG) administration and incidence of coronary artery abnormalities (CAAs) from the Nationwide Survey of Kawasaki Disease in Japan. Created by review author (TK) with data from the Nationwide Survey (with permission from the Director of the Nationwide Survey Kawasaki Disease in Japan)." data-id="CD014884-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-FIG-04.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Chronological changes of proportion of intravenous immunoglobulin (IVIG) administration and incidence of coronary artery abnormalities (CAAs) from the Nationwide Survey of Kawasaki Disease in Japan. Created by review author (TK) with data from the Nationwide Survey (with permission from the Director of the Nationwide Survey Kawasaki Disease in Japan). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-FIG-04.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Primary treatment ‐ IVIG (and ASA) versus ASA, Outcome 1: CAA: total dose of IVIG subgrouped by single or multiple infusion (up to 30 days)" data-id="CD014884-fig-0005" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Primary treatment ‐ IVIG (and ASA) versus ASA, Outcome 1: CAA: total dose of IVIG subgrouped by single or multiple infusion (up to 30 days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Primary treatment ‐ IVIG (and ASA) versus ASA, Outcome 2: CAA: total dose of IVIG subgrouped by single or multiple infusion (≥ 6 months)" data-id="CD014884-fig-0006" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Primary treatment ‐ IVIG (and ASA) versus ASA, Outcome 2: CAA: total dose of IVIG subgrouped by single or multiple infusion (≥ 6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Primary treatment ‐ IVIG (and ASA) versus ASA, Outcome 3: Adverse effects: total dose of IVIG subgrouped by single or multiple infusion" data-id="CD014884-fig-0007" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Primary treatment ‐ IVIG (and ASA) versus ASA, Outcome 3: Adverse effects: total dose of IVIG subgrouped by single or multiple infusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Primary treatment ‐ IVIG (and ASA) versus ASA, Outcome 4: Duration of fever from treatment onset (days): total dose of IVIG subgrouped by single or multiple infusion" data-id="CD014884-fig-0008" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Primary treatment ‐ IVIG (and ASA) versus ASA, Outcome 4: Duration of fever from treatment onset (days): total dose of IVIG subgrouped by single or multiple infusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Primary treatment ‐ IVIG (and ASA) versus ASA, Outcome 5: Duration of fever from KD onset (days): total dose of IVIG subgrouped by single or multiple infusion" data-id="CD014884-fig-0009" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Primary treatment ‐ IVIG (and ASA) versus ASA, Outcome 5: Duration of fever from KD onset (days): total dose of IVIG subgrouped by single or multiple infusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Primary treatment ‐ IVIG (and ASA) versus ASA, Outcome 6: Need for additional treatment: total dose of IVIG subgrouped by single or multiple infusion" data-id="CD014884-fig-0010" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Primary treatment ‐ IVIG (and ASA) versus ASA, Outcome 6: Need for additional treatment: total dose of IVIG subgrouped by single or multiple infusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 1: CAA: high‐dose regimens vs medium‐ or low‐dose regimens" data-id="CD014884-fig-0011" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 1: CAA: high‐dose regimens vs medium‐ or low‐dose regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 2: CAA: higher‐dose single‐infusion regimens vs lower‐dose single‐infusion regimens" data-id="CD014884-fig-0012" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 2: CAA: higher‐dose single‐infusion regimens vs lower‐dose single‐infusion regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 3: CAA: higher‐dose multiple‐infusion regimens vs lower‐dose multiple‐infusion regimens" data-id="CD014884-fig-0013" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 3: CAA: higher‐dose multiple‐infusion regimens vs lower‐dose multiple‐infusion regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 4: CAA: single‐infusion regimens vs multiple‐infusion regimens" data-id="CD014884-fig-0014" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 4: CAA: single‐infusion regimens vs multiple‐infusion regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 5: Adverse effects: high‐dose regimens vs medium‐ or low‐dose regimens" data-id="CD014884-fig-0015" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 5: Adverse effects: high‐dose regimens vs medium‐ or low‐dose regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 6: Adverse effects: higher‐dose single‐infusion regimens vs lower‐dose single‐infusion regimens" data-id="CD014884-fig-0016" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 6: Adverse effects: higher‐dose single‐infusion regimens vs lower‐dose single‐infusion regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 7: Adverse effects: higher‐dose multiple‐infusion regimens vs lower‐dose multiple‐infusion regimens" data-id="CD014884-fig-0017" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 7: Adverse effects: higher‐dose multiple‐infusion regimens vs lower‐dose multiple‐infusion regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 8: Adverse effects: single‐infusion regimens vs multiple‐infusion regimens" data-id="CD014884-fig-0018" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 8: Adverse effects: single‐infusion regimens vs multiple‐infusion regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 9: Duration of fever (days): high‐dose regimens vs medium‐ or low‐dose regimens" data-id="CD014884-fig-0019" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 9: Duration of fever (days): high‐dose regimens vs medium‐ or low‐dose regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 10: Duration of fever (days): higher‐dose single‐infusion regimens vs lower‐dose single‐infusion regimens " data-id="CD014884-fig-0020" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 10: Duration of fever (days): higher‐dose single‐infusion regimens vs lower‐dose single‐infusion regimens  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 11: Duration of fever (days): higher‐dose multiple‐infusion regimens vs lower‐dose multiple‐infusion regimens" data-id="CD014884-fig-0021" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 11: Duration of fever (days): higher‐dose multiple‐infusion regimens vs lower‐dose multiple‐infusion regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 12: Duration of fever (days): single‐infusion regimens vs multiple‐infusion regimens" data-id="CD014884-fig-0022" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 12: Duration of fever (days): single‐infusion regimens vs multiple‐infusion regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 13: Need for additional treatment: high‐dose regimens vs medium‐ or low‐dose regimens" data-id="CD014884-fig-0023" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 13: Need for additional treatment: high‐dose regimens vs medium‐ or low‐dose regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 14: Need for additional treatment: higher‐dose single‐infusion regimens vs lower‐dose single‐infusion regimens" data-id="CD014884-fig-0024" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 14: Need for additional treatment: higher‐dose single‐infusion regimens vs lower‐dose single‐infusion regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 15: Need for additional treatment: higher‐dose multiple‐infusion regimens vs lower‐dose multiple‐infusion regimens" data-id="CD014884-fig-0025" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 15: Need for additional treatment: higher‐dose multiple‐infusion regimens vs lower‐dose multiple‐infusion regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 16: Need for additional treatment: single‐infusion regimens vs multiple‐infusion regimens" data-id="CD014884-fig-0026" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 16: Need for additional treatment: single‐infusion regimens vs multiple‐infusion regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 17: Length of hospital stay (days): high‐dose regimens vs medium‐ or low‐dose regimens" data-id="CD014884-fig-0027" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 17: Length of hospital stay (days): high‐dose regimens vs medium‐ or low‐dose regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 18: Length of hospital stay (days): higher‐dose single‐infusion regimens vs lower‐dose single‐infusion regimens" data-id="CD014884-fig-0028" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 18: Length of hospital stay (days): higher‐dose single‐infusion regimens vs lower‐dose single‐infusion regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-002.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 19: Length of hospital stay (days): single‐infusion regimens vs multiple‐infusion regimens" data-id="CD014884-fig-0029" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-002.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2: Primary treatment ‐ IVIG versus IVIG, Outcome 19: Length of hospital stay (days): single‐infusion regimens vs multiple‐infusion regimens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-002.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Primary treatment ‐ IVIG versus prednisolone, Outcome 1: CAA: total dose of IVIG vs total dose of IV prednisolone" data-id="CD014884-fig-0030" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Primary treatment ‐ IVIG versus prednisolone, Outcome 1: CAA: total dose of IVIG vs total dose of IV prednisolone </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Primary treatment ‐ IVIG versus prednisolone, Outcome 2: Adverse events: total dose of IVIG vs total dose of IV prednisolone" data-id="CD014884-fig-0031" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Primary treatment ‐ IVIG versus prednisolone, Outcome 2: Adverse events: total dose of IVIG vs total dose of IV prednisolone </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Primary treatment ‐ IVIG versus prednisolone, Outcome 3: Duration of fever (days) : total dose of IVIG vs total dose of IV prednisolone" data-id="CD014884-fig-0032" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Primary treatment ‐ IVIG versus prednisolone, Outcome 3: Duration of fever (days) : total dose of IVIG vs total dose of IV prednisolone </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Secondary treatment ‐ IVIG versus infliximab, Outcome 1: CAA: total dose of single IVIG vs single infliximab" data-id="CD014884-fig-0033" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Secondary treatment ‐ IVIG versus infliximab, Outcome 1: CAA: total dose of single IVIG vs single infliximab </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Secondary treatment ‐ IVIG versus infliximab, Outcome 2: Adverse effects: total dose of single IVIG vs single infliximab" data-id="CD014884-fig-0034" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Secondary treatment ‐ IVIG versus infliximab, Outcome 2: Adverse effects: total dose of single IVIG vs single infliximab </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Secondary treatment ‐ IVIG versus infliximab, Outcome 3: Need for additional treatment: total dose of single IVIG vs single infliximab" data-id="CD014884-fig-0035" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Secondary treatment ‐ IVIG versus infliximab, Outcome 3: Need for additional treatment: total dose of single IVIG vs single infliximab </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Secondary treatment ‐ IVIG versus prednisolone, Outcome 1: CAA: single IVIG vs multiple prednisolone" data-id="CD014884-fig-0036" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Secondary treatment ‐ IVIG versus prednisolone, Outcome 1: CAA: single IVIG vs multiple prednisolone </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Secondary treatment ‐ IVIG versus prednisolone, Outcome 2: Adverse effects: IVIG vs multiple prednisolone" data-id="CD014884-fig-0037" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Secondary treatment ‐ IVIG versus prednisolone, Outcome 2: Adverse effects: IVIG vs multiple prednisolone </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Tertiary treatment ‐ IVIG versus prednisolone, Outcome 1: CAA: IVIG vs prednisolone" data-id="CD014884-fig-0038" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Tertiary treatment ‐ IVIG versus prednisolone, Outcome 1: CAA: IVIG vs prednisolone </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Tertiary treatment ‐ IVIG versus prednisolone, Outcome 2: Duration of fever (days): IVIG vs prednisolone" data-id="CD014884-fig-0039" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Tertiary treatment ‐ IVIG versus prednisolone, Outcome 2: Duration of fever (days): IVIG vs prednisolone </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Additional subgroup analysis: primary treatment ‐ IVIG (and ASA) versus ASA, Outcome 1: Analysis 1.1 subgrouped by geographic distribution" data-id="CD014884-fig-0040" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Additional subgroup analysis: primary treatment ‐ IVIG (and ASA) versus ASA, Outcome 1: Analysis 1.1 subgrouped by geographic distribution </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Additional subgroup analysis: primary treatment ‐ IVIG versus IVG, Outcome 1: Analysis 2.1.1 subgrouped by geographical distribution" data-id="CD014884-fig-0041" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Additional subgroup analysis: primary treatment ‐ IVIG versus IVG, Outcome 1: Analysis 2.1.1 subgrouped by geographical distribution </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Additional subgroup analysis: primary treatment ‐ IVIG versus IVG, Outcome 2: Analysis 2.2 subgrouped by geographical distribution" data-id="CD014884-fig-0042" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Additional subgroup analysis: primary treatment ‐ IVIG versus IVG, Outcome 2: Analysis 2.2 subgrouped by geographical distribution </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014884-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/urn:x-wiley:14651858:media:CD014884:CD014884-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Additional subgroup analysis: primary treatment ‐ IVIG versus IVG, Outcome 3: Analysis 2.4 subgrouped by geographical distribution" data-id="CD014884-fig-0043" src="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_t/tCD014884-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Additional subgroup analysis: primary treatment ‐ IVIG versus IVG, Outcome 3: Analysis 2.4 subgrouped by geographical distribution </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/media/CDSR/CD014884/image_n/nCD014884-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD014884-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Primary treatment with intravenous immunoglobulin (IVIG) compared to acetylsalicylic acid (ASA) for people with Kawasaki disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous immunoglobulin (IVIG) versus acetylsalicylic acid (ASA) for the primary treatment of Kawasaki disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people undergoing initial treatment for KD </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> IVIG<sup>a</sup> </p> <p><b>Comparison:</b> ASA<sup>b</sup> </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ASA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with IVIG</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of CAAs</b> </p> <p>(up to 30 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.60</b> (0.41 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1437</p> <p>(11 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is likely that the incidence of CAA was reduced in the IVIG group compared to the ASA group. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>295 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b><br/>(147 to 267) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of any adverse effects after treatment initiation</b> </p> <p>(from 30 days to 30 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.57</b> (0.17 to 1.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1376</p> <p>(10 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There was little or no difference in the numbers of adverse effects detected. See <a href="./full#CD014884-tbl-0002">Table 1</a> for adverse effects reported by study. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b><br/>(12 to 120) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute coronary syndrome</b> (such as MI or coronary thrombus) </p> <p>(to 30 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>202</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a> reported acute coronary syndromes: 30 months 2/17 participants in the ASA group had coronary thrombus compared to 0/7 in the IVIG group. <a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. ">Matsushima 1985</a> confirmed no acute coronary events occurred. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of fever</b> (days) </p> <p>(acute phase)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of fever from treatment onset across ASA group ranged from <b>6 to 7.9 days</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of fever from treatment onset in the IVIG group was <b>4 days lower</b> (5.06 lower to 2.93 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>307</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is likely that duration of fever was reduced in the IVIG group compared to the ASA group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Need for additional treatment</b> </p> <p>(up to 30 or 60 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.27</b> (0.05 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>272</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There was little or no difference in the need for additional treatment between groups.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> <p>(2 to 55)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of hospital stay</b> (days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies comparing IVIG with ASA reported on length of hospital stay.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality (all‐cause)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Details on the incidence of mortality were reported by 2 studies, with no deaths occurring in either study. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ASA:</b> acetylsalicylic acid; <b>CAA:</b> coronary artery abnormality; <b>CI:</b> confidence interval; <b>IVIG:</b> intravenous immunoglobulin; <b>KD:</b> Kawasaki disease; <b>MI:</b> myocardial infarction; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>IVIG total dose ranged from 100 mg/kg to 2 g/kg, via either single infusion or multiple infusions over three to five days. See <a href="./references#CD014884-sec-0139" title="">Characteristics of included studies</a> tables for specific details. All studies administered ASA to both arms, except for <a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. ">Furusho 1991B</a>, where one of two IVIG study arms did not receive ASA.<br/><sup>b</sup>Most studies administered ASA initially at 30 mg/kg/day, except for <a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. ">Newburger 1986</a>, who used 100 mg/kg/day every 6 hours to day 14 of illness, and <a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987A</a>, <a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. ">Okuni 1987B</a>, and <a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. ">Onouchi 1988</a>, who used 50 mg/kg/day.<br/><sup>c</sup>We downgraded by one level due to concerns related to risk of bias.<br/><sup>d</sup>We downgraded by one level due to concerns related to risk of bias, one level for inconsistency (I<sup>2</sup> = 73%), and one level for imprecision (small number of events, and confidence intervals include appreciable benefit or harm).<br/><sup>e</sup>We downgraded by one level due to concerns related to risk of bias and one level for imprecision (small numbers of participants and events).<br/><sup>f</sup>We downgraded by a total of one level due to concerns related to risk of bias and imprecision (small number of participants).<br/><sup>g</sup>We downgraded by one level due to concerns related to risk of bias and one level for imprecision (small numbers of participants and events, and confidence intervals include appreciable benefit or harm). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Primary treatment with intravenous immunoglobulin (IVIG) compared to acetylsalicylic acid (ASA) for people with Kawasaki disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014884-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events ‐ primary treatment with IVIG versus ASA</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>IVIG<sup>a</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ASA<sup>a</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0004" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]FurushoK , KamiyaT , NakanoH . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984;2(8411):1055-8. "><b>Furusho 1984</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/46 chills and fever</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/47 liver disorder</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIG discontinued, and ASA changed to IVIG.</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0006" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. "><b>Furusho 1991B</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reports no SAE, AE not detailed</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0010" title="MatsushimaM , NagashimaM , MatsuokaH . High dose immunoglobulin therapy for Kawasaki disease by a control study. Nihon Shounika Gakkai Zasshi [Journal of the Japanese Pediatric Society]1986;90:80-7. "><b>Matsushima 1985</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/17 pericardial effusion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/15 pericardial effusion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0014" title="NagashimaM , MatsushimaM , MatsuokaH . High-dose gammaglobulin therapy for Kawasaki disease. Journal of Pediatrics1987;110(5):710-2. "><b>Nagashima 1987</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/69 chills and fever</p> <p>1/69 urticaria</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In all cases, symptoms were transient and disappeared in a short time.</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0015" title="NewburgerJW , TakahashiM , BurnsJC . The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine1986;315(6):341-7. TakahashiM , NewburgerJW . Long-term follow-up of coronary abnormalities in Kawasaki syndrome treated with and without IV gamma globulin. Circulation1990;82:717. "><b>Newburger 1986</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 SAE</p> <p>3/84 mild congestive heart failure</p> <p>1/84 shaking/itching</p> <p>1/84 sepsis</p> <p>1/84 rash, fever, lymphadenopathy and splenomegaly</p> <p>1/84 neutropenia and splenomegaly</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/84 mild congestive heart failure</p> <p>1/84 neutropenia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0019" title="OgawaM , OginoH , HarimaY , KonoS , OhkuniH , NishidaM . High dose gamma-globulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1987;91(12):3763-71. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. "><b>Ogawa 1987</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/63 liver disorder</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/54 liver disorder</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0020" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Progress in Clinical and Biological Research1987;250:555-6. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NisidaM . Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease - trial of 200 mg/kg/day. Journal of the Japanese Pediatric Society1987;91(8):2849-56. "><b>Ogino 1987</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/42 liver disorder</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0021" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. "><b>Okuni 1987A</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0022" title="HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. OkuniM , HaradaK , YamaguchiH , YanagawaH , SonobeT , KawasakiT . Intravenous gamma globulin therapy in Kawasaki disease - trial of low dose gammaglobulin. Kawasaki Disease1987:433-9. "><b>Okuni 1987B</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/196</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/99</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. "><b>Onouchi 1988</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/97 erythema (200 mg/kg arm)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/48 liver disorder</p> <p>1/48 nasal haemorrhage</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0029" title="OginoH , OgawaM , HarimaY , KonoS , OhkuniH , NishidaM , et al. High-dose intravenous gammaglobulin treatment of Kawasaki disease. Progress in Medicine1990;10:29-38. YabikuM , KojimaS , OgawaM , OginoH , HarimaY , KonoS , et al. High dose gammaglobulin therapy for Kawasaki disease. Journal of the Japanese Pediatric Society1989;93(12):2721-31. "><b>Yabiku 1989</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/48 liver disorder</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/36 liver disorder</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>AE: adverse event<br/>ASA: acetylsalicylic acid<br/>IVIG: intravenous immunoglobulin<br/>SAE: serious adverse event<br/><sup>a</sup>See <a href="./references#CD014884-sec-0139" title="">Characteristics of included studies</a> tables for doses given. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events ‐ primary treatment with IVIG versus ASA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014884-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Primary treatment with intravenous immunoglobulin (IVIG) compared to different infusion regimens of IVIG for people with Kawasaki disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>High‐dose versus medium‐ or low‐dose intravenous immunoglobulin infusion (IVIG) regimens for the primary treatment of Kawasaki disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people undergoing initial treatment for KD </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> IVIG high‐dose regimens<sup>a</sup> </p> <p><b>Comparison:</b> IVIG medium‐ or low‐dose regimens<sup>b</sup> </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with medium‐ or low‐dose IVIG</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with high‐dose IVIG</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of CAAs</b> </p> <p>(up to 30 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.60</b><br/>(0.40 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1824</p> <p>(8 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is likely that the incidence of CAAs is reduced in the high‐dose infusion regimens compared to the medium‐ or low‐dose regimens. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b><br/>(93 to 186) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of any adverse effects after treatment initiation</b> </p> <p>(follow‐up ranged from 30 days to 5 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.11</b><br/>(0.52 to 2.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1659</p> <p>(6 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There was little or no difference in the number of adverse effects detected. See <a href="./full#CD014884-tbl-0004">Table 2</a> for adverse effects reported by study. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b><br/>(10 to 44) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute coronary syndrome</b> (such as MI or coronary thrombus) </p> <p>(up to 7 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of fever</b> (days) </p> <p>(acute phase)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of fever in the medium‐ or low‐dose infusion regimens ranged from<br/><b>5 days to 10.3 days</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of fever was <b>0.71 days lower</b><br/>(1.36 lower to<br/>0.06 lower) in the high‐dose infusion regimens. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>992</p> <p>(4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of fever may be slightly reduced in the high‐dose regimens compared to the medium‐ or low‐dose regimens. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Need for additional treatment</b> </p> <p>(up to 6 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.29</b><br/>(0.10 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1125</p> <p>(4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Need for additional treatment may be slightly reduced in the high‐dose regimens compared to the medium‐ or low‐dose regimens. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>116 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b><br/>(13 to 103) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of hospital stay</b> (days) </p> <p>(up to 28 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay<br/>(days) ranged from <b>8.3 days to 18.95 days</b> across medium‐ and low‐dose infusion regimens. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay was <b>0.24 days lower</b><br/>(0.78 lower to<br/>0.3 higher) in the high‐dose infusion regimens. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>752</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was little to no difference detected in the length of hospital stay between regimens. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality (all‐cause)</b> </p> <p>(up to 7 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>549</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. ">Newburger 1991</a> reported 1 death in the subacute phase of the 400 mg/kg/day for 4 days group. The cause of death was a giant aneurysm. The remaining studies did not report mortalities. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CAA:</b> coronary artery abnormality; <b>CI:</b> confidence interval; <b>IVIG:</b> intravenous immunoglobulin; <b>KD:</b> Kawasaki disease; <b>MI:</b> myocardial infarction; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We included studies that compared different doses or infusion regimens of IVIG for the primary treatment of KD. We defined high dose as single‐ or multiple‐infusion regimens of over 1600 mg/kg total IVIG.<br/><sup>b</sup>We defined medium dose to be single‐ or multiple‐infusion regimens of 1600 mg/kg to 1000 mg/kg total IVIG, and low dose to be single‐ or multiple‐infusion regimens of less than 1000 mg/kg total IVIG.<br/><sup>c</sup>We downgraded by one level due to concerns related to risk of bias.<br/><sup>d</sup>We downgraded by one level due to concerns related to risk of bias and one level for imprecision (small numbers of events, and confidence intervals include appreciable benefit or harm).<br/><sup>e</sup>We downgraded by one level due to concerns related to risk of bias and one level for inconsistency (I<sup>2</sup> = 71%).<br/><sup>f</sup>We downgraded by one level due to concerns related to risk of bias and one level for inconsistency (I<sup>2</sup> = 69%).<br/><sup>g</sup>We downgraded by a total of two levels due to concerns related to risk of bias and imprecision (confidence intervals include appreciable benefit or harm).<br/><sup>h</sup>We downgraded by one level for imprecision (small number of events reported). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Primary treatment with intravenous immunoglobulin (IVIG) compared to different infusion regimens of IVIG for people with Kawasaki disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014884-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events ‐ primary treatment with IVIG versus IVIG</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>IVIG</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>IVIG</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>IVIG</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0001" title="BarronKS , Murphy DJ Jr, SilvermanED , RuttenbergHD , WrightGB , FranklinW , et al. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics1990;117(4):638-44. "><b>Barron 1990</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/22</p> <p>1 g/kg single</p> <p>4 mild flushing, chills, and nausea and vomiting, mild hypotension, morbilliform rash</p> <p>6/22 pericardial effusion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/22</p> <p>400 mg/kg/day for 4 days</p> <p>3 shaking chills, chills and noisy breathing, headache, flushing, and abdominal cramping</p> <p>3/22 pericardial effusion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Numbers of participants with pericardial effusion added separately to other AE, as it is not clear from text if these were different participants to those reporting other AE. </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0005" title="FurushoK , KamiyaT , NakanoH , KiyosawaN , ShinomiyaK , HayashideraT , et al. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):799-804. [DOI: 10.1111/j.1442-200x.1991.tb02611.x]"><b>Furusho 1991A</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/41</p> <p>100 mg/kg/day for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/51</p> <p>200 mg/kg/day for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/53</p> <p>400 mg/kg/day for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE were detected. Unclear if this means no AE or not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0007" title="HaradaH , YamaguchiH . Intravenous gamma globulin treatment in Kawasaki disease - comparison between high dose and low dose. Progress in Medicine1989;9:45-8. HaradaK . Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1991;33(6):805-10. "><b>Harada 1989</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/125</p> <p>100 mg/kg/day for 5 days</p> <p>rash, mild hypotension</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/117</p> <p>400 mg/kg/day for 5 days</p> <p>anaphylactic shock</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0009" title="HeL , LiuF , HuangG . Multi centeral study on IVIG treatment to Kawasaki disease. Cardiology in the Young2017;27(4):S472. HeL , LiuF , YanW , HuangM , HuangM , XieL , et al. Randomized trial of different initial IVIG regimens in Kawasaki disease. Pediatrics International2021;63(7):757-63. HeL , NiuCW , LiuF , HuangGY , WuL , ChuC , et al. A prospective randomised study of intravenous immunoglobulin treatment regimens in acute Kawasaki disease. Journal of the Hong Kong College of Cardiology2016;24(1):49. NCT02439996. Different doses of IVIG for Kawasaki disease. clinicaltrials.gov/show/NCT02439996 (first received 12 May 2015). "><b>He 2021</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/129</p> <p>1 g/kg/day for 2 days</p> <p>chickenpox</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/132</p> <p>2 g/kg single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/138</p> <p>1 g/kg single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/129 recovered without complications.</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0013" title="MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1994;36(4):347-54. MorikawaY , OhashiY , HaradaK , AsaiT , OkawaS , NagashimaM , et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatrics International2000;42(5):464-9. "><b>Morikawa 1994</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/310</p> <p>200 mg/kg/day for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/156</p> <p>400 mg/kg/day for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All reported AE were mild to moderate and included fever, rash, shivering, peripheral cyanosis, hepatic dysfunction. </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0016" title="NCT00000520. Prevention of coronary aneurysms in Kawasaki syndrome. clinicaltrials.gov/show/NCT00000520 (first received 28 October 1999). NewburgerJW , TakahashiM , BeiserAS , BurnsJC , BastianJ , ChungKJ , et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine1991;324(23):1633-9. "><b>Newburger 1991</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/273</p> <p>2 g/kg single</p> <p>6/273 new or worsening congestive heart failure</p> <p>1/273 infusion was SC not IV – oedema and blistering</p> <p>1/273 generalised oedema</p> <p>1/273 nasal congestion, cough, nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/276</p> <p>400 mg/kg/day for 4 days</p> <p>3/276 new or worsening congestive heart failure</p> <p>2/276 had pruritis</p> <p>1/276 had generalised oedema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0017" title="NishiharaS , IshibashiK , MatsudaI . Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet1988;2(8617):973. "><b>Nishihara 1988</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not report</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0023" title="OnouchiZ , IsogaiY , YanagisawaM , YamanouchiT , MatsudaH , MoritaT , et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease. Journal of the Japanese Pediatric Society1988;92(11):2367-76. OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. "><b>Onouchi 1988</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/49</p> <p>200 mg/kg/day for 3 days</p> <p>erythema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/48</p> <p>400 mg/kg/day for 3 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0024" title="OnouchiZ , YanagisawaM , HirayamaT , KiyosawaN , MatsudaH , NakashimaM . Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease. Acta Paediatrica Japonica: Overseas edition1995;37(1):40-6. OnouchiZ , YanagisawaM , ShiraishiH , HirayamaT , KatsubeY , KiyosawaN , et al. Multi-centre randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. Journal of the Japanese Pediatric Society1992;96(12):2669-79. "><b>Onouchi 1992</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/57</p> <p>100 mg/kg/day for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52</p> <p>200 mg/kg/day for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/56</p> <p>400 mg/kg/day for 5 days</p> <p>nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0025" title="QinLJ , WangHW , HuXF , LiuQJ , ShiH , WeiYX , et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua er ke za zhi2006;44(12):891-5. "><b>Qin 2006</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/122</p> <p>2 g/kg single</p> <p>2 cases of rash, nausea, and abdominal pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/120</p> <p>1 g/kg single</p> <p>2 cases of rash, nausea, and abdominal pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Related to an allergic reaction to IVIG</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0026" title="OzawaS , SakataK , HamaokaK . Randomized-prospective study of a single infusion of 1g/kg gammaglobulin for reducing a total dose of gammaglobulin in Kawasaki disease treatment. Pediatric Research2003;53:181. SakataK , HamaokaK , OzawaSI , NiboshiA , YoshiharaT , NishikiT , et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. European Journal of Pediatrics2007;166(6):565-71. "><b>Sakata 2007</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not report</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014884-bbs2-0027" title="SatoN , SugimuraT , AkagiT , InoueO , OnoE , KatoH . Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days?Kawasaki Disease1995:332-8. SatoN , SugimuraT , AkagiT , YamakawaR , HashinoK , EtoG , et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatrics International1999;41(1):1-7. "><b>Sato 1995</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/72</p> <p>2 g/kg single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/73</p> <p>400 mg/kg/day for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported that there were no AE to IVIG treatment in either group</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>AE: adverse effects<br/>IV: intravenous<br/>IVIG: intravenous immunoglobulin<br/>SC: subcutaneous </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events ‐ primary treatment with IVIG versus IVIG</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014884-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Primary treatment with intravenous immunoglobulin (IVIG) compared to prednisolone for people with Kawasaki disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous immunoglobulin (IVIG) versus prednisolone for the primary treatment of Kawasaki disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people undergoing initial treatment for KD </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> IVIG<sup>a</sup> </p> <p><b>Comparison:</b> prednisolone<sup>b</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with prednisolone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with IVIG</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of CAAs</b> </p> <p>(acute phase)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.60</b> (0.24 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>140</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b><br/>(57 to 270) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of any adverse effects after treatment initiation</b> </p> <p>(up to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 4.18</b> (0.19 to 89.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>90</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There is little to no difference in the incidence of adverse effects.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0/40 in prednisolone group</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute coronary syndrome</b> (such as MI or coronary thrombus) </p> <p>(up to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>90</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a> reported an MI in the IVIG group (1/50 vs 0/40 in the prednisolone group). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of fever</b> (days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not pool, as considerable heterogeneity was detected.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Need for additional treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neither study comparing IVIG with prednisolone reported on the need for additional treatment. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of hospital stay</b> (days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither study comparing IVIG with prednisolone reported on length of hospital stay.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality (all‐cause)</b> </p> <p>(up to 30 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>90</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>e</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a> reported 1/50 deaths in the IVIG group compared to 0/40 in the prednisolone group. Cause of death was a giant aneurysm, intracranial bleeding, and MI. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CAA:</b> coronary artery abnormality; <b>CI:</b> confidence interval; <b>IVIG:</b> intravenous immunoglobulin; <b>KD:</b> Kawasaki disease; <b>MI:</b> myocardial infarction; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>IVIG dose was 400 mg/kg/day IVIG for 3 days, <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>, and 1 g/kg/day IVIG for 2 days, <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>. See <a href="./references#CD014884-sec-0139" title="">Characteristics of included studies</a> tables for specific details.<br/><sup>b</sup>Prednisolone dose was 2 mg/kg/day for 5 days, <a href="./references#CD014884-bbs2-0018" title="NonakaZ , MaekawaK , OkabeT , EtoY , KuboM . Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. Kawasaki Disease1995:328-31. ">Nonaka 1995</a>, or 2 mg/kg/day intravenous methylprednisolone for 5 days, <a href="./references#CD014884-bbs2-0031" title="YuanY . Analysis of recent effects for corticosteroid in treating Kawasaki disease. Chinese Journal of Practical Paediatrics2000;15:49. ">Yuan 2000</a>, then oral prednisolone until C‐reactive protein‐negative. This group did not receive IVIG.<br/><sup>c</sup>We downgraded by two levels due to concerns related to risk of bias and one level for imprecision (small numbers of events and participants).<br/><sup>d</sup>We downgraded by one level due to concerns related to risk of bias and one level for imprecision (small numbers of events and participants, very wide confidence interval).<br/><sup>e</sup>We downgraded by one level due to concerns related to risk of bias and one level for imprecision (small numbers of events and participants).<br/><sup>f</sup>We downgraded by one level due to concerns related to risk of bias, one level for inconsistency (I<sup>2</sup> = 82%), and one level for imprecision (small numbers of participants). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Primary treatment with intravenous immunoglobulin (IVIG) compared to prednisolone for people with Kawasaki disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014884-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Diagnosis of classic Kawasaki disease*</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Diagnosis of classic Kawasaki disease</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Classic KD is diagnosed in the presence of fever for at least 5 days (the day of fever onset is taken to be the first day of fever) together with at least 4 of the 5 following principal clinical features. In the presence of ≥ 4 principal clinical features, particularly when redness and swelling of the hands and feet are present, the diagnosis of KD can be made with 4 days of fever, although in rare cases experienced clinicians who have treated many patients with KD may establish the diagnosis with 3 days of fever. </p> <p> <ol id="CD014884-list-0001"> <li> <p>Erythema and cracking of lips, strawberry tongue, and/or erythema of oral and pharyngeal mucosa </p> </li> <li> <p>Bilateral bulbar conjunctival injection without exudate</p> </li> <li> <p>Rash: maculopapular, diffuse erythroderma, or erythema multiforme‐like</p> </li> <li> <p>Erythema and oedema of the hands and feet in acute phase and/or periungual desquamation in subacute phase </p> </li> <li> <p>Cervical lymphadenopathy (≥ 1.5‐centimetre diameter), usually unilateral</p> </li> </ol> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A careful history may reveal that ≥ 1 principal clinical features were present during the illness but had resolved by the time of presentation. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who lack full clinical features of classic KD are often evaluated for incomplete KD. If coronary artery abnormalities are detected, the diagnosis of KD is considered confirmed in most cases. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laboratory tests typically reveal normal or elevated white blood cell count with neutrophil predominance and elevated acute phase reactants such as C‐reactive protein and erythrocyte sedimentation rate during the acute phase. Low serum sodium and albumin levels, elevated serum liver enzymes, and sterile pyuria can be present. In the second week after fever onset, thrombocytosis is common. </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Other clinical findings may include the following:</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myocarditis, pericarditis, valvular regurgitation, shock</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coronary artery abnormalities</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aneurysms of medium‐sized non‐coronary arteries</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peripheral gangrene</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aortic root enlargement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Respiratory</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peribronchial and interstitial infiltrates on chest x‐ray</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary nodules</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Musculoskeletal</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arthritis, arthralgia (pleocytosis of synovial fluid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gastrointestinal</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea, vomiting, abdominal pain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hepatitis, jaundice</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gallbladder hydrops</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pancreatitis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nervous system</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Extreme irritability</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aseptic meningitis (pleocytosis of cerebrospinal fluid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Facial nerve palsy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sensorineural hearing loss</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Genitourinary</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urethritis/meatitis, hydrocele</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Desquamating rash in groin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retropharyngeal phlegmon</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anterior uveitis by slit lamp examination</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erythema and induration at BCG inoculation site</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>The differential diagnosis includes other infectious and non‐infectious conditions, including the following:</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measles</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other viral infections (e.g. adenovirus, enterovirus)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Staphylococcal and streptococcal toxin‐mediated diseases (e.g. scarlet fever and toxic shock syndrome) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drug hypersensitivity reactions, including Stevens‐Johnson syndrome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systemic onset juvenile idiopathic arthritis</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>With epidemiologic risk factors:</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rocky Mountain spotted fever or other rickettsial infections</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leptospirosis</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="1"> <div class="table-footnote"> <p>*American Heart Association guidelines (<a href="./references#CD014884-bbs2-0106" title="McCrindleBW , RowleyAH , NewburgerJW , BurnsJC , BolgerAF , GewitzM , American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, and Council on Epidemiology and Prevention, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation2017;135(17):e927-99. [DOI: 10.1161/CIR.0000000000000484]">McCrindle 2017</a>). </p> <p>BCG: Bacillus Calmette–Guérin (used in vaccine for prevention of tuberculosis)<br/>KD: Kawasaki disease </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Diagnosis of classic Kawasaki disease*</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/full#CD014884-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014884-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Primary treatment ‐ IVIG (and ASA) versus ASA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 CAA: total dose of IVIG subgrouped by single or multiple infusion (up to 30 days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.41, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 100 mg/kg over single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.60, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 1000 mg/kg over single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.29, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 600 mg/kg over 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.58, 5.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 1200 mg/kg over 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.27, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.5 1600 mg/kg over 4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.10, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.6 500 mg/kg over 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.30, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.7 1 g/kg over 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.13, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.8 1 g/kg over 5 days (no ASA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.08, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.9 2 g/kg over 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.10, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 CAA: total dose of IVIG subgrouped by single or multiple infusion (≥ 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.45, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 100 mg/kg over single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.43, 6.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 1000 mg/kg over single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.14, 3.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 600 mg/kg over 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.45, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 1200 mg/kg over 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.18, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.5 1600 mg/kg over 4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.05, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.6 2 g/kg over 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Adverse effects: total dose of IVIG subgrouped by single or multiple infusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.17, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 100 mg/kg over single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 1000 mg/kg over single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.12, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 600 mg/kg over 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.01, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 1200 mg/kg over 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.08, 34.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.5 1600 mg/kg over 4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.44, 4.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.6 500 mg/kg over 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.7 2 g/kg over 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.04, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Duration of fever from treatment onset (days): total dose of IVIG subgrouped by single or multiple infusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.00 [‐5.06, ‐2.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 600 mg/kg over 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.90 [‐5.54, ‐0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 1200 mg/kg over 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.84 [‐6.35, ‐1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 2 g/kg over 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.20 [‐5.77, ‐2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Duration of fever from KD onset (days): total dose of IVIG subgrouped by single or multiple infusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐2.69, ‐0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 1000 mg/kg over single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐1.54, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 600 mg/kg over 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.05 [‐3.56, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 1200 mg/kg over 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.40 [‐4.62, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 2 g/kg over 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.79 [‐2.99, ‐0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Need for additional treatment: total dose of IVIG subgrouped by single or multiple infusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.05, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 600 mg/kg over 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 4.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 1200 mg/kg over 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 2 g/kg over 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.06, 16.85]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Primary treatment ‐ IVIG (and ASA) versus ASA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014884-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Primary treatment ‐ IVIG versus IVIG</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 CAA: high‐dose regimens vs medium‐ or low‐dose regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.40, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 High‐dose single infusion vs medium‐dose single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.55, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 High‐dose multiple infusion vs medium‐dose single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.47, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 High‐dose multiple infusion vs medium‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.20, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 High‐dose multiple infusion vs low‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.20, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 CAA: higher‐dose single‐infusion regimens vs lower‐dose single‐infusion regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 High‐dose single infusion versus medium‐dose single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.59, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 CAA: higher‐dose multiple‐infusion regimens vs lower‐dose multiple‐infusion regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.32, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 High‐dose multiple infusion vs medium‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.20, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 High‐dose multiple infusion vs low‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.20, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Medium‐dose multiple infusion vs low‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.36, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 CAA: single‐infusion regimens vs multiple‐infusion regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.28, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 High‐dose single infusion vs high‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>918</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.23, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Medium‐dose single infusion vs high‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [0.18, 25.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Adverse effects: high‐dose regimens vs medium‐ or low‐dose regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.52, 2.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 High‐dose single infusion vs medium‐dose single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.14, 7.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 High‐dose multiple infusion vs medium‐dose single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.06, 38.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.3 High‐dose multiple infusion vs medium‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.50, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.4 High‐dose multiple infusion vs low‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.05, 5.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Adverse effects: higher‐dose single‐infusion regimens vs lower‐dose single‐infusion regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 High‐dose single infusion vs medium‐dose single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.14, 7.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Adverse effects: higher‐dose multiple‐infusion regimens vs lower‐dose multiple‐infusion regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.43, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 High‐dose multiple infusion vs medium‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.47, 2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 High‐dose multiple infusion vs low‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.05, 5.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.3 Medium‐dose multiple infusion vs low‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Adverse effects: single‐infusion regimens vs multiple‐infusion regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.74, 3.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 High‐dose single infusion vs high‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.49, 3.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 Medium‐dose single infusion vs high‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.22 [0.63, 7.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Duration of fever (days): high‐dose regimens vs medium‐ or low‐dose regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐1.36, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 High‐dose single infusion vs medium‐dose single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐1.56, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 High‐dose multiple infusion vs medium‐dose single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.94, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.3 High‐dose multiple infusion vs low‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐2.81, ‐0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Duration of fever (days): higher‐dose single‐infusion regimens vs lower‐dose single‐infusion regimens  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 High‐dose single infusion vs medium‐dose single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.68, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Duration of fever (days): higher‐dose multiple‐infusion regimens vs lower‐dose multiple‐infusion regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.64 [‐2.88, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 High‐dose multiple infusion vs low‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐2.81, ‐0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.2 Medium‐dose multiple infusion vs low‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐1.07, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Duration of fever (days): single‐infusion regimens vs multiple‐infusion regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐1.42, 0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 High‐dose single infusion vs high‐dose multiple infusion ‐ duration from onset of disease </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.09, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.2 High‐dose single infusion vs high‐dose multiple infusion ‐ duration from onset of treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>694</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.09 [‐2.63, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Need for additional treatment: high‐dose regimens vs medium‐ or low‐dose regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.10, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.1 High‐dose single infusion vs medium‐dose single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.01, 4.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.2 High‐dose multiple infusion vs medium‐dose single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.19, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.3 High‐dose multiple infusion vs medium‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.06, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.4 High‐dose multiple infusion vs low‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Need for additional treatment: higher‐dose single‐infusion regimens vs lower‐dose single‐infusion regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.1 High‐dose single infusion vs medium‐dose single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.01, 4.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Need for additional treatment: higher‐dose multiple‐infusion regimens vs lower‐dose multiple‐infusion regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.08, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.1 High‐dose multiple infusion vs medium‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.06, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.2 High‐dose multiple infusion vs low‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.3 Medium‐dose multiple infusion vs low‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.03, 3.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Need for additional treatment: single‐infusion regimens vs multiple‐infusion regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.38, 3.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.1 High‐dose single infusion vs high‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.38, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.17 Length of hospital stay (days): high‐dose regimens vs medium‐ or low‐dose regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.78, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.1 High‐dose single infusion vs medium‐dose single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐1.15, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.2 High‐dose multiple infusion vs medium‐dose single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.83, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.18 Length of hospital stay (days): higher‐dose single‐infusion regimens vs lower‐dose single‐infusion regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.1 High‐dose single infusion vs medium‐dose single infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐1.09, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.19 Length of hospital stay (days): single‐infusion regimens vs multiple‐infusion regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19.1 High‐dose single infusion vs high‐dose multiple infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.24 [‐3.86, 1.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Primary treatment ‐ IVIG versus IVIG</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014884-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Primary treatment ‐ IVIG versus prednisolone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 CAA: total dose of IVIG vs total dose of IV prednisolone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.24, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 1200 mg/kg IVIG over 3 days vs 10 mg/kg prednisolone over 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.17, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 2 g/kg IVIG over 2 days vs 10 mg/kg prednisolone over 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.18, 5.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Adverse events: total dose of IVIG vs total dose of IV prednisolone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 1200 mg/kg IVIG over 3 days vs 10 mg/kg prednisolone over 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.18 [0.19, 89.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Duration of fever (days) : total dose of IVIG vs total dose of IV prednisolone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [‐0.59, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 1200 mg/kg IVIG over 3 days vs 10 mg/kg prednisolone over 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.42, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 2 g/kg IVIG over 2 days vs 10 mg/kg prednisolone over 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.39, 0.59]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Primary treatment ‐ IVIG versus prednisolone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014884-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Secondary treatment ‐ IVIG versus infliximab</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 CAA: total dose of single IVIG vs single infliximab <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.46, 3.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 2 g/kg IVIG vs infliximab 5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.17, 5.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 2 g/kg IVIG vs infliximab 10 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [0.53, 5.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Adverse effects: total dose of single IVIG vs single infliximab <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.35, 3.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 2 g/kg IVIG vs infliximab 5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.17, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 2 g/kg IVIG vs infliximab 10 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [1.16, 5.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Need for additional treatment: total dose of single IVIG vs single infliximab <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.99 [1.98, 8.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 2 g/kg IVIG vs infliximab 5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.12 [1.39, 12.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 2 g/kg IVIG vs infliximab 10 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.89 [1.56, 9.70]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Secondary treatment ‐ IVIG versus infliximab</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014884-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Secondary treatment ‐ IVIG versus prednisolone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 CAA: single IVIG vs multiple prednisolone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.02, 9.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Total dose of IVIG 2 g/kg vs prednisolone 45 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Total dose of IVIG 2 g/kg vs prednisolone 90 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.22, 12.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Adverse effects: IVIG vs multiple prednisolone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 2 g/kg IVIG vs prednisolone 45 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 1.49]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Secondary treatment ‐ IVIG versus prednisolone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014884-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Tertiary treatment ‐ IVIG versus prednisolone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 CAA: IVIG vs prednisolone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 Total dose of IVIG 1 g/kg vs 20 mg/kg prednisolone over 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.06, 3.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Duration of fever (days): IVIG vs prednisolone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Total dose of 1 g/kg IVIG vs 20 mg/kg prednisolone over 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.40 [2.73, 4.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Tertiary treatment ‐ IVIG versus prednisolone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014884-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Additional subgroup analysis: primary treatment ‐ IVIG (and ASA) versus ASA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Analysis 1.1 subgrouped by geographic distribution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.41, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.43, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 USA and Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.10, 0.84]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Additional subgroup analysis: primary treatment ‐ IVIG (and ASA) versus ASA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014884-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Additional subgroup analysis: primary treatment ‐ IVIG versus IVG</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Analysis 2.1.1 subgrouped by geographical distribution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.55, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.55, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.26, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Analysis 2.2 subgrouped by geographical distribution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.59, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.59, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.26, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Analysis 2.4 subgrouped by geographical distribution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.28, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.53, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.2 Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.07, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.3 USA and Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.16, 2.43]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Additional subgroup analysis: primary treatment ‐ IVIG versus IVG</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014884.pub2/references#CD014884-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD014884.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD014884-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD014884-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD014884-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD014884-note-0014">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD014884-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD014884-note-0016">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD014884-note-0012">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD014884-note-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD014884-note-0011">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014884\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014884\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014884\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014884\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014884\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014884\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014884\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014884\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014884\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014884\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014884\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014884\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014884\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014884\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014884\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014884\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014884\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014884\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014884.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014884.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD014884.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD014884.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014884.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726009555"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014884.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726009559"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014884.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e892d7e769379',t:'MTc0MDcyNjAxMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 